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ABSTRACT 
Introduction: The idiopathic inflammatory myopathies (IIM): dermatomyositis (DM) 
and polymyositis (PM) have been historically defined by broad clinical and 
pathological criteria. These conditions affect both adults and children with clinical 
features including muscle weakness, skin disease and internal organ involvement. 
Using a clinico-serological approach DM and PM can be defined into more 
homogeneous subsets. Myositis-specific autoantibodies (MSAs) are directed against 
cytoplasmic or nuclear components involved in key regulatory intra-cellular 
processes including protein synthesis, translocation and gene transcription. Over the 
last few years MSAs have been better characterised including autoantibodies 
directed against the aminoacyl tRNA-synthetase (ARS) enzymes, the signal 
recognition particle and the Mi-2 protein. 
Aim: The overall aim of this thesis is to describe a comprehensive clinical and 
serological study of adult and juvenile IIM. Autoantigen targets including novel 
specificities were identified using protein immunoprecipitation. 
Results: The first part of this thesis is a descriptive study on known myositis 
autoantibodies in adult IIM, confirming the significant association of interstitial 
pneumonia with anti-ARS, severe myopathy with anti-SRP, and classic DM with 
anti-Mi-2 serotype. In the next section, new autoantigen systems in adult IIM are 
described including a new anti-ARS (anti-Zo) in the anti-synthetase syndrome. 
Further autoantibodies directed against small ubiquitin-like modifier enzyme and a 
p155/140 autoantigen are major serological subsets in adult DM, the latter 
significantly associated with malignancy. The final section outlines a large 
serological study of juvenile DM (JDM) and JDM-overlap showing the frequency and 
clinical associations of MSAs and myositis-associated autoantibodies, including 
work on two new major subsets anti-p155/140 and anti-p140, which appear to define 
more severe disease. 
Conclusion: The work in this thesis highlights the importance of autoimmunity in 
IIM and suggests a new approach where MSAs can classify patients into clinical 
syndromes, which predict outcomes and may as a result influence treatment  
strategies. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
The idiopathic inflammatory myopathies (IIM) are a group of rare autoimmune 
diseases that affect both adults and children. The major subtypes of IIM are 
polymyositis (PM) and dermatomyositis (DM) that are heterogeneous conditions  
characterised by skeletal muscle weakness, biochemical or histological evidence of 
muscle inflammation, skin lesions and systemic organ involvement (1, 2). Morbidity 
outcomes relate to well-known complications, e.g. cancer-associated myositis and 
interstitial pneumonia. In children there is also a significant morbidity associated with 
vasculopathic organ involvement, soft tissue calcinosis and skin ulceration. 
Response to immunosuppressive therapies is variable and patients may die from 
disease or treatment complications, or remain very disabled. The associations with 
cancer and interstitial pneumonia make IIM an important autoimmune model to  
investigate further. The precise aetiology is unknown, mechanisms  require further 
elucidation but the interaction between immunogenetic and environmental factors  
appears to play a major role (3). Like other systemic autoimmune diseases including 
systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), IIM is 
characterised by the production of autoantibodies. The identification and 
characterisation of autoantibodies is an important cornerstone in the diagnosis of 
autoimmune connective tissue disease (CTD) (4, 5). Autoantibodies and 
corresponding target autoantigens are the subject of considerable interest, and 
there is increasing evidence to support a critical association between genotype, 
serotype and clinical phenotype in both adult and juvenile myositis (6-10). 
1.2 Classification and diagnosis 
In 1975, Bohan and Peter first proposed criteria to aid the diagnosis and  
classification of PM and DM (1, 2). The five adapted criteria proposed were as 
follows: 
1.	 Symmetrical proximal weakness of the limb or pelvic girdle and anterior neck 
flexors progressing over weeks to months, with or without dysphagia or 
respiratory muscle involvement. 
2.	 Elevation of muscle enzymes, including creatinine kinase (CK). 
3.	 Abnormal electromyogram (EMG) with a triad of

 Short duration, small amplitude polyphasic motor unit potentials.
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 Fibrillations, positive sharp waves, increased insertional irritability. 
 Spontaneous, bizarre, high frequency repetitive discharges. 
4.	 Abnormal muscle biopsy demonstrating inflammatory cell infiltrate, muscle 
degeneration, regeneration or necrosis. 
5.	 Typical cutaneous signs of DM including 
 Heliotrope rash – violaceous erythema on upper eyelids 
 Gottron’s papules – violaceous keratotic papules on extensor aspects of 
fingers or elbows or knees. 
Exclusion criteria: absence of other forms of myopathy e.g. inclusion body myositis, 
metabolic, inherited or infectious forms of myopathy. 
Bohan and Peter suggested five subsets of myositis: PM, DM, cancer-associated 
myositis, juvenile myositis and myositis overlapping with CTD. Bohan and Peter also 
described that patients can develop cutaneous features of DM, which may precede 
the onset of myopathy (2). 
 Definite DM requires all five criteria.

 Definite PM requires first four criteria (without rash).

	 Probable disease requires three criteria out of first 4 criteria (for DM, one of 
which is rash i.e. criteria 5). 
	 Possible disease requires two criteria out of first 4 criteria (for DM, criteria 5 
plus one other. 
Overlap myositis: must fulfil criteria for their main CTD e.g. systemic sclerosis (11) 
or systemic lupus erythematosus (12), at least two of criteria 1 – 4, and at least one 
myositis-specific or associated autoantibody (see section 1.6.4). 
Tanimoto et al published further classification criteria for PM / DM in 1995 (13). 
1.	 Skin lesions:

 Heliotrope rash.

 Gottron’s papules (extensor aspect of fingers, elbows or knees.

2.	 Systemic inflammatory signs (elevated erythrocyte sedimentation rate, C-
reactive protein, pyrexias, weight loss). 
3.	 Non-erosive arthritis. 
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4. Myositis-specific autoantibodies e.g. anti-JO-1 
5. Elevated skeletal muscle enzymes. 
6. Myalgia at rest or with contraction. 
7. Proximal muscle weakness. 
8. Myopathic changes on EMG. 
9. Myositis changes on muscle biopsy. 
 For a diagnosis of definite PM – at least four from item list 2 – 9. 
 For a diagnosis of definite DM – at least four from item list 2 – 9 plus at least 
one feature from item 1. 
The IIM spectrum also includes a further subset, sporadic inclusion body myositis 
(IBM) and Griggs et al have subsequently proposed classification criteria (14). 
Unlike other IIM, sporadic IBM causes slowly progressive myopathy with atrophy 
with a distinctive pattern of muscle involvement that may be asymmetrical and affect 
distal rather than proximal muscle groups, and is often unresponsive to conventional 
immunomodulatory therapy (15). Historically, IBM cases have been seen and 
managed by Neurologists. Clinicians now recognise histopathology and other more 
specific investigations are required to exclude IBM, hereditary and other non-
immune mediated myopathies when applying the Bohan and Peter criteria. This 
study has not investigated this subgroup of patients and in this thesis IIM refers 
purely to PM and DM cases. 
1.3 Epidemiology 
The true frequency of PM and DM as stand-alone disorders or in association with 
other CTD is unknown. Reports of incidence and prevalence are limited based on 
different study populations. Estimates based on the diagnostic criteria proposed by 
Bohan and Peter (1, 2), may not be accurate due to difficulties distinguishing PM 
and IBM. Reports show an annual incidence of 2-7 / million population (16-18). The 
mean age of onset is 50 years affecting women more than men. Juvenile 
dermatomyositis (JDM) is the most common IIM of children and the reported 
incidence is 0.8-4.1 per million children per year (18-20). In contrast to adults, 
juvenile PM is rare (21), whereas JDM overlap with other connective tissue disease 
in particular SSc and SLE is more common. 
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1.4 Clinical features 
IIM is characterised by a spectrum of clinical features including skeletal muscle 
weakness, skin lesions and systemic organ involvement, in particular interstitial 
pneumonia and a risk of cancer in adults.  Children with JDM share some clinical 
features with adult patients in terms of muscle disease and characteristic skin 
lesions. Certain clinical features including skin ulceration, calcinosis and gastro-
intestinal involvement are more common in children and have been proposed as 
predictors of severe disease course in JDM (21-25). In contrast to adults with DM, 
both interstitial pneumonia and cancer-associated myositis are very rare in JDM.  
Delays in diagnosis, in particular recognising active muscle or lung disease and poor 
response to treatment mean that patients are often left disabled from irreversible  
damage. 
1.4.1 Myositis 
IIM can present with progressive symmetrical muscle weakness that usually 
develops over a few weeks to months. The proximal muscle groups such as the 
shoulder girdle, pelvic girdle, thigh muscles and neck flexors are typically involved. 
In severe cases, other muscle groups can be involved including chest wall 
weakness, which can compromise respiratory function. At onset, patients rarely 
complain of muscle pain but experience difficulties with activities of daily living, for 
example, rising from a chair, walking up the stairs and raising their arms. Depending 
on the severity of the case and the response to treatment muscle atrophy can 
develop that leads to severe irreversible weakness. 
1.4.2 Cutaneous manifestations 
Classic DM skin lesions are generally present at the time of diagnosis and in some 
cases may precede the development of muscle inflammation or other organ 
involvement (see Section 1.5.3) (26). Gottron’s sign is an erythematous, scaly 
plaque-like lesion usually found over the dorsal surface of the metacarpophalageal 
or proximal interphalangeal joints and the extensor surfaces of the knees or elbows. 
Heliotrope rash is a purple violaceous eruption of the upper eyelids, often with 
cutaneous oedema. More extensive skin involvement includes the V-sign and 
Shawl-sign rash over the anterior triangle of the neck, and the back of the neck and 
shoulders respectively. Erythroderma can develop on the face (malar distribution or 
forehead). All these rashes are diffuse, flat and erythematosus and may be 
photosensitive. The skin lesions can have a poikilodermatous appearance with a 
combination of atrophy, pigment changes and telangiectasia. Periungal erythema  
16

with abnormal dilated nailfold capillaries is another feature. Mechanic’s hands are a 
characteristic cutaneous manifestation that is pathonomonic of the clinical and 
serological subset termed the anti-synthetase syndrome (see Section 1.5.1). The 
description refers to dry, cracked or fissured skin with hyperkeratosis over the lateral 
aspects of the inter-digits especially the index and middle fingers. Certain features 
secondary to persistent cutaneous vasculitis are more common in JDM, in particular 
generalised oedema, skin ulceration and soft tissue calcification (calcinosis) (21-25). 
1.4.3 Interstitial pneumonia 
Diffuse parenchymal lung disease (DPLD) is a major cause of morbidity and 
mortality in IIM (27). Primary lung involvement or ventilatory failure secondary to  
muscle weakness is common, more so in adult IIM (28-30). Interstitial pneumonia is 
the most frequent sub-type of DPLD in IIM, with studies showing an overall 
frequency of between 20-60% (29, 31). Interstitial pneumonia (also termed  
interstitial lung disease) are a heterogeneous group of non-malignant and non-
infectious lung disorders that comprise of a number of clinico-pathological entities 
that are sufficiently different to be designated as separate diseases. The 
characteristic hallmark is that of varying patterns of inflammation and fibrosis 
affecting the lung parenchyma. 
In 2002 the American Thoracic Society and the European Respiratory Society 
(ATS/ERS) published the consensus classification for interstitial pneumonia that is  
equally applicable in CTD (32). Based on radiological and histopathological patterns, 
interstitial pneumonia can be further subdivided into several subsets including usual 
interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), organising 
pneumonia (OP) and acute interstitial pneumonia (AIP), which are recognised in 
CTD (32, 33). The histological hallmark of UIP is the presence of fibroblastic foci 
with a subpleural, basal and peripheral distribution (32, 34). The most important 
differential pattern of UIP, particularly in CTD is NSIP, which has a similar subpleural 
and basal distribution. Katzenstein et al first described NSIP characterised by 
cellular and fibrotic changes with the absence of dense fibrosis or fibroblastic foci 
(35). With the advent of high-resolution computerised tomography (HRCT), 
interstitial pneumonia patterns in CTD can be categorised radiologically with good  
histological correlation (36, 37). 
NSIP has been reported to be the most frequent subtype on both HRCT and lung 
biopsy in IIM (38). AIP, COP and UIP have also been reported and identified as 
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patterns responsible for acute or rapidly progressive interstitial pneumonia with AIP 
and UIP associated with the worst prognosis (28-31, 33, 39). It is well recognised 
that interstitial lung involvement may be the first or predominant organ manifestation 
preceding muscle or skin disease, particularly in the anti-synthetase syndrome (see 
Section 1.5.1) and in patients with clinically-amyopathic DM (CADM) (see Section 
1.5.3) (29, 31, 40-42). 
1.4.4   Arthritis and overlap features 
Non-erosive inflammatory arthritis is a frequent manifestation of IIM, particularly in 
anti-synthetase syndrome and overlap conditions such as SSc, mixed connective  
tissue disease and SLE. Raynaud’s phenomenon characterised by vasospasm and 
structural changes of the digital microvasculature is a common feature. Joint 
disease with contractures and lipoatrophy of soft tissues is more frequent in JDM  
particularly in patients with overlap scleroderma. General features include fatigue, 
weight loss and fever. 
1.4.5   Other organ manifestations 
Other organs can be involved including the striated muscles of oropharyngeal and 
upper oesophagus causing dysphagia, and gastro-intestinal tract vasculopathy 
leading to ischaemic ulceration with pain and bleeding, the latter a more common 
complication in JDM (43). Cardiac involvement including myocarditis has been  
reported with subsequent conduction defects and ventricular failure (44, 45). 
Although rare, cardiac disease confers a high risk for mortality in patients with IIM 
(27, 44). 
1.5 Specific clinical subsets 
1.5.1 Anti-synthetase syndrome 
The anti-aminoacyl tRNA synthetase (anti-ARS) autoantibodies (see Section 1.6.2) 
define the anti-synthetase syndrome recognised as a spectrum of myositis,  
interstitial pneumonia, non-erosive arthritis, fever, Raynaud’s phenomenon and 
mechanic’s hands (46). Patients may have different clinical features within the 
syndrome, but overall there is a significant association with  interstitial pneumonia 
and studies have described the frequency to be as high as 95% (28-30, 47, 48). 
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1.5.2 Cancer-associated myositis 
The association between cancer and adult DM is well recognised particularly in the 
older age groups (49-54). Because IIM can have a chance association with 
malignancy, cancer-associated myositis is defined by a temporal association of less 
than three years between cancer and DM onset (50, 51). The association with PM is 
uncertain with some studies reporting an increased relative risk but some not (53, 
55, 56). Hill et al conducted a pooled analysis of published national data from 
Sweden, Denmark, and Finland on all patients with DM and PM (over the age of 15 
years). The study calculated standardised incidence ratios (SIR) for individual 
cancer sites for dermatomyositis and polymyositis separately, using national cancer 
rates by country, sex, age, and date. The frequency of cancer in the DM cohort was 
32% (58% of which developed cancer after the diagnosis of DM), with a SIR of 3.0. 
The most common cancer observed was ovarian followed by lung, pancreatic, non-
Hodgkin lymphoma stomach and colorectal. 15% of PM cases were associated with 
cancer (70% developed after the diagnosis of PM), with a SIR of 1.3. PM was 
associated with a higher risk of non-Hodgkin lymphoma, then lung and bladder 
malignancy. In both DM and PM, the risk of malignancy was highest at the time of 
myositis diagnosis (within the first year) with a markedly reduced relative risk over 
time. For DM the SIR of cancer by year after diagnosis of myositis was 13.5 (0-1 
year), 2.5 (2-5 years) and 1.4 (>5 years). In the PM group the SIR of cancer by year 
after diagnosis of myositis was 2.6 (0-1 year), 1.5 (2-5 years) and 0.9 (>5 years). In 
the DM cohort the number of cancers recorded in patients under the age of 44 years 
was small, and there was no increase in risk in PM patients (53). In contrast to 
adults, JDM appears not  to be associated with malignancy (53, 57). Historically, 
cancer-associated myositis has not been associated with specific myositis 
autoantibodies, but recent reports including work described in this thesis have 
described a novel autoantibody marker in this clinical subset (see section 1.6.2). 
1.5.3 Clinically-amyopathic dermatomyositis (CADM) 
Patients may only develop DM skin changes with no clinical evidence of myopathy, 
termed DM sine myositis or amyopathic DM (ADM) (40). Clinically-amyopathic DM 
(CADM) is a designation for patients who either have ADM or those patients who 
have DM skin lesions, no muscle weakness but evidence of sub-clinical myopathy 
on further testing (muscle enzymes, EMG, imaging or biopsy), termed 
hypomyopathic DM. 
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1.6 Treatment 
The treatment of both PM and DM is often empirical and in general is influenced by 
clinical experience rather than robust clinical data. There remains a paucity of 
standardised clinical trials due to the relative rarity of PM and DM. In addition, 
perhaps due to historical classification tools including the Bohan and Peter criteria, 
IIM is a heterogeneous condition, which makes designing trials and interpreting 
treatment outcomes in different disease subtypes difficult. For example, optimal 
treatment strategies for ASS with lung disease may be different to other subgroups, 
CADM or immune-mediated necrotising myopathy. Moreover, the absence of 
standardised disease activity and outcome measures has made the assessment of 
treatment response difficult. Classifying patients into more homogenous subsets 
based on serotype / clinical phenotype, and the advent of validated myositis disease 
activity tools (see section 1.7) will facilitate the design of clinical trials, which can  
capture clinically significant changes. 
Based on personal clinical experience and limited trial data there are several 
treatments that are effective treating patients with IIM. 
Glucocorticoids 
Prednisolone is recognised as the first line treatment for PM or DM including those 
with internal organ complications e.g. ASS with interstitial lung involvement. This is 
primarily based on clinical experience rather than trial data. In the majority of cases, 
the initial dose in 0.5-1mg/kg daily, and depending on clinical response the dose is 
weaned over a number of months. Patients may remain on low dose prednisolone 
for a number of years, particularly those with ASS and ILD, which appears to be 
very steroid responsive but also steroid dependant with disease flares on steroid 
withdrawal (48) (personal observation). In severe cases of myositis with internal  
organ involvement (including those with gastrointestinal involvement e.g.  
vasculopathy or pharyngeal dysfunction), patients may require induction with 
intravenous methylprednisolone pulses. 
Specific immunomodulatory therapy 
In patients who respond to steroids, the goal is to induce disease control and thus 
remission as quickly as possible at the same as minimising steroid requirements. In 
mild to moderate cases, for example those with purely muscle and / or skin disease, 
this may be achieved with either Azathioprine or Methotrexate (58-61). An 
alternative to Azathioprine and Methotrexate is Ciclosporin, the latter two agents 
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have also been compared in a small randomised controlled trial, with no significant 
difference observed, although appeared effective (62). However, the side effect of 
profile may be higher with Ciclosporin, which often limits its use in clinical practice. 
In moderate to severe cases, induction therapy in combination with pulsed / oral  
prednisolone may be required. The efficacy of intravenous immunoglobulin (IV IG) 
has been demonstrated, especially in DM, in a randomised controlled trial (63). In 
DM patients who response to standard regimes with prednisolone and Azathioprine / 
Methotrexate is inadequate or in those patients with severe disease at presentation 
(not complicated by interstitial pneumonia), IV IG is the preferred agent of choice. 
Repeated infusions may be required to achieve disease control followed by 
maintenance therapy as outlined above. In severe cases, including those with 
significant interstitial pneumonia and / or severe necrotising myopathy, based on 
personal clinical experience, IV Cyclophosphamide (CYC) may be a useful adjuvant 
therapy. In general, induction with 4-8 pulsed infusions given every 3-4 weeks is an 
optimal strategy. If this treatment fails or is contra-indicated, the novel biologic agent 
Rituximab (monoclonal antibody against CD20-positive B cells) appears to be an 
attractive treatment option, especially in myositis-autoantibody-positive refractory 
patients e.g. ASS patients with interstitial pneumonia and DM (64). A multi-centre / 
international randomised placebo controlled has recently completed recruitment 
(http://www.edc.gsph.pitt.edu/rimstudy/index.html). There is now preliminary data for 
newer agents in moderate disease or as maintenance therapy following induction 
with IV IG, IV CYC or Rituximab. Mycophenolate Mofetil inhibits the de novo 
pathway of nucleotide synthesis leading to an anti-proliferative affect directed 
against T and B lymphocytes. It appears to be a useful agent particularly in those 
patients where Azathioprine or Methotrexate is ineffective or poorly tolerated. There 
is also preliminary data that suggests Mycophenolate may be beneficial in refractory 
IIM cases associated with interstitial pneumonia (65-67). A further option is 
Tacrolimus, a calcineurin inhibitor that blocks T cell signal transduction and IL-2 
signalling. This drug can be effective in some difficult-to-treat cases of polymyositis / 
ASS, especially in patients with interstitial lung disease (68, 69). 
1.7 Assessment Tools 
In a clinical setting, proximal myopathy is often assessed by physician tested 
medical research council (MRC) scale for muscle strength. Manual muscle testing, 
however, has a number of limitations. One limitation is that the MRC scale is an 
ordinal scale with disproportional distances between grades. Another limitation of 
the MRC scale is that the scoring depends on the judgment of the examiner. Finally, 
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with the 6-point ordinal MRC scale, it is difficult to identify relatively small but 
clinically relevant changes in muscle strength. Alternative more objective tests to 
assess proximal muscle function have been devised, including two isotonic tests (1 
kg arm lift for upper limb function and a 30 second chair stand test for lower limb 
function. These tests exhibit excellent test-retest reliability, demonstrate construct 
validity and are responsive to changes in disease activity in IIM (70). New tools have 
been devised to standardise the conduct and reporting on IIM clinical trials. Two 
tools, known as the myositis intention to treat index (MITAX) and the myositis 
disease activity assessment visual analogue scale (MYOACT), have been 
developed to measure activity in patients with IIM 
(www.niehs.nih.gov/research/resources/collab/imacs/docs/activity/MDAAT_Scoring_ 
2009.pdf). In addition, the myositis damage index (MDI) has been devised to assess 
the extent and severity of damage developing in different organs and systems. 
These measures have been reviewed by the International Myositis Assessment and 
Clinical Studies (IMACS) group and have been found to have good face validity (71). 
A recent study has demonstrated that the myositis disease activity assessment tool 
(MITAX and MYOACT) has good interrater reliability and validity in clinical practice 
(72). In addition to these tools, specific disease assessment scales have also been 
designed in juvenile IIM, which are used in routine clinical practice, as well as 
research studies (see section 5.1.2 and appendix 5.5). 
1.8 Pathogenesis and aetiology 
It is becoming increasingly clear that IIM is a useful model to study the relationship 
between immunogenetic profiles, autoimmune targets and clinical phenotype in  
CTD. The development of IIM appears to be secondary to the combination of 
genetic factors and exposure to environmental agents that may initiate specific 
autoimmune responses in certain individuals. 
1.8.1 Pathogenesis 
Classic descriptions 
Cellular and humoral autoimmune mechanisms that target skeletal muscle, the 
lungs, the skin, and associated microvasculature are implicated in the pathogenesis 
of IIM. In broad terms, in DM, immune responses are said to primarily target the 
microvascular endothelium leading to activation of the complement cascade, 
upregulation of cytokines and chemokines, and thus endothelial damage. 
Inflammatory lesions with B and CD4 positive T cells are predominately found in 
perivascular and perimysial regions with perifascicular atrophy. Endothelial 
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hyperplasia and fibrin thrombi are seen in both endomysial and dermal capillaries 
(17, 73, 74). Cytokines are released, which leads to upregulation of vascular-cell 
adhesion protein-1 (VCAM-1) and intercellular adhesion molecule (ICAM-1), which 
promotes endothelial damage. Historically in PM, myocytotoxicity is said to be 
mediated by cellular responses where clonally expanded CD8 positive T cells are 
primed against muscle fibres expressing MHC class I antigens leading to an 
inflammatory cell infiltrate that invades muscle fascicles (17, 75). Previous 
descriptions have suggested B cells are sparse within the inflammatory cell infiltrate 
of PM specimens (76).  
Shared cellular and humoral mechanisms 
It is now becoming increasingly clear that both T and B cell responses occur in both 
subtypes of IIM. Both CD4 and CD8 T cells have been demonstrated in PM and DM 
muscle tissue (77). In addition, cytokines, chemokines and their receptors, are 
strongly expressed by endothelial and inflammatory cells in both subtypes. CD4+ 
cells previously characterised as T cells have been identified as plasmacytoid 
dendritic cells (pDCs). Large-scale gene expression studies have confirmed a type 1 
interferon (IFN) signature with abundant pDCs in DM muscle and skin (78, 79). More 
recently, type 1 IFN α /β producing pDCs have also identified in PM muscle (80), 
highlighting the potential role of this cytokine system in the pathogenesis of IIM. 
Furthermore, antigen-driven B cell humoral responses have now been demonstrated 
within muscle in PM, as well as DM. A previous study has shown that  
immunoglobulin transcripts are prominent in PM muscle, with a relative abundance 
of CD138+ plasma cells (81). Further work has confirmed local B cell maturation 
occurs within myositis muscle in both subtypes of IIM; B cells and corresponding 
plasma cells were clonally expanded, had class-switched and undergone mutation 
(82). This suggests antigen-driven responses may play a crucial role in disease 
pathogenesis. The role for B-cell autoimmunity in PM and DM is further emphasised 
by the production of autoantibodies against specific intra-cellular protein targets, 
including the aminoacyl-tRNA-synthetases, signal recognition particle and Mi-2. 
Non-immune mechanisms 
It has been suggested that non-immune mechanisms may play a role in disease 
pathogenesis. The rationale being some patients can have minimal inflammatory 
cell infiltrate but marked structural changes on muscle biopsy with significant 
weakness. In a mouse model, over-expression of class I MHC molecules has been 
shown to mediate skeletal muscle fibre damage, even in the absence of T and B 
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cells (83). Similarly, in human myositis, induction of class I MHC in muscle fibres 
occurs before mononuclear cell infiltration (84, 85). Recent data suggests 
continuous upregulation of MHC class I on muscle fibers leads to an endoplasmic 
reticulum (ER) stress response. A potential mechanism has been proposed whereby 
ER overload leads to activation of nuclear factor kappa-B pathway combined with 
the ER unfolded protein response, which in turn promotes pro-inflammatory cytokine 
activity, cell death and muscle fibre necrosis (86). 
1.8.2 Immunogenetics 
Evidence for a genetic basis for IIM has largely accumulated through candidate 
gene studies, although a familial predisposition is suggested from case reports of 
familial clustering (87). Candidate gene studies have confirmed that HLA-
DRB1*0301 and HLA-DQA1*0501 are definite risk factors for the development of 
Caucasian IIM (9, 87-89). These alleles form part of the conserved, ancestral 
Caucasian haplotype, A1-B8-Cw7-DRB1*0301-DQA1*0501. Recent studies have  
confirmed IIM in different ethnic groups are associated with different HLA-DR and 
DQ alleles (8, 89-91). 
Major histocompatibility complex (MHC) differences exist between the traditional  
clinical PM and DM sub-types, where HLA-DRB1*07 confers risk for DM but is 
protective for PM (9). The 8.1 ancestral MHC haplotype, (HLA-B*08-DRB1*03-
DQA1*05-DQB1*02) is associated with adult and juvenile IIM (9, 10), where the 
strongest signal appears to come from the HLA class I region (89, 92). Furthermore, 
TNF-308A single nucleotide polymorphisms (SNP) are associated with IIM, but only 
due to strong linkage disequilibrium with HLA-B*08, thus forming part of an 
extended 8.1 haplotype (92). Clinical phenotype is more strongly associated with 
myositis autoantibodies than with traditional clinical sub-type in adult Caucasian IIM 
(9, 89). HLA class II haplotype (DRB1-DQA1-DQB1) is in turn associated with 
antibody status. For example in adults, the DRB1*07-DQA1*02-DQB1*02 haplotype 
is strongly associated with anti-Mi-2, whereas the 8.1 haplotype is strongly 
associated with anti-Jo-1 autoantibodies (see also Section 1.6.2) (9). 
1.8.3 Environmental factors 
Environmental triggers may also influence the development of myositis. Evidence 
implicating potential environmental factors includes the observation that seasonal 
patterns are associated with the development of specific IIM-serological syndromes 
e.g. anti-Jo-1 positive patients have been shown to develop disease in the Spring 
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(93, 94). In a recent study, seasonal birth patterns in myositis subgroups suggested 
an aetiological role of early environmental exposures (95). In particular, birth 
distributions appeared to have a stronger seasonal association in JDM, suggesting a 
potential role for specific perinatal exposure. 
There is evidence to suggest an aetiological role of ultra-violet (UV) light in the 
pathogenesis of autoimmune CTD. From a clinical perspective SLE and DM are 
associated with photosensitive rashes, and disease flares can be induced by 
sunlight exposure. Studies have demonstrated that UV-B light induces apoptosis of 
keratinocytes, which leads to the redistribution of certain intracellular proteins that 
are classically recognised by SLE-associated autoantibodies (96-98). In particular, 
autoantigens were shown to be clustered into two distinct populations, either in 
surface blebs or larger surface bodies on apoptotic cells (96). Apoptotic blebs 
contained cytoplasmic components including fragmented endoplasmic reticulum and 
the Ro52 protein. Apoptotic bodies contained nuclear associated autoantigens, 
nucleosomal DNA, Ro60, La, and the small nuclear ribonucleoproteins. These 
findings implicate apoptotic cells as an important potential source of concentrated or 
modified autoantigens that may drive autoantibody production and skin disease in 
SLE (97). Similar to SLE, there is evidence to suggest an aetiological role of UV-
light in the pathogenesis of DM. Firstly, the incidence of DM cases has been shown 
to be higher in countries with a latitudinal gradient towards the equator  (99). 
Secondly, surface UV-radiation intensity has been shown to be associated with the 
relative frequency of DM cases, especially those with anti-Mi-2 autoantibodies 
(classically associated with hallmark cutaneous DM lesions, see section 1.6.4.1). 
Collectively, this data provides insight into the possible aetiological mechanisms of 
the development of DM. 
1.8.4 Autoantibodies and targeted autoantigens 
The identification and characterisation of autoantibodies is an important cornerstone 
in the diagnosis of autoimmune CTD (4, 100, 101). Autoantibodies target nuclear or 
cytoplasmic intra-cellular components and specific profiles are associated with 
clinical phenotypes within the CTD disease spectrum. Autoimmunity is characterised 
by the loss of tolerance to self-proteins or autoantigens. In recent years there have 
been several attractive paradigms proposed to explain why certain seemingly 
ubiquitously expressed proteins are selectively targeted by autoantibodies. 
Autoantigens appear to be critical partners in driving autoreactivity, unified by their 
susceptibility to cleavage by certain apoptotic substrates. Studies have 
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demonstrated the protease granzyme B, an enzyme released by cytotoxic T cells, 
generates a unique form of apoptosis that leads to the cleavage of certain intra-
cellular proteins into novel fragments. These fragments become clustered and may 
trigger autoreactive responses. This mechanism has been strongly implicated in the 
pathogenesis of several autoimmune diseases including SLE, SSc and IIM (96, 97, 
102-106). Furthermore, this apoptotic trigger is likely to occur in specific pro-immune 
microenvironments and there is now emerging evidence to suggest that specific 
autoantigens are upregulated in different cell types and lesional tissues, particularly 
in IIM (107, 108). 
1.8.4.1 Autoantibodies in myositis 
Previous studies have shown that autoantibodies are detected in approximately 50-
60% of IIM patients depending on the detection methods used (46, 109, 110). The 
standard techniques have included immunofluorescence on human-epithelial cell 
lines (HEp-2 cells), generic or antigen-specific ELISA tests, immunodiffusion and 
counter-immunoelectrophoresis. More specific techniques including immunoblotting 
and in particular protein radioimmunoprecipitation (IPP) have the advantage of being 
able to detect novel autoantigen targets. The major advantage of IPP is that it 
identifies those autoantibodies that target conformational epitopes. In addition, novel 
targets are amenable to identification using a proteomic approach. The identification 
and characterisation of novel autoantibody subsets in IIM in this study are based on 
the method of IPP. 
Autoantibodies in IIM can be divided broadly into two groups, myositis-specific 
autoantibodies (MSAs) or myositis-associated autoantibodies (MAAs). MAAs are 
found in myositis overlap syndromes, in particular SSc, MCTD and SLE. In general, 
MSAs are unique to PM and DM, and the previously described specificities are 
outlined below. See Tables 1 and 2, and Figure 1. 
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Anti-synthetase autoantibodies 
Autoantibodies against the cytoplasmic aminoacyl-tRNA synthetase enzymes (ARS) 
are the most frequently detected in adult patients with myositis. The first to be 
described and most common autoantigenic target is Jo-1 (histidyl tRNA-synthetase) 
(111), which is found in approximately 20% of IIM patients (112, 113)  . 
Autoantibodies to six other ARS molecules; PL-7 (threonyl), PL-12 (alanyl), EJ 
(glycyl), OJ (isoleucyl), KS (asparaginyl) and Ha (tyrosyl) have been described 
collectively in approximately 20% of patients with IIM (frequency of patients with 
each non-Jo-1 anti-ARS is between 1-5% (114-119). A further anti-ARS termed anti-
Zo (phenylalanyl) has been discovered by our group and will be described in 
Chapter 4 (120). The ARS are a distinct group of enzymes that catalyse the binding 
of specific amino acids to their cognate tRNA for incorporation into growing 
polypeptide chains. The anti-ARS autoantibodies define the anti-synthetase 
syndrome, which has been described in Section 1.5.1. 
Anti-SRP autoantibodies 
Patients with autoantibodies to the signal recognition particle (SRP) appear to form 
a further distinct clinical and histopathological subset. Reeves et al were the first to 
report SRP as an autoantigen target in myositis (121). The SRP autoantigen is a 
ribonucleoprotein complex (proteins-7SLRNA) with the 54 kDa and 72 kDa 
polypeptides most frequently targeted. The cytoplasmic SRP protein recognises 
secretory or membrane bound proteins and regulates protein translocation through 
the endoplasmic reticulum. Anti-SRP autoantibodies are found in approximately 5% 
of patients with IIM (122, 123). Patients with anti-SRP can present with acute onset 
severe myopathy with significant muscle enzyme elevation and systemic features 
including dysphagia that can be refractory to standard treatments (123, 124). 
Anti-Mi-2 autoantibodies 
Anti-Mi-2 is classically detected in adult and juvenile patients with DM clinical 
features. Anti-Mi-2 is detected in between 5-20% of patients with DM (6, 10, 125-
128). Mi-2, a nuclear helicase protein forms part of the nucleosome remodelling 
deacetylase (NuRD) complex, which plays a role in gene transcription (129). This 
autoantibody specificity is described in patients with hallmark cutaneous DM lesions 
including Gottron’s papules, heliotrope rash, cuticular overgrowth and the V-sign / 
Shawl-sign. Moreover, patients may have milder muscle involvement with a lower 
risk of interstitial pneumonia and respond well to therapy (6, 125-127). 
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Anti-CADM-140 autoantibodies 
A novel autoantibody specificity termed anti-CADM-140 in a Japanese cohort  
associated with CADM and rapidly progressive  interstitial pneumonia (130). This 
autoantibody specificity was not seen in classic DM, PM or any other CTD cases. 
Using a series of molecular techniques the CADM-140 autoantigen has recently 
been identified as the cytoplasmic protein melanoma-differentiation associated gene 
5 (MDA5) (131). MDA5 is involved in innate immune responses against viral 
infections (132). 
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Table 1: Myositis-associated autoantibodies, autoantigen targets and clinical 
features 
Autoantibodies 
Anti-U1-RNP 
Autoantigen and function 
snRNP ribonucleoprotein 
complex 
Splicing mRNA 
Clinical Phenotype 
Mixed connective tissue disease – 
overlap features including myositis, 
arthritis, sclerodactly, Raynaud’s, 
diffuse parenchymal lung disease, 
pulmonary hypertension 
Anti-Ro52/60 Ro ribonucleoprotein complex 
(proteins hYRNA) 
SLE, Sjogren’s, overlap myositis, 
reported in association with anti-
ARS autoantibodies 
Binding to DNA and 
transcription factors 
Anti-PM-Scl Nucleolar multi-protein 
Biogenesis of ribosomes 
Myositis-scleroderma overlap 
Anti-U3-RNP Nucleolar fibrillarin 
ribonucleoprotein 
Pre-ribosomal RNA processing 
Myositis-scleroderma overlap 
Anti-Ku Heterodimer Ku-p350 complex 
DNA repair and phosphorylation 
of transcription factors 
Myositis-scleroderma overlap 
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Table 2: Myositis-specific autoantibodies, autoantigens and clinical features 
Autoantibodies Autoantigen and function Clinical Phenotype 
Anti-ARS 
Anti-Jo-1 
Anti-PL-7 
Anti-PL-12 
Anti-EJ 
Anti-OJ 
Anti-KS 
Anti-Ha 
Anti-SRP 
ARS – intracytoplasmic protein 
synthesis (binding of specific amino 
acid to its cognate tRNA for 
incorporation into polypeptide 
chains) 
Histidyl 
Threonyl 
Alanyl 
Glycyl 
Isoleucyl 
Asparaginyl 
Tyrosyl 
SRP – intracytoplasmic protein 
translocation from ribosome into 
endoplasmic reticulum 
Anti-synthetase syndrome 
Myositis, mechanic’s hands, 
Gottron’s papules, arthritis, 
fever, Raynaud’s 
phenomenon, high frequency 
of interstitial pneumonia 
Acute onset necrotizing 
myopathy 
Anti-Mi-2 
(6 polypeptides and 
ribonucleoprotein 7SLRNA) 
Helicase nuclear protein -
transcription, remodelling of 
nucleosomes 
Hallmark cutaneous DM, 
milder muscle disease 
Anti-CADM-140 Intracytoplasmic MDA5 – innate 
immune responses against viral 
infections 
CADM 
Rapidly progressive interstitial 
pneumonia 
ARS, aminoacyl-tRNA synthetases; SRP, signal recognition particle; NuRD, 
nucleosome remodelling histone deacetylase; MDA5, melanoma-differentiation 
associated gene 5; DM, dermatomyositis; CADM, clinically-amyopathic 
dermatomyositis. 
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Figure 1: Autoantibodies in myositis and systemic sclerosis 
1A: Systemic sclerosis and myositis overlap 
Systemic sclerosis specific: 
 Topo-I: Topoisomerase 
 RNAP I-III: RNA polymerase I-III 
 Centromere 
 Th/To RNP 
Myositis-associated (overlap with systemic sclerosis): 
 U1RNP 
 U3RNP 
 PM-Scl 
 Ku 
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Figure 1 
1B: Anti-synthetase syndrome 
Anti-synthetase syndrome 
 Myositis 
 Raynaud’s phenomenon 
 Arthritis 
 Mechanic’s hands 
 Gottron’s lesions 
 Fever 
 Interstitial pneumonia 
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Figure 1 
1C: Myositis-specific autoantibodies 
 Anti-synthetase – anti-synthetase syndrome 
 Anti-SRP – acute necrotising myopathy 
 Anti-Mi-2 – classic DM with hallmark skin disease 
 Anti-MDA5 – clinically-amyopathic DM with significant lung involvement 
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1.8.4.2 Autoantigens and disease mechanisms 
Identification of autoimmune targets in IIM has led to further insights into 
pathogenesis. Perhaps the most striking feature is that groups of autoantigens with 
analogous cellular functions are associated with similar clinical subsets. For 
example, the target molecules in the anti-ARS autoantibody phenotype (anti-
synthetase syndrome) and the anti-SRP autoantibody phenotype (severe 
necrotizing myopathy) are found in the cytoplasm with distinct functions involved in 
protein synthesis and translation. In contrast, the other myositis autoantigen targets 
are all nuclear proteins involved in gene transcription and DNA processing. Recent 
work has proposed the hypothesis that the dysregulated autoimmune response in 
myositis syndromes is driven by specific antigens in distinct tissue 
microenvironments. Two studies have demonstrated that certain autoantigens are 
enriched in lesional tissue involved in IIM (107, 108). Several myositis-specific and 
associated autoantigens were shown to be upregulated in myositis muscle in 
comparison to normal muscle especially in regenerating muscle cells. Of further 
interest was the observation that Mi-2 was preferentially expressed in DM muscle 
rather than PM muscle. The theory that distinct microenvironments may shape 
disease expression was emphasised with the finding that a novel conformation of 
Jo-1 following cleavage by granzyme B is enriched in the alveolar-epithelial layer of 
the lung in comparison to other tissues including muscle (108). This has lead to the 
suggestion that the initiating target tissue for the autoimmune response in the anti-
Jo-1 syndrome is the lung with secondary attack to muscle. Further evidence 
implicating autoantigen driven responses has been suggested by an antigen-
induced model of IIM following immunisation of congenic mice with murine Jo-1 
protein (133). Antibody responses were species-specific and following immunisation 
mice developed the ASS clinical phenotype with muscle and lung inflammation. The 
potential role of other autoantigens driving autoimmunity in IIM has been highlighted 
by work on the chromatin remodeler Mi-2. Using a conditional transgenic mouse 
model, a major function of the Mi-2 protein has been elucidated (134). In particular, 
Mi-2 is essential for development and repair of the basal epidermis, this observation 
may give further insight into the pathogenic mechanisms of the anti-Mi-2 
autoantibody clinical subset, of which the predominant clinical manifestation is skin 
disease. Further evidence to suggest a central pathogenic role of the autoantigen in 
IIM comes from the demonstration that certain autoantigenic ARS proteins, histidyl 
(Jo-1) and asparaginyl (KS) can induce leukocyte migration. In contrast, non -
antigenic ARS (aspartyl-tRNA and lysyl-tRNA synthetases) were not chemotactic. 
The study proposed that autoantigenic ARS are over-expressed in damaged muscle 
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cells; their pro-inflammatory properties promote the immune response and thus the 
development of myositis (135). See Section 1.6.5, Figure 2. 
1.8.4.3 MSAs and histopathological associations 
There is also evidence to suggest that there are histopathological associations with 
certain MSAs, which highlights the overlap between the broad IIM subtypes. For 
example, patients with ASS associated myositis have distinct histopathological 
features with prominent perimysial inflammation, connective tissue fragmentation 
and perifascicular myopathic changes, in contrast to endomysial inflammation (136). 
Also, typical histopathological changes have been described in muscle biopsies 
from patients with anti-SRP autoantibodies; sparse inflammatory cell infiltrate, 
prominent muscle fibre necrosis and endomysial fibrosis (123, 124). 
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1.8.5 A proposed model for autoimmunity in IIM 
Figure 2: Initiation of autoimmunity in IIM 
Cleaved autoantigens 
acquire chemokine 
properties 
Environmental factors (e.g. viruses / uv light) 
Genetics 
Expression 
of cellular 
proteins 
Impaired 
clearance 
Autoantibodies 
E.g. Anti-Jo-1 – chemokine 
properties 
Cytokines 
INFLAMMATION 
Novel fragmentation of proteins 
“relocalisation” 
B 
DC 
Cytotoxic Tcell induced apoptosis etc. 
Based on their studies, Casciola-Rosen and Rosen have proposed a hypothesis that 
the dysregulated autoimmune response in myositis syndromes is driven by novel 
patterns of antigen expression or conformation in distinct tissue microenvironments 
(107, 108, 137, 138). It is likely that a specific stimulus, for example tissue injury 
secondary to an infective or a toxic agent leads to a perturbed pro-immune setting 
in a genetically suceptible individual. In IIM, there may be three or four key initiating 
microenvironments i.e. muscle, lung or perhaps even skin or tumour tissue. As a 
result, altered antigen expression and the presentation of novel or previously 
unrecognised epitopes to the immune system leads to a loss of tolerance and 
initiation of disease. Subsequent generation of autoantibodies and generation of T  
cell responses may promote or propagate disease mechanisms. 
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1.9 Aims of study 
As outlined in this chapter, in view of the clinical heterogeneity of these conditions 
diagnosing patients as purely DM or PM is perhaps too broad. Many investigators  
have proposed new sets of criteria based on updated insights. Studies suggest that 
clinical stratification is more appropriate according to the MSA / MAA, as the 
detected autoantibody and clinical phenotype are closely associated (6, 139, 140). 
The hypothesis for this body of research is that adult and juvenile IIM is associated 
with autoantibodies that recognise specific autoantigen systems, which define 
patients into homogeneous clinical phenotypes. To address this hypothesis the 
overall aim of this thesis is to describe a comprehensive clinical and serological 
study of adult and juvenile IIM, including the identification of novel autoantibody 
subsets. 
Aim 1: 
To establish the prevalence  and clinical features, in particular subtypes of 
recognised MSAs in the Royal National Hospital for Rheumatic Diseases (RNHRD) 
adult IIM cohort in comparison to previous published series. 
Aim 2: 
To investigate and characterise novel autoantibody specificities and corresponding 
autoantigen targets in patients recruited to the RNHRD and UK Adult Onset Myositis 
Immunogenetic Collaboration (AOMIC) IIM cohorts. 
Aim 3: 
To perform a clinical and serological study of children with JDM and JDM-overlap 
recruited to the UK and Ireland JDM Registry (UK JDM Cohort Study). To identify 
novel autoantibody-autoantigen systems, define clinical manifestations and thus 
markers of disease severity. 
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CHAPTER TWO 
PATIENTS AND METHODS 
2.1 Patients and sera 
Subjects for the studies described in this thesis were recruited from three sources: 
a) The Royal National Hospital for Rheumatic Diseases Adult Connective 
Tissue Disease Clinic (RNHRD) 
b) The UK Adult Onset Myositis Immunogenetic Collaboration 
c) The Juvenile Dermatomyositis Registry and Repository, UK and Ireland 
2.1.1 Clinical diagnosis 
Adult IIM patients, aged 18 years of age or older at disease onset, were recruited  
through the RNHRD and the UK Adult Onset Myositis Immunogenetic Collaboration, 
(AOMIC) (9). JDM patients were recruited to the UK and Ireland JDM National 
Registry and Repository (JDRR) (24). The JDRR has recruited patients with 
juvenile-onset myositis, below the age of 16 years at disease onset and diagnosis. 
All adult PM/DM and JDM cases had probable or definite disease according to 
Bohan and Peter criteria  (1, 2). For adult myositis/CTD-overlap cases recruited to 
AOMIC, patients were included if they fulfilled all of the following: a) met published 
criteria for their primary CTD or mixed connective tissue disease (MCTD)  (11, 12, 
141, 142); b) possessed at least two of four Bohan and Peter criteria; (c) possessed 
at least one MSA/MAA. JDM-scleroderma overlap (JDM-SSc) was defined as JDM 
children with a history of Raynaud’s phenomenon, sclerodactly and other 
sclerodermatous skin changes (two or more of the above features). 
Demographic and clinical data were recorded at diagnosis using standardised 
proformas (see Section 2.1.2 and 2.1.3). Serial clinical data was also available on  
patients attending the RNHRD and recruited through the JDRR. Data were stored 
using anonymous codes onto a central database. Serum and DNA samples were 
taken at the time of diagnosis and stored at -20oC until required. 
2.1.2 Adult-onset inflammatory myopathy clinical proformas 
See Chapter 2.5, Appendix I-III, pages 50-52. 
2.1.3 Juvenile-onset inflammatory myopathy clinical proformas 
See Chapter 2.5, Appendix IV, pages 53-60. 
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2.1.4 Preparation and storage of sera 
Serum samples: approximately 5 ml of blood was venesected into a standard clotted 
sample tube. Once the blood had clotted, tubes were centrifuged at 3000 rpm for 10 
min (Hereaus Labofuge 6000 Centrifuge). The serum fraction was extracted with a 
pipette into 500µl aliquots (adult samples) or 150µl aliquots (juvenile samples). 
Serum samples were stored at -20ºC. 
2.1.5 Ethical approval 
Collection of data and blood from patients and controls was undertaken under the 
regulation of the local research ethics committees and informed consent was 
obtained according to the Declaration of Helsinki. 
2.2 Tissue culture techniques 
All techniques were performed in class II tissue culture cabinets with sterile 
equipment. All reagents and media were purchased from Sigma, UK unless  
otherwise stated. 
2.2.1 Preparation of tissue culture media 
RPMI media 
One litre of RPMI-1640 medium (with NaHCO3, without L-glutamine) was 
supplemented with 10 ml 200 mM L-glutamine solution. Additionally, 100 ml foetal 
calf serum (heat inactivated) was also added for RPMI + FCS (10% foetal calf  
serum). 
Preparation of dialysed foetal calf serum (FCS) 
Two sections of dialysis tubing were cut (1 metre each, medium width), placed in a 
beaker of tap water and left under a running tap for 3-4 hr. The tubing was 
transferred to 300 ml 3% (v/w) sodium sulphide at 80ºC for 1 min, 300 ml distilled 
water at 60ºC for 2 min and 300 ml 0.2% (v/v) sulphuric acid at room temperature 
for 1 min before being rinsed in distilled water. Tubing was finally placed in 200 ml 
0.02% (w/v) sodium azide and stored at 4ºC. 
500 ml FCS was thawed at 37ºC overnight and PBS (2 x 3 l) was cooled at 4ºC 
overnight. The following day, lengths of treated dialysis tubing were rinsed in 
distilled water. FCS was transferred to the treated dialysis tubing, placed in 3 l cold 
PBS (prepared according to the manufacturer’s instructions) and stirred at 4ºC for 6 
hr. The PBS was replaced with a further 3 l cooled PBS and stirred at 4ºC for a 
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further 22 hr. Dialysed FCS was transferred to a tissue culture flask and sterile  
filtered through a 0.22µM filter unit. Filtered FCS was aliquoted into 50 ml tubes and 
stored at -20ºC until required. The sterility of the dialysed FCS was tested by adding 
2 ml to 20ml RPMI + FCS and incubating at 37ºC for 48 hr. 
Methionine free RPMI media (with dialysed foetal calf serum) 
One hundred ml RPMI-1640 medium (modified) (with NaHCO3, without methionine, 
cystine and L-glutamine) was supplemented with 62 µl 10% (w/v) cystine (prepared 
in 2M HCl and sterile filtered) and 1 ml 200mM L-Glutamine. Five ml dialysed FCS 
was added for methionine deficient RPMI + 5% dialysed FCS. 
2.2.2 Cell culture 
The non-adherent K562 cell line (human chronic myelogenous leukaemic cells) was 
obtained from European Collection of Cell Cultures (Salisbury, UK) (89121407). 
Cells were stored under liquid nitrogen at the University of Bath and transported to 
the cell culture facilities on dry ice. 
Thawing K562 cell lines 
Vials of K562 cells in 90% FCS and 10% DMSO (dimethyl sulfoxide) were  
transferred to dry ice and transported to the BIRD laboratory, RNHRD. Aliquots were 
thawed at 37ºC and added to 50 ml conical tubes containing 45 ml pre-heated RPMI 
+ 10% FCS. Cells were incubated at 37ºC for 10 min, before being centrifuged at 
2000 rpm for 5 min (Heraeus Labofuge 6000). Supernatants were discarded and the 
pellets were resuspended in 25 ml pre-heated RPMI + 10% FCS. Cells were 
transferred to 60 ml flasks containing pre-heated RPMI + 10% FCS. 
K562 cells were cultured and maintained in approximately 50 ml RPMI + 10% FCS, 
in vented, canted, tissue culture flasks. Cells were incubated in a 5% carbon dioxide 
humidifier incubator set at 37 ºC. 
2.3 Serological Methods 
Anti-nuclear autoantibody screening was performed by indirect immunofluorescence 
of NOVALite HEp-2 cells INOVA Diagnostics, UK). Autoantibody specificity was 
further characterised by immunoprecipitation of radiolabelled cell extracts. All 
reagents and media were purchased from Sigma, UK unless otherwise stated. 
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2.3.1 Indirect immunofluorescence 
Serum was incubated against a fixed substrate (HEp-2 cells) to allow binding of 
autoantibodies to their respective antigen(s). A secondary goat polyclonal antibody 
conjugated to fluorescein was incubated against the substrate-antibody used at  
1/150 dilution in the assay). Slides (binding site slides) were mounted and studied 
under a fluorescence microscope. The presence of ANA was recognised by 
particular patterns of fluorescence. 
2.3.2 Radio immunoprecipitation (IPP) of protein targets 
Serum was incubated with protein-A coated Sepharose beads to enable IgG present 
in the serum to bind to the protein-A via the Fc fragment. Beads were washed and 
supernatant removed (to remove any unbound material) and the beads incubated 
with radiolabelled K562 cell extract. Beads were washed further and the supernatant 
removed. Samples were re-suspended in Laemmli sample buffer. Finally, samples  
were boiled to remove and denature bound autoantigens from the Sepharose 
protein-A and radiolabelled proteins were separated by SDS-PAGE electrophoresis. 
Gels were analysed following autoradiography, protein targets were recognised by 
the characteristic gel fingerprint and the molecular weight of the band. 
Figure 3: Protein immunoprecipitation (IPP) 
Immobilise immunoglobulins from serum samples 
using protein-A linked to sepharose beads 
Select autoantibody targets by adding a detergent 
extract of radiolabelled proteins 
Add denaturing agents and separate 
proteins according to size using 
polyacrylamide gel electrophoresis 
YProtein A 
Visualise radiolabelled proteins by autoradiography 
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Preparation of the of K562 cell extract with Methionine410 
K562 culture supernatants from 6 x 150 ml flasks were transferred by pipette to 8 x 
50 ml conical tubes. These were centrifuged at 2000 rpm for 5 min (Heraeus 
Labofuge 6000). Supernatants were sterilely removed and the pellets were pooled 
and re-suspended in 2 conical tubes containing 40 ml methionine free medium 
(without dFCS). Cells were centrifuged at 2000 rpm for 5 min and the supernatants 
sterilely removed. Pellets were re-suspended in 2 conical tubes each containing 40 
ml methionine free medium (with FCS). A cell count (1/10 dilution) was completed 
on each tube. 120 x 106 cells were added to 4 x 120 ml flasks and the flasks were 
topped up to 120 ml with methionine free medium (with dFCS). Cells were incubated 
at 37°C for 40 min. Two hundred and fifty µl radioactive methionine (Perkin-Elmer, 
UK EasyTag L-35S-Methionine, 5mCi (185 MBq) Stabilised Aqueous Solution) was 
added to each flask. The flasks were gently mixed and left at 37°C overnight. 
Culture supernatants were poured into 8 x conical tubes and were centrifuged at  
2000 rpm for 5 min. The supernatants were discarded and the pellets pooled in 1 x 
conical tube containing 40 ml ice-cold Tris Buffered Saline (TBS) (10 mM Tris-HCl 
pH 7.4, 150 mM NaCl). A cell count was completed prior to centrifugation at 2000 
rpm for 5 min. Supernatant was discarded and the cells were re-suspended in ice-
cold immunoprecipitation (IPP) buffer (10 mM Tris-HCl pH 8.0, 500 mM NaCl 0.1% 
v/v Igepal) at a concentration of 12 x 106 cells / ml. The extract was sonicated using 
a Soniprep 150 MSE sonicator over iced-water in 7.5 ml batches (amplitude 4.5, 1 
min on, 20 sec off x 4 or until no viscous lumps remained). Sonicated extract was 
pooled into a fresh 50 ml conical tube and then aliquoted into 1.5 ml tubes. Extract 
was centrifuged at 120000 rpm for 20 min at 1°C (MSE Hawk 15/05). Supernatants 
were pooled, transferred to fresh tubes 1.5 ml tubes (1 ml aliquots); snap frozen in 
dry-ice and ethanol and stored at -80°C. Any radioactive contamination was cleaned 
up using lipsol and appropriate standard operating procedures. 
Preparation of protein-A Sepharose beads 
Protein-A Sepharose beads were washed and hydrated in 40 ml IPP buffer by 
rotation at room temperature for 30 min. Hydrated Sepharose beads were 
centrifuged at 1100 rpm for 1 min (Heraeus Labofuge 6000). Supernatant was 
discarded and the pelleted beads were re-washed in 40 ml IPP buffer. Samples 
were re-centrifuged at 1100 rpm for 1 min, the supernatant was discarded and 
beads were re-suspended in IPP buffer at a concentration of 2 mg / ml. 
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Immobilisation of Antibodies 
For each sample, 10 µl patient sera was mixed with 2 mg hydrated, washed protein-
A Sepharose beads in 500 µl IPP buffer at room temperature for 30 min with end-
over-end rotation. Autoantibody-coated Sepharose beads were pelleted at 2000 rpm 
for 1 min (MSE Hawk 15/05). Supernatant was discarded and the beads re-
suspended in 1 ml ice-cold IPP buffer. The beads were washed a further 3 times by 
pelleting at 2000 rpm for 1 min, removing the supernatant and re-suspending in 1 ml 
ice-cold IPP buffer. After pelleting a final time at 2000 rpm for 1 min, the supernatant 
was discarded and the beads were resuspended in 380 µl ice-cold IPP buffer 
Immunoprecipitation of Antigen 
Radiolabelled K562 cell extract was thawed and 120 µl was added to each sample. 
Samples were mixed with end-over-end rotation at 4°C for 2 hr. Samples were 
centrifuged at 2000 rpm for 1 min and the supernatant discarded. Beads were 
washed 3 times in IPP (as outlined in the paragraph above) and once in 1 ml ice 
cold TBS. Beads were pelleted a final time at 2000 rpm for 1 min, the supernatant 
was discarded and beads were re-suspended in 50 µl SDS Laemmli sample buffer. 
Samples were vortexed briefly and stored at -80°C until required. 
2.3.3 SDS polyacrylamide gel electrophoresis 
Assembly of apparatus 
The Maxi gel electrophoresis equipment (Hoefer, UK) was assembled according to 
manufacturer’s instructions. Glass plates were washed with water, dried and 
cleaned with methanol. One ml thick spacers separated Glass plates and 15 well 
combs were used. 
Preparation of gels 
A 10% resolving gel was used as the standard for this procedure (see Chapter 2, 
Appendix V for gel recipes). Resolving gel mixture was poured into the assembled 
gel apparatus up to 2 cm from the top of the glass plates. Water saturated butan-2-
ol (approximately 300 µl) was layered onto the top of each gel. Gels were left for at 
least 15 min to polymerise prior to being rinsed with distilled water. The components 
for a 5% stacking gel were mixed and layered on top of the resolving gel to the top 
of the glass plates. Teeth combs were inserted to approximately 1 cm from the top 
of the resolving gel. The stacking gel was left to polymerise for approximately 15 min 
prior to the combs being removed and the wells rinsed with distilled water. 
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Sample preparation 
Immunoprecipitated samples were taken out of the -80°C freezer to thaw. Samples 
were placed into the heating block and boiled at 95°C for 4 min, removed and briefly 
vortexed. Samples were centrifuged at 2000 rpm for 1 min (MSE Hawk 15/05) to 
pellet the beads. 
Gel loading and electrophoresis 
Wells were loaded with 25 µl supernatant per sample. On each gel, 1 well was 
reserved for 15 µl pre-stained molecular weight marker (Biorad, UK). When not all  
the wells were used samples were spaced evenly across the gel. Once loaded, the 
gel apparatus was fully assembled according manufacture’s instructions and 
transferred to the buffer chamber along with a cooling coil. Four L running buffer (25 
mM Tris-base, pH7.4 190 mM Glycine and 0.1% w/v SDS) was added to the lower 
chamber and 500 ml running buffer was added to the upper chamber. A constant 
current of 60 mA was run until the dye from the sample buffer and markers had 
passed through the stacking gel layer (approximately 1 hr). The current was then 
increased to 120 mA run until the dye had passed through the resolving gel 
(approximately 3 hr). 
Gel fixing and drying 
Gels were removed from the glass plates and the stack layers discarded. The 
resolving gels were soaked in 0.5M sodium salicylate (enhancer) for 15 min in 
shallow trays. Salicylate solution was discarded; gels were rinsed in distilled water 
and placed in gel fix solution (methanol:water:glacial acid (4.5 :4.5:1 ratio)) for 30 
min on a rocking platform. The fixative was drained off and the gels transferred onto 
blotting paper. The gels and blotting paper were placed on a gel dryer (Rapidry gel 
dryer ATTA Electrophoresis) and covered with cling-film. Gels were dried at 70°C for 
70 min. 
Autoradiography 
Labelled proteins were analysed by autoradiography. In a dark room, dried gels 
were placed into X-ray cassettes and overlaid with Kodax Biomax film (mat side 
down). Cassettes were stored in a -80°C freezer for 1-4 weeks (time stored was 
dependant on the age of the radioactive preparation and the immunoreactivity of the 
autoantigen target). Development of films was undertaken manually in the dark 
room. Films were placed in 47 ml Kodax developer solution mixed with 460 ml 
distilled water for 2 min (until bands were exposed). Films were rinsed in distilled 
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water and placed into 47 ml Kodax fixer solution mixed with 460 ml distilled water for 
5 min. Films were immersed in distilled water again and then left to dry at room  
temperature. 
See Chapter 2, Appendix VI, Table 3: summary data of molecular weights / apparent 
molecular weight run on 10% SDS-PAGE of recognised myositis-specific 
autoantigen targets. 
2.3.4 Immunodepletion 
See 2.3.2 for basic IPP methods and reagents. This technique was used to establish 
whether autoantibodies that recognised a novel autoantigen of the same molecular 
weight (in specific patient cohorts) were targeting the same protein specificity. In 
summary, radiolabelled cell extracts were immunoprecipitated with prototype sera 
(sera known to contain the novel autoantibody specificity): Serum was incubated 
with protein-A bound Sepharose beads and incubated with radiolabelled K562 cell 
extract. On this occasion, the pelleted beads bound to the autoantibody-autoantigen 
complex were removed and the supernatant (unbound cell extract) preserved. This 
procedure was repeated to ensure complete depletion of the target antigen from the 
cell extracts. Reference depleted cell extracts were then used for further 
immunoprecipitations with other autoantibody positive sera. 
In detail, for each sample, duplicate tubes each containing 10 mg hydrated protein-A 
Sepharose beads (prepared as Section 2.3.2) and 50 µ l reference sera in 1 ml IPP 
buffer were mixed with end-over-end rotation at room temperature for 30 min. 
Autoantibody-coated Sepharose beads were washed 4 x in IPP buffer (see section 
2.3.2). After the beads were pelleted for the final time, supernatants were discarded. 
One tube for each sample (A) was placed on ice, whilst 150 µ l [35S]-methionine-
labelled K562 cell extract and 380 µl IPP buffer was added to the remaining tube 
(B). Tube B was mixed with end-over-end rotation at 4°C for 2 hr after which the 
supernatant was transferred to tube A. This was mixed at 4°C for a further 2 hr. The 
supernatant from tube A was transferred to a fresh tube (C) and stored at -80°C. 
Immunoprecipitations using positive sera and either 120µl control [35S]-methionine-
labelled cell extract or the immunodepleted supernatants (C) were completed and 
subject to SDS-PAGE electrophoresis as described in Section 2.3.2. 
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2.3.5 Immunoprecipitation Western Blotting 
Immunoprecipitation Western Blotting (IPP-WB) was used to determine the identify 
of specific autoantigens recognised by autoantibodies. Autoantigens were selected 
from patient’s sera by immunoprecipitation and SDS-PAGE. Proteins were 
transferred to nitrocellulose membrane by immunoblotting. Membranes were 
incubated in a protein rich solution to block any remaining non-specific binding sites 
and probed with commercial antibody to a specific protein. Membranes were 
incubated with an appropriate secondary labelled anti-immunoglobulin followed by a 
conjugated staining substrate. 
Preparation of unlabelled K562 cell extract 
K562 cultures were grown to confluence in 6 flasks each containing 150 ml 
complete RPMI with FCS (see section 2.2.1). Supernatants were transferred to 8 x 
50 ml conical tubes and centrifuged at 2000 rpm for 5 min (Heraeus Labofuge 
6000). Supernatants were removed and the pellets resuspended in 2 x conical tubes 
each containing 40 ml ice-cold TBS. A cell count (1/10 dilution) was completed on 
each tube. Cells were centrifuged at 2000 rpm for 5 min, the supernatants were 
discarded and the pellets combined in a single conical tube containing ice-cold IPP 
buffer at a concentration of 15 x 106 cells / ml. Extract was sonicated using a  
Soniprep 150 MSE sonicator over iced-water in 7.5 ml batches (amplitude 4.5, 1 min 
on, 20 sec off x 4 or until no viscous lumps remained). Sonicated extract was pooled 
into a fresh 50 ml conical tube and aliquoted into 1.5 ml tubes. Extract was 
centrifuged at 120000 rpm for 20 min at 1°C (MSE Hawk 15/05). Supernatants were 
pooled, transferred to fresh 1.5 ml tubes (1.2 ml aliquots); snap frozen in dry-ice and 
ethanol and stored at -80°C. 
Antigen preparation for IPP WB 
See 2.3.2 for IPP methods and reagents. Samples, each containing 40 µl serum and 
2 mg hydrated protein-A Sepharose beads (prepared as Section 2.3.2) in 500 ml 
IPP buffer were mixed with end-over-end rotation at room temperature for 30 min. 
Autoantibody-coated Sepharose beads were centrifuged at 2000 rpm for 1 min 
(MSE Hawk 15/05), supernatant was discarded and beads re-suspended in 1 ml 
0.2M tri-ethanolamine pH 8.1. Beads were washed a second time (centrifuged at 
2000 for 1 min and re-suspended in tri-ethanolamine) prior to being centrifuged 
again and re-suspended in 5 mM bis-(sulphosuccinimidyl)-suberate cross-linker 
(Perbio, UK) in 1 ml 0.2M tri-ethanolamine. Beads were mixed with end-over-end 
rotation at room temperature for 30 min and centrifuged at 2000 rpm for 1 min. 
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Beads were re-suspended in 1 ml 50 mM Tris-Cl pH 7.5 and mixed with end-over-
end rotation at room temperature for 15 min. Beads were centrifuged at 2000 rpm 
for 1 min and washed three times in PBS  and two times in ice-cold IPP buffer. 
Beads were incubated in 1 ml unlabelled K562 cell extract with end-over-end 
rotation for 1 hr at 4°C, centrifuged at 2000 rpm for 1 min and resuspended in 1 ml 
fresh K562 unlabelled cell extract. Samples were incubated for a further 1 hr at 4°C 
with end-over-end rotation. Beads were washed 4 times in ice-cold IPP buffer and 
once in TBS. Samples were finally re-suspended in 80 µl SDS sample buffer and 
stored at -80°C until required. 
SDS-PAGE and transfer 
Proteins were fractionated using by 10% SDS-PAGE as per standard methods (see 
2.3.3), however samples were loaded at 80 µ l per lane. During the electrophoresis, 
blotting sheets and nitrocellulose membranes were soaked in Transfer Buffer pH7.4 
(40mM tris, 20 mM Sodium acetate, 2mM EDTA, 20% v/v methanol and 0.1% w/v 
SDS). Once electrophoresis had been completed, gels were placed in the 
immunoblotting transfer apparatus according to manufacturers’ instructions. 
‘Transfer sandwiches’ were prepared as scotchbrite, blotting paper, nitrocellulose 
membrane, gel, blotting paper and scotchbrite. The surfaces of the ‘transfer 
sandwiches’ were smoothed over to remove any air-bubbles. The ‘transfer 
sandwiches’ were placed into the tank apparatus that was filled with Transfer Buffer. 
A cooler system was inserted and proteins were transferred from the gels to the 
nitrocellulose membranes using a constant current at 220 mA for 4.5 hr. 
Nitrocellulose sheets were removed and the corners were marked. Membranes 
were rinsed in distilled water and were Ponceau stained for 5 min. Membranes were 
rinsed again for 4 x 15 sec in distilled water and air-dried overnight. Membranes 
were stored in a sealed container at 4°C until required. 
Immunoblotting and staining 
Membranes were washed in PBS-0.05%Tween for 5 min and blocked for 90 min in 
block solution (5% milk powder in PBS-0.05%Tween, pH7.4). Membranes were 
incubated with commercial primary antibody (diluted in block solution accordingly to 
manufacturer’s instructions) for 90 min. Membranes were washed 5 x 5 min in PBS-
0.05%Tween and re-incubated with the corresponding secondary antibody 
(commercial anti-IgG) at a 1:20000 dilution for 90 min. Membranes were washed 5 x 
5 min in PBS-0.05%Tween and finally incubated in substrate stock for 10-20 min. 
Membranes were rinsed with distilled water for 5 min and air-dried overnight. 
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2.4 Statistical analysis 
Clinical and autoantibody associations were derived from 2×2 contingency tables 
using the chi-squared test with Yates’ continuity correction, or two-tailed Fisher’s 
exact test where individual cells valued five or less. Where significant, data were 
expressed as odds ratios (OR) with exact 95% confidence intervals (CI). Where data 
was not normally distributed the Mann-Whitney-U test was used to compare 
continuous data. Median values (inter-quartile ranges) were expressed where 
appropriate. P values (Pcorr) were adjusted using the Bonferroni correction when 
comparing clinical associations. Uncorrected probabilities are presented for possible 
clinico-serological associations. P values <0.05 were considered significant. SPSS 
for Windows (version 14) was used to perform statistical analysis. 
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2.5 Appendix 
I. RNHRD Clinical proforma (Page 50) 
II.	 AOMIC Clinical Proforma (Page 51) 
III.	 Autocure Clinical Proforma (Page 52) 
IV.	 JDRR clinical Proforma (forms 1 and 2) (Pages 53-60) 
V.	 Reagents and gel recipes (Pages 61-63) 
VI.	 Table 3: Summary data of molecular weights / apparent molecular weight run 
on 10% SDS-PAGE of recognised myositis-specific autoantigen targets 
(Page 64) 
Permission to reproduce AOMIC, Autocure and JDRR proformas granted by: 
*Dr. Hector Chinoy, Consultant Senior Lecturer, University of Manchester 
**Prof. Lucy Wedderburn, Scientific Director, JDRR, University College London 
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V. Reagents 
 RPMI x1 liquid (Sigma)

 10% FCS or FBS (Sigma)

 L-glutamine, 200mM (Sigma)

 Methionine free medium; solid (Sigma)

 L-leucine; solid (Sigma)

 L-lysine; solid (Sigma)

 Sodium bicarbonate (Tissue culture grade, Sigma)

 S35 methionine (Amersham Biosciences (GE Healthcare) AG 1095 5mCi)

 Protein A or protein G sepharose beads (Sigma)

 Immunoprecipitation (IPP) buffer

(10mM Tris/HCl, pH 8.0, 500mM NaCl, 0.1% v/v Igepal; previously known as

Nonidet P-40)

 Tris buffered saline (TBS) buffer

(10mM Tris/HCl, pH 7.4 + 150mM NaCl)

 Sodium Phosphate (crosslinking for MS)

0.1M Sodium Phosphate pH8.1 (0.1M NaH2PO4 to 500ml 0.1M Na2HPO4 until 
pH=8.1) 
 Tris-Cl (crosslinking stop buffer)

1.0M Tris base pH7.5

 Triethanolamine (crosslinking reaction buffer)

0.2M Triethanolamine pH8.1

 Laemmli sample Buffer (SDS-PAGE)

Sigma S3401

 Western Blot Substrate

Sigma B1911

 SDS-PAGE Marker

Biorad Kaleidoscope Marker - 161-0324

 Blocking powder (Western Blot)

5% Sainsburys semi-skimmed milk powder, pH 7.4 (with NaOH)

 PBS-Tween

PBS with 0.05% Tween

 Phosphate Buffered Saline

Sigma P4417 (1 tablet per 200 ml water)

 Western Blot Transfer Buffer

40 mM Tris, 20 mM Sodium Acetate and 2 mM EDTA

pH 7.4 with acetic acid

Trizma base (Sigma)
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V. Reagents 
 Glycine 
 Sodium chloride (BDH) 
 Conc. HCl (Sigma) 
 Glacial acetic acid (Sigma) 
 PBS tablets (Sigma) 
 Acrylamide/bis-acrylamide, 30% solution (Sigma) 
 Ammonium persulphate (Sigma) 
 Kalidescope markers, broad range containing glycerol, protein and 
bromophenol blue (Bio-Rad) 
 TEMED (Sigma) 
 Sodium dodecyl sulphate (SDS), (Sigma) 
 Sample buffer containing mercaptoethanol, glycerol, bromophenol blue, tris 
and SDS (Sigma) 
 Methanol (Sigma) 
 Butan-2-ol (Sigma) 
 Sodium salicylate (Sigma) 
 DMSO (Sigma) 
 Trypan blue (Sigma) 
 Conc. Sulphuric acid (BDH) 
 Sodium sulphide (Sigma) 
 Sodium azide (Sigma) 
 pH buffer standards (Lab 3) 
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V. Gel recipes 
Percentage acrylamide in gel mixture (volumes are per gel) 
Vol (ml) 5% 8% 9% 10% 12.5% 15% 
Water 11.8 14.5 13.5 12.5 10 7.5 
Lower gel buffer 7.5 7.5 7.5 7.5 7.5 
Upper gel buffer 5 
Acrylamide mixture 3.2 8 9 10 12.5 15 
AMPS 0.1 0.21 0.175 0.15 0.11 0.09 
TEMED 0.03 0.06 0.04 0.03 0.02 0.02 
Total volume ~20 ~30 ~30 ~30 ~30 ~30 
30% (w/v) acrylamide:bisacrylamide (30:5:1) 
Lower gel buffer stock: 1.5M Tris/HCl, pH 8.8 + 0.4% (w/v) SDS 
Upper gel buffer stock: (*5% upper gels in this procedure) 0.5M Tris/HCl pH 6.8 + 
0.4% (w/v) SDS 
10% (w/v) ammonium persulphate 
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VI. Table 3: Summary data of molecular weights / apparent molecular 
weight run on 10% SDS-PAGE of recognised myositis-specific autoantigen 
targets 
Autoantigen Molecular Weight Runs at (10% SDS-
(kDa) PAGE) (kDa) 
Jo-1 Histidyl-tRNA synthetase 57.4 52 
PL-7 Threonyl-tRNA synthetase 83.4 80 
PL-12 Alanyl-tRNA synthetase 106.7 110 
KS Asparaginyl-tRNA synthetase 62.9 65 
EJ Glycyl-tRNA synthetase 83.1 75 
OJ Multi-enzyme complex 
Leucyl-tRNA synthetase 125.0 130 
Isoleucyl-tRNA synthetase 145.0 150 
Glutaminyl-tRNA synthetase 160.0 170 
Ha Tyrosyl-tRNA synthetase 59 62 
SRP Signal recognition particle 262.3 240 
Mi-2 SNF2 super-family helicase 55.7 54 
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CHAPTER THREE 
RESULTS 
RNHRD clinico-serological study of myositis-specific autoantibodies in adult-
onset inflammatory myositis 
3.1 Introduction 
There is increasing evidence that patients with adult-onset idiopathic inflammatory 
myopathies (IIM); polymyositis (PM) and dermatomyositis (DM) have serological 
profiles within the disease spectrum (7, 46, 112, 139). Myositis specific 
autoantibodies (MSAs) appear to be important prognostic markers and are 
associated with specific clinical features. 
The aim of this study, described in this chapter, was to investigate the prevalence of 
recognised MSAs in the Royal National Hospital for Rheumatic Diseases (RNHRD) 
IIM cohort in comparison to previous published series (6, 46, 112). This study also 
highlights the clinical features associated with the different MSAs, in particular lung 
disease. The work described here has been presented at the British Society of 
Rheumatology 2008 and the American College of Rheumatology 2006: 
 Gunawardena H, Betteridge Z and McHugh NJ. The prevalence and clinical 
associations of myositis specific and associated autoantibodies in idiopathic 
inflammatory myopathy (abstract). Rheumatology 2008;47(S2):ii84. 
 Gunawardena H, Robinson G, Betteridge Z, North J, Carmichael C, Foley 
NM, McHugh NJ. Interstitial pneumonia in polymyositis and dermatomyositis 
(abstract). Arthritis Rheum. 2006;54:S660. 
3.2 Patients and Methods 
3.2.1 Patients 
Patients with a diagnosis of adult IIM (age of onset 18 years or over) were identified 
from the RNHRD CTD database and clinics. Cases of myositis / connective tissue 
disease (CTD) overlap were excluded. The clinical notes were reviewed to confirm 
the diagnosis of PM or DM based on the Bohan and Peter criteria (1, 2), and clinical 
data were retrospectively recorded using a standardised proforma (see Chapter 2, 
Appendix 1). Data recorded included details on initial presentation, creatinine kinase 
(CK) at disease onset and maximum CK during disease course. The degree of 
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cutaneous involvement and other features were noted including the presence of  
lung disease and cancer-associated myositis. 
3.2.2 Assessment of interstitial pneumonia 
High resolution computerised tomography (HRCT) scans were re-reviewed under 
the guidance of Consultant Thoracic Radiologist (GR) and the subtype of interstitial 
pneumonia was categorised based on the American Thoracic Society / European 
Respiratory Society classification (32). 
3.2.3 Serological Methods 
ANA-Immunofluorescence (IIF) 
IIF was previously performed by standard methods (PO and JD) using HEp-2 cells 
and fluorescein-labelled anti-human IgG immunoglobulin (Sigma, UK). The ANA IIF 
results were reviewed from the clinical notes and RNHRD / Bath Institute for 
Rheumatic Diseases serological database. The ANA titre and pattern was recorded. 
Protein Radio-immunoprecipitation (IPP) 
Sera stored at -20oC were thawed at room temperature. IPP from K562 cell extracts 
was performed as previously described in Chapter 2, see Sections 2.3.2 and 2.3.3. 
Briefly, 10 µl sera was mixed with 2 mg protein-A-Sepharose beads (Sigma, UK) in 
IPP buffer (10 mM Tris-Cl pH 8.0, 500 mM NaCl, 0.1% v/v Igepal) at room 
temperature for 30 min. Beads were washed in IPP buffer prior to the addition of 120 
µl [35S] methionine labelled K562 cell extract. Samples were mixed at 4°C for 2 hr. 
Beads were washed in IPP buffer followed by TBS buffer (10 mM Tris-Cl pH 7.4, 
150 mM NaCl) before being resuspended in 50 µ l SDS sample buffer (Sigma, UK). 
After heating, proteins were fractionated by 10% SDS-PAGE, enhanced, fixed and 
dried. Labelled proteins were analysed by autoradiography. 
3.2.4 Ethical approval 
All patients gave fully informed written consent to participate and provide biological 
samples according to the Declaration of Helsinki under local ethical committee 
regulations. 
3.3 Results 
Fifty patients with adult-onset IIM were identified from the RNHRD CTD database. 
The serological profiles and clinical associations are described below: 
66

3.3.1 Serological profiles 
Following IPP, autoantibody specificity was categorised into recognised MSAs, 
myositis-associated autoantibodies (MAAs), unidentified or negative. The frequency 
of recognised MSAs in this cohort of 50 patients was: anti-aminoacyl-tRNA 
synthetases (anti-ARS) 28%, anti-SRP 8% and anti-Mi-2 4%. Fourteen% of cases 
had MAAs (8% anti-PM-Scl, 4% anti-Ro, 2% anti-Ku). Twenty-two% had 
autoantibodies that appeared to recognise distinctive autoantigen bands (see 
Chapter 4). Twenty-four% of patients sera were either negative or precipitated non-
specific bands by IPP. See Table 4 for summary and Figure 4. 
3.3.2 Clinical associations 
The main clinical features of patients with MSAs; anti-ARS, anti-SRP, anti-Mi-2 and 
MAAs (anti-PMScl, anti-Ku, anti-Ro) are described in  Table 5. The clinical 
associations of the novel autoantibody specificities are described in Chapter 4. The 
main clinical features of anti-ARS positive patients (n=14) were arthritis 78.6%, 
mechanic’s hands 57.1%, interstitial pneumonia 71.4% and Raynaud’s phenomenon 
71.4%, and 71.4% initially presented with arthritis or respiratory disease prior to 
myositis onset. Anti-SRP positive patients (n=4) were characterised by severe 
disease; including severe myopathy (median CK 11036 IU/L), with systemic features 
of weight loss (50%) or fever (50%), arthritis (75%) and Raynaud’s phenomenon 
(75%) and cardiac involvement (50%). No anti-SRP patents had interstitial 
pneumonia. Muscle biopsies were available from two anti-SRP-positive patients 
demonstrating predominant muscle fibre necrosis, endomysial fibrosis and scanty 
inflammatory cell infiltrate. Both anti-Mi-2 positive cases had classic DM skin lesions 
and myositis but no other systemic organ involvement. 
3.3.3 Subtypes of interstitial pneumonia 
Ten (71.4%) anti-ARS-positive patients and two (29%) of MAA-positive patients had 
evidence of interstitial pneumonia on HRCT. No anti-Mi-2-positive, anti-SRP-positive 
or autoantibody-negative patients had evidence of interstitial pneumonia. As 
observed in previous studies (28-30, 47, 48), anti-ARS autoantibodies were a 
significant risk factor for interstitial pneumonia in comparison to other autoantibody 
subsets (anti-ARS-negative patients) (Puncorr=0.02, odds ratio 2.4, 95% confidence 
interval 1.3-4.6). The interstitial pneumonia radiological subtypes are described in  
Table 6. 
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The main subtype of interstitial pneumonia observed in anti-ARS-positive cases was 
fibrotic non-specific interstitial pneumonia (NSIP), in 5 out of 10 patients. This HRCT 
appearance was defined by the degree of reticular changes, with predominately a 
subpleural and basal distribution. The fibrosing pattern was homogenous with 
absence of dense fibrosis i.e. no significant traction bronchiectasis or 
honeycombing. Three anti-ARS-positive patients (two anti-PL-7 and one with anti-
PL-12 autoantibodies) had signs consistent with usual interstitial pneumonia (UIP) 
on HRCT, characterised by significant reticular changes including traction 
bronchiectasis and honeycombing. Four patients (two anti-Jo-1-positive and two 
anti-PM-Scl-positive cases) had HRCT features of limited NSIP i.e. predominately 
ground glass pattern, which is suggestive of fine fibrosis or alveolitis with a limited 
subpleural or basal distribution. One patient with limited NSIP had co-existent 
features of organising pneumonia (OP), characterised by patchy air-space 
consolidation, in the same distribution. See Figures 5-7 - HRCT images of 
corresponding interstitial pneumonia subtypes. 
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Table 4: Serological profiles (RNHRD IIM study) 
Frequency (%) 
Autoantibody RNHRD cohort Previous studies** 
(n=50) 
Anti-ARS 
Anti-Jo-1 16 20 
Anti-PL-12 2 <5 
Anti-PL-7 4 <10 
Anti-OJ 2 <5 
Anti-KS 0 <5 
Anti-EJ 0 <10 
Anti-Ha 0 <1 
Anti-Zo* 4 0 
Anti-SRP 8 5 
Anti-Mi-2 4 <10 
Novel autoantibodies* 
-p155/140 kDa target 14 21 
-p140 kDa target 2 0 
-p40/90 kDa target 6 0 
Non-specific or negative 24 n/a 
MAAs 
Anti-PM-Scl 8 <10 
Anti-Ro 4 <10 
Anti-Ku 2 <10 
*Novel autoantibodies: anti-Zo, -p155/140, -p40/90 – see Chapter 4, p140 – see 
Chapter 7 
**References: (112, 143) 
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Table 5: Clinical characteristics of anti-ARS, anti-SRP, anti-Mi-2 and MAA-
positive patients 
Autoantibody

Anti-ARS Anti-SRP Anti-Mi-2 MAAs Negative*

(n=14) (n=4) (n=2) (n=7) (n=12)

Female 79 50 100 71 100 
Median age at onset (yrs) 51.5 48.5 62.5 36 62.5 
Median CK at onset 1421 11036 4092 2347 655 
(IU/L) 
Skin lesions 
Heliotrope 14 0 100 14 25 
Gottron’s 43 0 100 29 33 
Periungal 36 25 0 29 25 
V-sign 0 0 100 0 17 
Shawl-sign 0 0 50 0 17 
Mechanic’s hands 57 0 0 43 8 
Fever 57 50 0 29 8 
Weight loss 36 100 0 57 8 
Dysphagia 0 50 0 14 25 
Raynaud’s 71 75 0 71 25 
Arthritis 79 75 0 57 25 
Interstitial pneumonia 71 0 0 29 0 
Cardiac 0 50 0 0 0 
CAM 0 0 0 0 0 
*Negative or non-specific unidentified bands on IPP 
Percentages are shown unless otherwise stated 
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Figure 4: Immunoprecipitation of myositis-specific autoantigens 
Autoradiogram of 10% SDS PAGE of immunoprecipitates of [35S] labelled K562 cell 
extracts. The reference sera used for immunoprecipitation were; Lane 1: normal 
serum (QC4), Lane 2: anti-Jo-1 (QC78), Lane 3: anti-PL-12 (R12501), Lane 4: anti-
PL-7 (R18134), Lane 5: anti-EJ (AOMIC MM182), Lane 6: anti-KS (AOMIC MM020), 
Lane 7: anti-OJ (AOMIC MM63), Lane 8: anti-Zo (R21845), Lane 9: anti-SRP 
(R7417), Lane 10: anti-Mi-2 (R18411). 
Arrows indicate molecular weights (kDa) –see Chapter 2, Appendix, Table 4 for 
running molecular weights of 10% SDS=PAGE. 
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Table 6: Subtypes of interstitial pneumonia in anti-ARS-positive and MAA-
positive patients (RNHRD IIM study) 
Patient Autoantibody HRCT IP subtype 
R16716 Anti-Jo-1 Fibrotic NSIP 
R9435 Anti-Jo-1 Fibrotic NSIP 
R13077 Anti-Jo-1 Limited NSIP 
R5477 Anti-Jo-1 Fibrotic NSIP 
R12707 Anti-Jo-1 Limited NSIP and OP 
R18134 Anti-PL-7 UIP 
R19896 Anti-PL-7 UIP 
R12501 Anti-PL-12 UIP 
R15222 Anti-Zo* Fibrotic NSIP 
R21845 Anti-Zo* Fibrotic NSIP 
R8125 Anti-PM-Scl Limited NSIP 
R10686 Anti-PM-Scl Limited NSIP 
*See Chapter 4 
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Figure 5: Non-specific interstitial pneumonia 
Figure 6: Usual interstitial pneumonia 
Figure 7: Organising pneumonia 
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3.4 Discussion 
Historically, PM and DM has been defined based on broad pathological and clinical 
criteria (1, 2). There is now increasing evidence that these disorders characterised 
by a wide clinical spectrum can now be classified into more homogeneous clinico-
serological syndromes (6, 46, 112, 139). Autoantibodies found exclusively in IIM, 
termed MSAs are directed against cytoplasmic or nuclear components involved in  
key regulatory processes such as protein synthesis, translocation and nuclear 
transcription, and have been the subject of major interest over the last few years. 
Unlike myositis-associated autoantibodies (MAAs) found in principally myositis-
scleroderma overlap syndromes; MSAs are highly selective, mutually exclusive and 
are associated with characteristic clinical profiles. As described in Chapter 1; several 
myositis specific autoantigen systems have been described including the aminoacyl-
tRNA synthetases (ARS) (111, 114-119), signal recognition particle (SRP)  (121, 
122) and Mi-2 (126). 
Consistent with previous observations (112), in this study the most frequently 
detected MSA group were anti-ARS, with a lower frequency of anti-SRP and anti-Mi-
2 autoantibodies. Using IPP, a number of novel autoantibody specificities were  
identified, which are described fully in Chapter 4. 
The clinical manifestations of anti-ARS-positive patients were consistent with the 
anti-synthetase syndrome, with a high frequency of mechanic’s hands, fever, 
arthritis, Raynaud’s phenomenon and interstitial pneumonia. As previously  
described in anti-synthetase syndrome (42), the majority of patients presented with 
extra-muscular manifestations, in particular interstitial pneumonia, prior to their 
myositis onset. Clinically-amyopathic disease or milder muscle involvement is 
described especially in non-Jo-1 anti-ARS-positive cases (42, 144-148). In 
comparison to anti-ARS-negative cases, anti-ARS-positivity was a significant risk 
factor for the presence of interstitial pneumonia, as observed previously (6, 31, 42, 
48, 144-147, 149-152). Consistent with previous findings (30, 38), NSIP was the 
frequent interstitial pneumonia subtype observed in anti-ARS-positive patients 
(including all anti-Jo-1-positives). Interestingly, anti-PL-7 or -12 positivity was 
associated with UIP, the radiological and histological pattern synonymous with 
idiopathic pulmonary fibrosis. Indeed, the predominant clinical manifestation in two 
of these patients was interstitial pneumonia, with one patient (anti-PL-7-positive) 
developing myositis approximately 10 years after the onset of lung disease and one 
74

patient (anti-PL-12-positive) has never developed clinical myositis. In some cases, 
IPF may actually represent a formes frustes of autoimmune connective tissue 
disease, especially in patients with non-Jo-1 anti-ARS (150), which may not be 
tested for in routine clinical practice. In a study by Matsushita et al 25% of patients 
with idiopathic interstitial pneumonia were anti-ARS positive (152). At present, it 
remains unclear why Jo-1 is the most common autoantigenic target in ASS or why 
patients with anti-ARS autoantibodies have differences in their clinical presentation. 
In these patients, a high index of clinical suspicion including the recognition of other 
subtle clinical features, for example a history of arthralgia or fever, is required. 
Similar to previous studies (122-124), all patients with anti-SRP autoantibodies had 
evidence of severe myopathy with markedly elevated CK at disease onset. In 
addition, patients had systemic features, cardiac involvement and arthritis but no 
significant skin disease, and none had evidence of IP. Therefore, identification of 
anti-SRP autoantibodies at disease onset has prognostic implications, identifying 
those patients at risk of severe muscle disease that may be refractory to standard 
treatments and thus require more intensive management. Anti-Mi-2 is a DM-specific-
autoantibody (6, 10, 125-128), and in this study, both patients with anti-Mi-2 
autoantibodies had myositis associated with classic cutaneous DM lesions with no 
systemic features or internal organ involvement. 
In summary, the MSAs: anti-ARS, -SRP, -Mi-2, identify IIM patients into three 
distinct clinical phenotypes. Rather than diagnose patients as purely DM or PM, if 
we adopt a serological classification to define patients into clinical syndromes this 
may help predict outcomes, in particular, identify those patients who are at risk of 
severe disease, which in turn may influence treatment strategies. 
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3.5 Appendix 
I. SUBJECTS 
Code IIF pattern IPP result HRCT pattern 
R12707 Coarse Cytoplasmic Speckle Jo-1 Limited NSIP/OP 
R16716 Cytoplasmic Speckle Jo-1 Fibrotic NSIP 
R13077 Discrete Cytoplasmic Speckle Jo-1 Limited NSIP 
R9435 FS Jo-1 Fibrotic NSIP 
R5477 Negative Jo-1 Fibrotic NSIP 
R4480 Discrete Speckles Jo-1 n/a 
R11739 Not available Jo-1 n/a 
R8452 FS and Discrete Cytoplasmic Jo-1 n/a 
R12501 Coarse Cytoplasmic Speckle PL-12 UIP 
R18134 Fine Cytoplasmic Speckle PL-7 UIP 
R19896 FSNS and Strong Fine PL-7 UIP 
Cytoplasmic Speckle 
R16682 Not available OJ n/a 
R15222 Strong Cytoplasmic Speckle Zo* Fibrotic NSIP 
R21845 Strong Cytoplasmic Speckle Zo* Fibrotic NSIP 
R20227 FSNS and Strong Fine SRP n/a 
Cytoplasmic Speckle 
R7417 Negative SRP n/a 
R22034 Homogeneous with Fine SRP n/a 
Cytoplasmic Speckle 
R12767 FSNS SRP n/a 
R18411 Homogeneous Mi-2 n/a 
R16125 Homogeneous Mi-2 n/a 
R8125 Nucleolar PM-Scl Limited NSIP 
R10686 Not available PM-Scl Limited NSIP 
R17606 Homogeneous and nucleolar PM-Scl n/a 
R14303 FS and nucleolar PM-Scl n/a 
R9980 Negative Ro n/a 
R15323 DCNS Ro n/a 
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Code IIF pattern IPP result HRCT pattern 
R21233 Homogeneous and Fine Non-specific bands n/a 
Cytoplasmic Speckle 
R18506 FS and nucleolar Non-specific bands n/a 
R13440 FSNS Non-specific bands n/a 
R19013 FSNS Ku n/a 
R13902 Homogeneous and Nucleolar Non-specific bands n/a 
R13408 Negative Negative n/a 
R7544 FS Negative n/a 
R21308 FSNS Negative n/a 
R10290 Negative Negative n/a 
R14789 Homogeneous and Coarse Negative n/a 
Cytoplasmic Speckle 
R9674 Homogeneous Negative n/a 
R21140 DCNS Negative n/a 
R19484 FSNS and Cytoplasmic Speckle Negative n/a 
R20125 FSNS 155 and140 kDa bands* n/a 
R9316 FSNS 155 and140 kDa bands* n/a 
R7505 DCNS 155 and140 kDa bands* n/a 
R16815 FSNS 155 and140 kDa bands* n/a 
R8315 DCNS 155 and140 kDa bands* n/a 
R13064 Homogeneous 155 and140 kDa bands* n/a 
R11248 Homogeneous 155 and140 kDa bands* n/a 
R18883 FS and Fine Cytoplasmic Speckle 140 kDa* n/a 
R16316 CS 40 and 90 kDa bands* n/a 
R11040 DCNS 40 and 90 kDa bands* n/a 
R20894 FSNS 40 and 90 kDa bands* n/a 
*See Chapter 4 
N.A. – not applicable

ANA IIF patterns - abbreviations:

C: coarse 
D: diffuse 
F: fine 
S: speckle 
NS: nucleolar sparing 
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CHAPTER FOUR 
RESULTS 
Identification and characterisation of novel autoantigen systems in adult-
onset inflammatory myositis 
4.1 Introduction 
To date, several myositis specific autoantibodies (MSAs) have been described 
including the anti-aminoacyl-tRNA synthetases (ARS) (6, 114-119), -signal 
recognition particle (SRP) (6, 123, 124) and  -Mi-2 (6, 125-127) (as described in  
Chapter 1, see Table 2, for summary). Over the last few years, new MSAs have 
been described in adult IIM. 
Sato et al have described an autoantibody termed anti-CADM-140 in a Japanese 
cohort of adult patients with clinically amyopathic dermatomyositis (CADM) (130). 
.As defined by Gerami et al, patients with CADM have hallmark cutaneous features 
of DM but no clinical evidence of myositis (40). Moreover, CADM patients especially 
those of Asian origin, appear to have an increased risk of more severe interstitial  
pneumonia (31, 41, 153). In this study by Sato et al, anti-CADM-140 autoantibodies 
were detected in 8 out of 42 DM patients (19%) but not in patients with PM, other 
CTDs or control groups. All 8 patients with anti-CADM-140 autoantibodies were 
clinically amyopathic. Anti-CADM-140-positive sera demonstrated a granular or 
reticular cytoplasmic staining pattern on immunofluorescence (IIF) using HEp-2 
cells. Following radio-immunoprecipitation (IPP) using 35S-methionine-labelled K562 
cell extract, anti-CADM serum recognised an ~140 kDa polypeptide, which was 
distinguishable from other known MSAs, and immunodepletion studies confirmed 
that this autoantibody recognises the same target. Of interest, the frequency of 
severe interstitial pneumonia was significantly increased in the anti-CADM-140-
positive group compared to anti-CADM-140 negatives (50% versus 6%, p=0.008) 
(130). Using a series of molecular techniques including a HeLa cell-derived 
complementary DNA library, the identity of the ~140 kDa protein has recently been 
identified as a RNA helicase encoded by melanoma differentiation-associated gene 
5 (MDA5) (131). MDA5 is involved in innate immune responses against viruses 
(132, 154, 155). This finding suggests that a specific viral infection in genetically 
susceptible individuals may play a direct role in the pathogenesis of CADM and 
severe interstitial pneumonia, particularly as this MSA has been detected in 
Japanese patients, and confirmed in a further cohort recently (156). 
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A further novel MSA, termed anti-p155 or anti-p155/140 has been reported in adult 
DM. In the study by Targoff et al, following IPP using HeLa cell extract, anti-p155-
positive sera recognised a distinct 155 kDa protein (along with a weaker 140 kDa 
protein in most cases) in 8 out of 39 DM patients (21%). Anti-p155 sera revealed a 
nuclear speckled pattern on IIF with HEp-2 cells (143). Kaji et al have demonstrated 
what is likely to be the same autoantibody, termed anti-p155/140, in 7 out of 52 DM 
patients (13%) using IIP with K562 cells (157). Both studies showed that anti-
p155/140 autoantibodies also appear to identify a distinct clinical phenotype with 
more severe skin involvement. Moreover, the most striking feature is the clear 
association with malignancy and Chinoy et al have confirmed this. The authors  
showed that anti-p155/140 positivity confers a significant risk for cancer-associated-
myositis with a high specificity, moderate sensitivity and high negative predictive 
value (158). In preliminary work, the identity of the p155 protein target is consistent 
with transcriptional intermediary factor 1-gamma (TIF-1-γ), a nuclear transcription 
protein involved in cellular differentiation (159). 
This chapter describes data from the RNHRD IIM cohort on anti-p155/140 
autoantibodies, and also work describing two novel MSAs (termed anti-Zo and anti-
SAE). The work in this chapter has been published, as listed below: 
	 Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase 
syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase 
(anti-Zo) associated with polymyositis and interstitial pneumonia. 
Rheumatology. 2007;46:1005-1008. (120) 
	 Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a 
novel autoantibody in dermatomyositis directed against small ubiquitin-like 
modifier activating enzyme. Arthritis Rheum. 2007;56:3132-3137. (160) 
	 Gunawardena H, North J, Wedderburn LR, Davidson JE, Betteridge ZE, 
Dunphy J, Chinoy H, Cooper RG, McHugh NJ. Clinical associations of anti-
p155/140 autoantibodies in adult and juvenile dermatomyositis. Ann Rheum 
Dis. 2007;66:S68. (161) 
	 Betteridge ZE*, Gunawardena H*, Chinoy H, North J, Ollier WER, Cooper 
RG, McHugh NJ. Clinical and HLA-class II haplotype associations of 
autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-
specific autoantigen target, in UK adult-onset Caucasian myositis. Ann 
Rheum Dis. 2009;68:1621-5. (*co-first author) (162) 
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4.2 Patients and Methods 
4.2.1 Patients 
Patients with a diagnosis of adult IIM (age of onset 18 years or over) were identified 
from the RNHRD CTD database and clinics. Cases of myositis / CTD overlap were 
excluded. The clinical notes were reviewed to confirm the diagnosis of PM or DM 
based on the Bohan and Peter criteria (1, 2), and clinical data were recorded using a 
standardised proforma (see Chapter 2, Appendix 1). Data recorded included details 
on initial presentation, creatinine kinase (CK) at disease onset and maximum CK 
during disease course. The degree of cutaneous involvement and other features 
were noted including the presence of lung disease and cancer-associated myositis. 
For the studies on anti-SAE autoantibodies (see Section 4.3.2) clinical data and  
serum samples were also available from the UK Adult Onset Myositis  
Immunogenetic Collaboration (AOMIC) (collaborators Dr Hector Chinoy and Dr 
Robert Cooper). 
Sera from disease controls (150 with SSc / 40 with SLE) and 40 normal controls 
were also analysed (available from the RNHRD Bath Institute for Rheumatic 
Diseases Repository). All patients with SSc and SLE fulfilled recognised published 
criteria (11, 12). 
4.2.2 Serological Methods 
ANA Immunofluorescence (IIF) 
IIF was previously performed by standard methods (PO and JD) using HEp-2 cells 
and fluorescein-labelled anti-human IgG immunoglobulin (Sigma, UK). 
Protein Radio-immunoprecipitation (IPP) 
Sera stored at -20oC were thawed at room temperature. IPP from K562 cell extracts 
was performed as described in Chapter 2, see Sections 2.3.2 and 2.3.3. Briefly, 10 
µl sera was mixed with 2 mg protein-A-Sepharose beads (Sigma, UK) in IPP buffer 
(10 mM Tris-Cl pH 8.0, 500 mM NaCl, 0.1% v/v Igepal) at room temperature for 30 
min. Beads were washed in IPP buffer prior to the addition of 120 µl [35S] methionine 
labelled K562 cell extract. Samples were mixed at 4°C for 2 hr. Beads were washed 
in IPP buffer followed by TBS buffer (10 mM Tris-Cl pH 7.4, 150 mM NaCl) before 
being resuspended in 50 µl SDS sample buffer (Sigma, UK). After heating, proteins 
were fractionated by 10% SDS-PAGE, enhanced, fixed and dried. Labelled proteins 
were analysed by autoradiography. 
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Immunodepletion experiments 
As described in Chapter 2, section 2.3.4: duplicate samples each containing 10 mg 
protein A Sepharose beads in 1 ml IPP buffer and 50 µl serum were mixed with end-
over-end rotation at room temperature for 30 min. Beads were washed four times in 
1 ml IPP buffer and 1 tube (A) was placed on ice whilst 150 µ l [35S] methionine-
labelled K562 cell extract and 350 µl IPP buffer was added to the remaining tube 
(B). Tube B was mixed at 4°C for 2 hr after which the supernatant was transferred to 
tube A, this was mixed at 4°C for a further 2 hr. The supernatant from tube A was 
then transferred to a fresh tube (C) and stored at -80°C. IPP using reference sera 
and either 150 µ l control [35S] methionine-labelled cell extract or the 
immunodepleted supernatants (C) were completed as described for IPP using [35S] 
methionine. 
Protein isolation and mass spectrometry 
Autoantigen isolation and identification experiments were carried out by ZB (see 
Appendix 4.5 for details). Therefore, the methodology has not been described in  
Chapter 2, but is outlined in brief in this section. Forty µ l of reference sera was 
mixed with 2 mg protein-A-Sepharose beads in 500 µl IPP buffer at room 
temperature for 30 min with end-over-end rotation. Beads were washed two times in 
1 ml 0.2M triethanolamine pH 8.2 (Sigma, UK) and bound antibodies were 
crosslinked to the beads using 5mM bis-(sulphosuccinimidyl)-suberate (Perbio, UK) 
in 1 ml triethanolamine, mixing at room temperature for 30 min. The reaction was 
stopped with 1 ml 50mM Tris-Cl pH 7.5, mixing at room temperature for 15 min. The 
antibody coated Sepharose beads were washed three times in phosphate-buffered-
saline and twice in IPP buffer prior to the addition of 1 ml K562 cell extract, 
corresponding to approximately 1 x 106 cells. Samples were mixed end-over-end 
rotation at 4°C for 1 hr. The supernatant was removed and the beads were 
resuspended in a further 1 ml K562 cell extract and were mixed for 1 hr at 4°C. 
Beads were washed four times in IPP buffer and once in TBS before being 
resuspended in 80 µl SDS sample buffer. After heating (95°C for 4 min), proteins 
were fractionated by 10% SDS-PAGE. Gels were washed 3 x 5 min in pure water, 
stained for 60 min using Imperial Protein Stain (Perbio, UK) and destained overnight 
in pure water. Unique bands were removed to a 96-well plate. 
Mass Spectrometry (MS) 
Samples were prepared for MS at the University of the West of England using an 
Ettan robotic digester (GE Biosciences). Gel pieces were destained in 50% 
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Methanol / 50mM Ammonium Bicarbonate, dehydrated in 70% acetonitrile, air dried 
and digested overnight at room temperature with 20 ng/µl modified porcine trypsin 
(Promega) in 20mM ammonium bicarbonate. Peptides were extracted from gel 
pieces to a clean plate using 50% Acetonitrile / 0.1% TFA (trifluoroacetic acid) that 
was then dried down. The peptides were redissolved in 50% Acetonitrile / 0.1% TFA 
and mixed with an equal amount of 10 mg/ml alpha-cyano-4-hydroxycinnamic acid 
before being spotted on the MALDI target plate using an Ettan Robotic Spotter (GE 
Biosciences, UK). Peptide mass fingerprints were acquired using Waters Micromass 
Matrix-assisted laser desorption/ionisation-time of flight mass spectrometry (MALDI-
TOF) with data acquisition and processing carried out using the MassLynx software. 
The database searching was performed by ProteinLynx software. 
4.2.3 Ethical approval 
All patients gave fully informed written consent to participate and provide biological 
samples according to the Declaration of Helsinki under local ethical committee 
regulations. 
4.3 Results 
4.3.1 Anti-Zo, a novel autoantibody in the anti-synthetase syndrome 
Identification of anti-Zo autoantibodies to phenylalanyl tRNA synthetase 
Prior to this study, seven anti-aminoacyl-tRNA (ARS) synthetase autoantibodies had 
been described (see Chapter 1, Section 1.6.4.1 and Table 1).  As part of the work 
related to the study described in Chapter 3, it was noted that two IIM sera (R15222 
and R21845) from the RNHRD cohort study had a strong discrete cytoplasmic  
speckle on IIF using HEp-2 cells, the pattern of which was suggestive of anti-ARS 
autoantibodies (see Figure 8). Protein IPP with the two prototype sera produced a 
novel pattern with two bands at approximately 60 and 70 kDa (see Figure 9A). The 
molecular weights of the bands immunoprecipitated did not match any of the known 
tRNA synthetases associated with myositis, including Jo-1, PL-7 and PL-12 (see 
Figure 9B) and as described for KS, EJ and OJ (see Chapter 3, Figure 4), implying 
that both index cases serum (R15222 and R21845) IPP pattern was due to a novel 
anti-ARS autoantibody. This pattern was not observed in any other disease or 
control groups. 
In order to further characterise the anti-ARS, the corresponding autoantigen was 
purified and identified using SDS-PAGE and MALDI-TOF MS. Sera from either the 
index cases or patients with known autoantibodies to Jo-1, PL-7 or PL-12 were used 
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to immunoprecipitate autoantigens from a K562 cell extract. A Coomassie stained 
SDS-PAGE of the immunoprecipitates showed bands of expected molecular weight 
for the Jo-1, PL-7 and PL-12 controls (see Figure 9B) as well as 60 and 70 kDa 
bands from the index case. The bands were digested by trypsin, analysed by MS 
and SwissProt database matched. Matches required peptide coverage of over 20% 
and scores of approximately 12. All matches were repeated on at least two separate 
occasions for the controls and three separate occasions for the index case 
immunoprecipitates. Table 7 demonstrates the correct identification of Jo-1, PL-7 
and PL-12 autoantigens in the control sera and the database matching of the 
autoantigens precipitated by the index case. On each of the three separate 
occasions, the 60 kDa band was matched to phenylalanyl tRNA synthetase alpha 
chain (57 kDa protein) and the 70 kDa band was matched to phenylalanyl tRNA 
synthetase beta chain (66 kDa protein). 
Clinical features of anti-Zo autoantibodies 
Index case 1 (R15222) 
A 49 year old woman presented with shortness of breath; six months later she 
developed proximal muscle weakness, Raynaud’s phenomenon, puffy fingers, 
mechanic’s hands and arthralgia. Clinical findings demonstrated a proximal 
myopathy with a creatinine kinase (CK) of 9533 IU/L. Muscle biopsy confirmed a 
necrotising myopathy with inflammatory cells. Pulmonary function tests revealed a 
restrictive pattern and high-resolution computerized tomography (HRCT) showed 
signs of fibrotic non-specific interstitial pneumonia (NSIP). 
Index case 2 (R21845) 
A 34 year old man presented with shortness of breath on exertion. Over the next 
three months he developed Gottron’s papules on the extensor aspects of his fingers, 
mechanic’s hands, proximal myopathy with a CK of 4276 IU/L (muscle biopsy 
demonstrated a necrotising myopathy with inflammatory cell infiltrate), fever, 
Raynaud’s and arthritis. HRCT thorax showed signs of fibrotic NSIP. 
In summary, both patients with anti-Zo autoantibodies had typical clinical 
manifestations of the anti-synthetase syndrome. 
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Figure 8: ANA IIF – anti-Zo autoantibodies 
Indirect immunofluorescence staining of Hep-2 cells after incubation with index case 
1 serum (R15222) and fluorescein-labelled anti-human immunoglobulin. The 
cytoplasmic speckle seen at 40x magnification is shown. 
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Figure 9: IPP - anti-Zo autoantibodies 
A – Autoradiogram of 10% SDS-PAGE of immunoprecipitates using [35S] labelled 
K562 cell extracts. B – Coomassie stained 10% SDS-PAGE of immunoprecipitates 
using unlabelled K562 cell extract. Sera used for immunoprecipitation include; Lane 
1; control serum; Lanes 2-5, anti-synthetase sera with autoantibodies to; Lane 2 – 
Jo-1; Lane 3 – PL-7; Lane 4 – PL-12 and Lane 5 – index case serum,  R15222 
(containing autoantibodies to phenylalanyl tRNA synthetase). Molecular weight 
markers are indicated on the left of panel B and bands corresponding to the tRNA 
synthetase targets are marked. 
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Table 7 - Results of Matrix-assisted laser desorption/ionisation-time of flight mass 
spectrometry (MALDI-TOF MS) and SwissProt database matching. Comparison of  
peptide fragments of antigens precipitated by serum containing anti Jo-1, PL-7 and 
PL-12 along with peptides from the 60 kDa and 70 kDa bands precipitated by two 
index cases sera. Mass peptide fingerprints matched to histidyl-, threonyl- and  
alanyl-, phenylalanyl (alpha chain)- and phenylalanyl (beta chain)- tRNA synthetase 
respectively. Matches were deemed positive if the peptide coverage was over 20%, 
the same major theoretical and experimental peaks were present and the maximal 
MALDI-TOF score (using the software and database combination) was 
approximately 12. 
Accession Name Description 1Mwt 2PI Coverage Score 
Number (Da) 
P12081 SYH_Human Histidyl tRNA 57348 5.827 21.6% 11.7 
synthetase (Jo-1) 
P26639 SYTC_Human Threonyl tRNA 83381 6.592 32.0% 12.3 
synthetase cytoplasmic 
(PL-7) 
P49588 SYA_Human Alanyl tRNA synthetase 106734 5.387 27.0% 11.5 
(PL-12) 
Q9Y285 SYFB_Human Phenylalanyl tRNA 57396 7.881 29.2% 12.2 
synthetase alpha chain 
Q9NSD9 SYFB_Human Phenylalanyl tRNA 66087 6.777 33.4% 12.3 
synthetase beta chain 
1Mwt –theoretical molecular weight, 2PI – therotical isoelectric point. 
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4.3.2 Anti-SAE: autoantibodies targeting small ubiquitin-like modifier 
activating enzyme in adult dermatomyositis 
4.3.2.1 Anti-SAE: autoantibodies targeting small ubiquitin-like modifier 
activating enzyme in adult dermatomyositis (RNHRD study) 
Identification of anti-SAE autoantibodies in index cases 
The RNHRD IIM study described in Chapter 3 identified two DM patients with the  
same previously unidentified autoantibody pattern (R16316 and R11040). Sera from 
these patients gave a speckled nucleolar sparing staining pattern on IIF (R16316 
serum also showed a fine cytoplasmic speckle) (data not shown) and were found to 
immunoprecipitate proteins of approximately 40 kDa and 90 kDa (see Figure 10) 
that did not correspond to any known autoantigen profile. This pattern was not 
observed in any other disease or control groups. 
Autoantigen identification 
Immunodepletion studies were completed to demonstrate that the IPP pattern seen 
with R16316 and R11040 were due to the precipitation of the same autoantigens.  
Cell extracts were depleted of antigen targets using normal, R16316 and R11040 
sera before being used in further IPP using R16316 and R11040 sera. When the cell 
extracts were pre-depleted with normal serum, the 40 and 90 kDa antigens were still 
visible after IPP with each of the patient’s sera (see Figure 10, Lanes 2 and 6). 
However, after pre-depletion with either patient’s sera and removal of the 
corresponding targets, the 40 and 90 kDa bands were absent after subsequent IPP 
by either patient’s sera (see Figure 10, Lanes 3-4 and 7-8). These results therefore 
provided good evidence that the serum from R16316 and R11040 both contained 
the same autoantibody specificity. 
Identification of the SAE antigens 
Non-radiolabelled IPP and Coomassie stained SDS-PAGE demonstrated the 
presence of 40 kDa and 90 kDa bands using both R16316 and R11040 serum (see 
Figure 11). MALDI-TOF MS and Swiss Prot analysis of the peptide fingerprints from 
these bands corresponded to SUMO 1 Activating Enzyme A subunit (SAE1) (38 kDa 
protein) for the 40 kDa band and SUMO 1 activating enzyme B subunit (SAE2) (71 
kDa protein) for the 90 kDa band (see Table 8). 
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Clinical features of anti-SAE autoantibodies in index cases 
Index Case 1 (R16316) 
A 52 year old lady presented with a three month history of DM rash, including  
periungal erythema, V-sign rash and heliotrope rash. She had no muscle symptoms 
with a normal CK and electromyography (EMG). Six months later she developed  
proximal myopathy (CK 797 IU/L), dysphagia, and worsening skin disease with the 
Shawl-sign rash. Muscle biopsy confirmed necrotising myopathy with persistent 
inflammatory change. Screening investigations showed no sign of an underlying 
malignancy. HRCT showed limited peripheral lung involvement consistent with 
limited mild NSIP. 
Index Case 2 (R11040) 
A 62 year old man presented with clinical features of cutaneous DM, including a 
heliotrope rash and Gottron’s papules. Six months later he developed proximal 
myositis with pharyngeal involvement. CK was 1086 IU/L and the diagnosis was  
confirmed following EMG study. Further investigations excluded an underlying 
malignancy but did show changes consistent with peripheral limited mild NSIP. 
In summary, the results from this study suggest that anti-SAE autoantibodies may  
form a further serological subset in adult IIM with similar clinical manifestations. A 
further patient (R20894) was subsequently identified as anti-SAE-positive, with this 
finding included in the anti-SAE UK AOMIC study described below. 
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Table 8 – Results of MALDI-TOF MS and SwissProt database matching. 
Comparison of mass peptide fragments of antigens precipitated by patient 1 and 2 
sera to small ubiquitin like 1 activating enzyme (SAE1) and (SAE2). Results from a 
total of three separate occasions (with two matches for R16316 and one match for 
R11040) are shown. Matches were deemed positive if the peptide coverage was 
over 20 percent and the same major theoretical and experimental peaks were 
present. 
Accession Name Description 1Mwt 2PI Coverage 
Number (Da) 
Q9UBE0 ULE1A_ Ubiquitin like 1 activating enzyme 38426 5.23 47.1% 
Human E1A SUMO1 (activating enzyme 46.2% 
subunit 1) 41.0% 
Q9UBT2 ULE1B_ Ubiquitin like 1 activating enzyme 71179 5.19 25.8% 
Human E1B SUMO1 (activating enzyme 37.8% 
subunit 2) 29.4% 
1Mwt –theoretical molecular weight, 2PI – therotical isoelectric point. 
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4.3.2.2 Anti-SAE autoantibodies in UK AOMIC cohort 
The AOMIC registry has recruited UK Caucasian patients with adult-onset myositis, 
18 years or over at disease onset, from hospitals around the UK. All patients had 
probable or definite myositis according to the Bohan and Peter diagnostic criteria (1, 
2). A standardised proforma, including demographic and clinical data, was used 
throughout (see Chapter 2, Appendix). Cancer associated myositis defined as  
cancer occurring within 3 years of diagnosing myositis (as per the modified Bohan 
and Peter classification used in a previous study  (9)) was confirmed by the local 
clinician caring for individual patients. Patients were investigated for interstitial 
pneumonia based on clinical symptoms and pulmonary function testing and where 
indicated HRCT thorax. Clinical data and serum samples from 266 myositis patients 
were available for analysis for this study. The median age of disease onset was 50 
years (IQR 37-61) and 195 (73%) cases were female. One hundred and thirty one 
cases had DM, 124 PM and 11 myositis / CTD overlap. Sera and DNA samples  
were taken at the time of diagnosis and stored at -20oC until required. 
Identification of anti-SAE autoantibodies in UK AOMIC cohort 
Sera from 266 myositis patients were screened for anti-SAE autoantibodies. 
Excluding the reference cases (R16316 and R11040) (as described in Section 
4.3.2.1), nine further patients were identified as having 40 kDa and 90 kDa bands on 
SDS-PAGE, previously described as corresponding to SAE1 and SAE2 respectively 
(see Section 4.3.2.1 and Reference (160)). The presence of anti-SAE 
autoantibodies in these sera was confirmed by immunodepletion experiments. 
Immunoprecipitations on the 40kDa and 90 kDa positive sera were completed using 
cell extracts depleted with either the index case serum (anti-SAE), or with healthy 
control serum. All sera were positive for the 40 kDa and 90 kDa bands using healthy 
control depleted cell extract but were negative for the 40 kDa and 90 kDa bands with 
the index case (anti-SAE) depleted extract (see Figure 12). These results provide  
confirmation that the serum from the index cases and the nine additional patients 
contain the same autoantibody specificity, anti-SAE. Anti-SAE autoantibodies were 
not detected in any of the disease or normal control groups. 
None of the 11 anti-SAE positive sera were found to co-immunoprecipitate any other 
recognised MSAs, although 5 patients did co-immunoprecipitate additional 
unidentified non-specific bands on IPP. IIF on anti-SAE positive sera demonstrated 
a fine speckled nucleolar-sparing pattern (titres ranging from 1/160 to 1/2560) in ten 
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patients with two sera also showing a fine cytoplasmic speckle (1/40 titre) and a 
homogeneous pattern (1/640 titre) in one case. 
Clinical features of anti-SAE autoantibodies in UK AOMIC cohort 
The overall frequency of anti-SAE autoantibody positive cases in the myositis cohort 
was 4%. Anti-SAE was found exclusively in DM patients (n=131), with a frequency 
of 8%. The detailed clinical features of the 11 anti-SAE positive patients are 
described in Table 9. Seven (64%) were female and the mean age was 62 years  
(IQR 54-68). Nine patients (82%) had a heliotrope rash, 9 (82%) patients had 
Gottron’s lesions on the fingers and 7 (64%) had Gottron’s over the large joints 
(elbow or knee). Eight out of 8 patients (100%) (data not available on 3 patients) 
had periungal changes. Seven out of 9 patients (78%) (data not available on 2 
patients) had dysphagia, 3 of which had profound swallowing dysfunction, which 
required enteral feeding. Nine out of 11 patients (82%) had systemic features as 
defined by fever, weight loss and raised inflammatory markers. Two patients (18%) 
had cancer-associated myositis. Two patients (18%) had radiological evidence of 
ILD (limited non-specific interstitial pneumonia with less than 10% lung involvement 
on HRCT scored by a thoracic radiologist) but neither of these 2 patients had 
respiratory symptoms. Seven anti-SAE positive cases (78%) (data not available on 2 
patients) presented with cutaneous DM only (no weakness and normal CK), but then 
went onto develop frank myositis. The median disease duration between the initial 
presentation of skin disease and myositis onset was 3 months (IQR 1, 6). After 
multiple corrections were applied, no significant clinical associations were observed 
when comparing anti-SAE positive patients with anti-SAE negative DM patients 
except for a higher frequency of periungal changes in the anti-SAE positive group 
(Pcorr=0.03). In addition, data on the type of presentation i.e. skin disease first or skin 
/ muscle disease at onset was not available on the anti-SAE negative DM group to 
make this comparison. The data is summarised in  Table 10. This study has 
confirmed that SAE is an important autoantigen target in DM with specific clinical 
associations. 
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Table 9: Clinical features of patients with anti-SAE autoantibodies in UK 
AOMIC cohort 
Patient
 1 2 3 4 5 6 7 8 9 10 11 
Age at onset 51 62 75 46 59 75 63 52 56 78 66 
Sex F M F M F F M F M F F 
Heliotrope Yes Yes Yes Yes Yes Yes Yes No Yes Yes No 
Gottron’s 
Fingers* No Yes Yes Yes No Yes Yes Yes Yes Yes Yes 
Other** No No Yes Yes No No Yes Yes Yes Yes Yes 
Periungal Yes Yes Yes Yes Yes Yes Yes Yes ~ ~ ~ 
V-sign Yes Yes No Yes No No No ~ ~ ~ ~ 
Shawl-sign Yes Yes No Yes No No No ~ ~ ~ ~ 
MH No No No No No No No ~ ~ ~ ~ 
Dysphagia Yes Yes Yes Yes No No Yes Yes ~ Yes ~ 
Systemic Yes Yes Yes Yes No No Yes Yes Yes Yes Yes 
Weakness# Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Raised CK Yes Yes Yes Yes Yes No Yes Yes Yes No Yes 
ILD Yes Yes No No No No No No No No No 
CAM No No No No No No Yes Yes No No No 
Arthritis No No No No No No Yes No No No Yes 
Presentation S S S S S/M S S S ~ S/M ~ 
(months)@ (6) (6) (6) (3) (2) (3) (2) 
93

Key to Table 9: 
*Gottron’s lesions over the extensor aspects of fingers 
**Gottron’s lesions over the extensor aspects of elbows or knees 
~Clinical information not available 
#Weakness – objective signs defined by manual muscle testing 
MH (mechanic’s hands) 
ILD (interstitial lung disease) – patients asymptomatic / limited mild non-specific 
interstitial pneumonia on high resolution CT scan 
CAM (cancer-associated myositis) 
@S=presented skin disease first (number of months before myositis onset), S / M = 
presented with skin and muscle disease 
Cases 1 and 2 (index cases R16316 and R11040 – RNHRD study) 
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Table 10: Comparison of selected clinical features in anti-SAE positive vs. 
anti-SAE negative dermatomyositis patients* (UK AOMIC cohort study) 
Anti-SAE positive Anti-SAE negative 
(n=11)** (n=120)** 
Females 64 74 
Heliotrope 82 71 
Gottron’s papules (fingers) 82 63 
Gottron’s lesions (other) 64 48 
Periungal erythema 100 # 46 
V-sign rash 43 35 
Shawl-sign rash 43 37 
Dysphagia 78 43 
Systemic 82 54 
Weakness 100 89 
Elevated CK 82 85 
Interstitial pneumonia 18 18 
CAM 18 16 
Arthritis 18 22 
*Values are the percentage of patients who had the clinical feature. **Not all patients 

had data on each clinical feature. CAM: cancer-associated myositis.

#Pcorr=0.03 compared to anti-SAE negative DM patients.
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Figure 10: IPP - anti-SAE autoantibodies 
IPP of antigens recognised by patients R16316 and R11040. Autoradiogram of 10% 
SDS-PAGE of immunoprecipitates using either R16316 and R11040 serum with 
control [35S] methionine-labelled cell extract or [35S] methionine-labelled cell extract 
depleted with either normal sera (NS), patient R16316 sera (1) or patient R11040 
sera (2). The bands corresponding to SAE1 (40 kDa band) and SAE2 (90 kDa band) 
are indicated. 
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Figure 11: Coomassie stained IPP of proteins using anti-SAE antibodies 
Coomassie stained 10% SDS-PAGE of immunoprecipitates using either patient 1 
(R16316) or 2 (R11040) crosslinked serum precipitated with unlabelled K562 cell 
extract. The molecular weight markers are indicated in kDa on the left and the bands 
corresponding to SAE1 (40 kDa band) and SAE2 (90 kDa band) are indicated on the 
right. 
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Figure 12: SAE Immunodepletion 
Autoradiogram of 10% SDS-PAGE of immunoprecipitates using anti-SAE positive 
patient serum and either normal serum depleted [35S] methionine – labelled cell  
extract (A) or SAE depleted [35S] methionine – labelled cell extract (B) NS – IPP of 
normal serum and undepleted [35S] methionine – labelled cell extract, SAE  – IPP  
using anti-SAE positive serum and undepleted 35S methionine. Bands 
corresponding to SAE1 (40 kDa band) and SAE2 (90 kDa band) are indicated. 
A B
SAE1 
SAE2 
      NS SAE  1  2  3  4  5  6  7  8  9   10  11   NS SAE 1  2  3  4  5  6  7  8  9   10   11 
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4.3.3 Anti-p155/140: autoantibodies targeting 155/140 kDa doublet protein in 
adult dermatomyositis 
Identification of anti-p155/140 autoantibodies 
The RNHRD IIM study described in Chapter 3 identified seven DM patients with the 
same previously unidentified autoantibody pattern and similar clinical features: 
R7505 R13064 
R8315 R16815 
R9316 R 20125 
R11248 
Following IPP testing, sera from the above cases of adult DM recognised two 
distinct proteins forming a doublet with molecular weights of 155 kDa and 140 kDa 
(see Figure 13). In each case a weak, non-specific nuclear pattern was detected on 
IIF (data not shown). 
Immunodepletion studies were undertaken in order to ascertain whether the IPP 
pattern seen in the adult DM cases was due to precipitation of the same  
autoantigens. Immunoprecipitations on the different anti-p155/140 kDa positive sera 
were completed using cell extracts depleted with a reference index case anti-
p155/140 serum (R7505), or with healthy control serum. All sera were positive for  
the p155/140 kDa bands using healthy control depleted cell extract but were 
negative for the p15/140 kDa bands with the index case (R7505) depleted extract 
(see Figure 14). These results provide confirmation that the serum from the index  
case and the six additional patients contain the same autoantibody specificity, anti-
p155/140. None of the seven anti-p155/140 positive sera were found to co-
immunoprecipitate any other recognised MSAs. 
Frequency of anti-p155/140 autoantibodies 
A total of seven out of 50 (14%) adult IIM patients were positive for autoantibodies to 
the p155/140 kDa doublet. Anti-p155/140 was only detected in adult DM cases with 
a frequency of 26.9%. Anti-p155/140 autoantibodies were not found in any of the 
disease or normal control groups. 
Clinical features of anti-p155/140-positive patients 
Findings are summarised in Table 11 and Table 12. Four adult DM patients with 
anti-p155/140 had a history of malignancy, which was diagnosed either at onset or 
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within three months of their DM. The remaining three anti-p155/140 patients had 
clinically-amyopathic DM (CADM) based on clinical findings and normal creatinine 
kinase levels since diagnosis, and no history of malignancy (median seven years 
from diagnosis to time of study). 
In comparison to anti-p155/140 negative adult DM patients, anti-p155/140-positive 
patients had a higher frequency of cutaneous lesions; including V-sign rash, Shawl 
sign rash, heliotrope rash and Gottron’s lesions. In addition, systemic manifestations 
including dysphagia were more frequent. No anti-p155/140-positive patients had 
interstitial pneumonia. 
There was a significant association with anti-p155/140-positivity and malignancy 
(Pcorr=0.03, odds ratio 7.3). The types of cancer seen in this group of patients were 
varied but all patients had evidence of solid organ malignancy. 
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Table 11: Clinical features of anti-p155/140-positive adult DM vs. anti-
p155/140-negative adult DM π 
Anti-p155/140 (adult DM) 
Positive (n=7) Negative (n=19) 
Median age at diagnosis (yrs) 54 (33, 71) 51 (49, 58) 
Females 71.4 89.5 
Heliotrope rash 85.7 63.2 
Gottron’s papules 100 84.2 
Periungal erythema 71.4 63.2 
V-sign rash 71.4 26.3 
Shawl-sign rash 85.7 26.3 
Dysphagia 57.1 21.0 
Weight loss 28.6 26.3 
Weakness 57.1 73.7 
Elevated CK 57.1 78.9 
Interstitial pneumonia 0 31.6 
CAM 57.1 # 0 
Arthritis 28.6 36.8 
Calcinosis 14.3 0 
Mechanics hands 0 15.8 
πValues are in percentages unless otherwise indicated 
CK: creatinine kinase 
CAM: cancer-associated myositis 
#Pcorr=0.03 compared to anti-p155/140 negative DM patients (P=0.002), odds ratio 
7.3, 95% CI 2.56-20.99) 
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Table 12: Anti-p155/140-positive patients (types of malignancy) 
Patient 
1 
Diagnosis 
DM 
Age at onset 
82 
Malignancy 
Small cell carcinoma adrenal metastasis 
2 DM 71 Bone and liver metastasis 
3 DM 50 Breast carcinoma 
4 DM 77 Gastric carcinoma 
5 CADM 28 No 
6 CADM 24 No 
7 CADM 56 No 
CADM: clinically-amyopathic dermatomyositis 
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Figure 13: IPP anti-p155/140 autoantibodies 
Immunoprecipitation of p155/140 kDa autoantigens and other selected MSAs. 10% 
SDS PAGE of immunoprecipitates of [35S] labelled K562 cell extracts. Sera used for 
immunoprecipitation include Lanes 1-6; adult anti-p155/140 positive serum, Lane 7; 
threonyl tRNA synthetase, Lane 8; alanyl tRNA synthetase, Lane 9; histidyl tRNA 
synthetase, Lane 10; Mi-2, Lane 11; signal recognition particle and Lane 12; normal 
serum. Positions of the p155 and p140 antigens are indicated on the left. Positions 
of the Mi-2 bands at 240, 65 and 63 kDa are indicated. The 54, 83 and 108 kDa 
molecular weight markers correspond to signal recognition particle, threonyl tRNA 
synthetase and alanyl tRNA synthetase respectively. 
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Figure 14: Immunodepletion experiments (anti-p155/140) 
Immunodepletion experiments - Autoradiogram of 10% SDS-PAGE of 
immunoprecipitates using adult positive anti-p155/140 serum: R7505, R8315 and 
R9316. Immunoprecipitation was performed with control  [35S] methionine-labelled 
cell extract or [35S] methionine-labelled cell extract depleted with either normal 
serum (NS) or adult positive anti-p155/140 serum (R7505). The bands 
corresponding to the p155 and p140 autoantigens are indicated. 
1 2 3 4 
Depletion serum None NS R7505    R7505 
IPP serum         R8315    R9316  R8315    R9316 
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4.4 Discussion 
This chapter outlines work that characterises three new MSAs in adult IIM. The first 
is a new anti-ARS (-Zo) that targets phenylalanyl tRNA synthetase, which is the 
eighth autoantigenic ARS to be identified. The second is an autoantibody that  
targets SAE, an enzyme involved in post-translational modification, a completely 
novel system in adult DM. Finally, the clinical specificity of anti-p155/140 
autoantibodies are described in patients recruited to the RNHRD IIM cohort study. 
4.4.1 Anti-Zo; autoantibodies against phenylalanyl tRNA-synthetase 
The aminoacyl tRNA-synthetases are a distinct group of enzymes that catalyse the 
ATP-dependent binding of an amino acid to its cognate tRNA during protein 
synthesis. ARS are functionally related enzymes; each amino acid has its own 
corresponding tRNA-synthetase, except glutamic acid and proline, which have both 
been shown to be catalysed by a single polypeptide encoding the ‘gluprolyl’ tRNA 
synthetase (163). Previously, seven anti-ARS have been described (see Chapters 1 
and 3) (111, 114-119). ARS belong to one of two classes depending on the amino 
acid they are responsible for. Both classes are multi-domain proteins with a catalytic 
domain and an anti-codon binding domain (ensures binding of the correct tRNA to 
the protein). Five ARS; histidyl (Jo-1), threonyl (PL-7), alanyl (PL-12), asparaginyl 
(KS) and glycyl (EJ) are class II synthetases found free in the cell cytoplasm. They 
have three highly conserved motifs, are generally dimeric or tetrameric, and attach 
their amino acid to the 3' hydroxy (OH) of their tRNA. The other two autoantigenic 
ARS: isoleucyl (OJ) and tyrosyl (Ha) are class I enzymes with two highly conserved 
motifs, are generally monomeric, and attach the carboxyl of their target amino acid 
to the 2' OH of adenosine 76 in the tRNA molecule. Anti-OJ autoantibodies are 
primarily directed against isoleucyl-tRNA syntheatse but can react against multiple 
syntheases as part of a class I multi-enzyme complex including leucyl and 
glutaminyl-tRNA (117). Prior to this study; several ARS have not be shown to be 
autoantigenic (see Table 13). Either these synthetases are not targeted as part of an 
autoimmune response or autoantibodies directed against them are extremely rare. It 
is also feasible that it has not been possible to identify autoantibodies to the 
remaining synthetases using conventional diagnositic techniques. 
Phenylalanyl tRNA synthetase is the eighth autoantigen associated with anti-
synthetase syndrome to be identified . Similar to the majority of autoantigenic ARS, 
phenylalanyl is a class II synthetase but it aminoacylates at the 2' OH of the same 
adenosine, rather than at 3' OH. 
105

Manifestations of anti-synthetase syndromeare described in Chapters 1 and 3. It is 
noteworthy that the two index cases identified as having anti-Zo autoantibodies had 
clinical features consistent with this syndrome. In particular, as well as myositis, both 
patients developed NSIP, the presence of which influenced treatment. As 
highlighted in Chapters 1 and 3, a major and sometimes predominant manifestation 
of ani-synthetase syndrome is interstitial pneumonia, which can be the major factor 
in terms of prognosis (42, 48). The different manifestations are not universal 
between patients and it is posible that each anti-ARS may define more specific 
clinical subsets within the syndrome itself. This is perhaps most notable in patients 
with non-Jo-1-anti-ARS (-KS, -PL-12, -PL-7) with lung disease in the absence of 
clinically apparent myositis (42, 48, 118, 144, 145). In a study by Yoshifuji H et al, 
the frequency of intestitial lung involvement in their patients with anti-synthetase 
syndrome was as high as 95%. Interestingly in terms of interstitial pneumonia being 
the first disease manifestation; anti-ARS autoantibodies were detected in 77% of 
this subgroup of patients with lung disease preceeding myositis by a median of 11 
months. However, in patients who developed myositis first, anti-ARS were only 
found in 20%. This study also looked at patients with interstitial pneumonia sine  
myositis; defined by anti-ARS, lung disease, no muscle disease either clinically or 
biochemically and no cutaneous IIM signs. All patients in this subgroup had non-Jo-
1-anti-ARS (48). Similarly, the index anti-Zo-positive cases in this study initially 
presented with respiratory symptoms; the onset of myositis with other characteristic 
features occurring later. It is possible that non-Jo-1-anti-ARS may identify patients at 
one end of the spectrum. The question remains do anti-ARS have a predictive value 
in the context of idiopathic interstitial pneumonia i.e. do a proportion of these 
patients actually have a “forme fruste” of autoimmune CTD, as suggested in 
previous studies (48, 150). Detection of anti-ARS autoantibodies in these patients 
may influence treatment strategies, as highlighted by Yoshifuji H et al, who showed 
that patients with anti-ARS-associated interstitial pneumonia respond significantly 
better to corticosteroids compared to “seronegative” interstitial pneumonia. However 
the anti-ARS-positive group were also shown to have a higher rate of relapse with 
recurrent lung disease (48). This suggests the need to treat patients aggressively 
with early intervention, with slower tapering of corticosteroids together with 
additional immunomodulatory therapy. From a clinical perspective, early 
identification of this subset of patients may influence management. Furthermore, 
studies described in Section 1.6.4.2 suggest a potential direct role of both candidate 
autoantigens and specific anti-ARS autoantibodies in disease pathogenesis that 
may lead to more specific targeted therapies (80, 107, 135, 164). 
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Table 13: Aminoacyl-tRNA synthetases 
Class I tRNA synthetases 
Arginyl 
Class II tRNA synthetases 
Alanyl (PL-12) π 
Cysteinyl Asparaginyl (KS) π 
Glutamyl Histidyl (Jo-1) π 
Glutaminyl* Glycyl (EJ) π 
Isoleucyl (OJ)* π Lysyl 
Leucyl* Phenylalanyl (Zo) π 
Methionyl Prolyl 
Tryptophanyl Seryl 
Tyrosyl (Ha) π Threonyl (PL-7) π 
Valyl 
πautoantigenic ARS molecules 
*autoantibodies to isoleucyl (OJ) also react against other synthetases as part of a 
class I multi-enzyme complex including leucyl and glutaminyl-tRNA 
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4.4.2 Anti-SAE autoantibodies 
Work described in this chapter has confirmed that SAE is an important autoantigen 
target in IIM where it is associated with specific clinical and associations. Anti-SAE, 
like anti-Mi-2, appears to be highly specific for DM. The frequency of anti-SAE in the 
AOMIC / RNHRD DM cohort was 8%. This is in comparison to Mi-2 which,  
depending on detection methods, is seen in 10-20% of DM patients (126, 128). Anti-
SAE autoantibody positive DM patients have signs of hallmark cutaneous disease 
whereas interstitial lung involvement appears to be rare, and when present is mild. 
Systemic features including weight loss and dysphagia are a common manifestation 
of this subgroup. Furthermore, anti-SAE may be an important prognostic marker in 
patients who initially present with cutaneous DM. The majority of anti-SAE positive 
cases presented with skin lesions first and all went onto develop myositis. This 
finding requires further validation in larger patient groups such as those presenting 
with clinically-amyopathic DM under the care of dermatologists. The association with 
cancer and anti-SAE does not appear as strong as the now well recognised 
association with anti-p155/140 autoantibodies as described previously  (143, 157, 
158), and also in this chapter. Interestingly, the frequency anti-SAE autoantibodies 
with cancer-associated myositis were similar to that found for anti-Mi-2 
autoantibodies in a recent study (158). In the future, larger studies will facilitate more 
detailed investigation of the clinical specificity of anti-SAE in comparison to other 
DM-specific autoantibodies. 
Post-translational modifications are essential for full biological activity and allow a 
rapid cellular mechanism in response to changes in the environment. However, 
these modifications can also lead to the creation of novel self-antigens and the 
development of autoimmunity. Examples of this can be seen with glycosylation and 
hydroxylation modifications in collagen-induced arthritis, citrullination in rheumatoid 
arthritis and phosphorylation in SLE (165). 
Small ubiquitin-like modifiers (SUMO) play a key role in the post-translational 
modification of specific proteins. The SUMO family consists of four members of 
which SUMO-1 is the best characterised. Sumoylation leads to the formation of 
stable conjugates of target proteins including protein kinases and transcription 
factors (166-169). Studies have implied a role for sumoylation in nucleo-cytoplasmic 
transport and signal transduction (167, 168). SUMO has been linked to certain 
inflammatory diseases. Franz et al demonstrated high levels of SUMO-1 mRNA 
expression in rheumatoid synovial tissue compared to controls. The relevance of 
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this over-expression is unclear but it was suggested that through inhibition of 
apoptosis, the survival of synovial fibroblasts may be increased (170). In addition, 
Janka et al have reported the presence of autoantibodies against SUMO-1 and 
SUMO-2 autoantigens in patients with primary biliary cirrhosis (PBC) (171). PBC is 
associated with other autoimmune conditions and several case reports have 
described PBC with co-existent myositis (172, 173). 
SAE is a heterodimer composed of the subunits SAE1 and SAE2. Desterro et al 
have shown that the two polypeptides SAE1 and SAE2 have apparent molecular 
weights of 40 and 90 kDa respectively, with predicted molecular masses of 38 kDa 
and 72 kDa (174). These results are consistent with the data found in this study, 
where SAE2 was found to migrate at a higher molecular weight than predicted on 
SDS-PAGE. SAE functions in an ATP-dependant manner and forms a thioester 
bond between the SAE2 subunit and SUMO, prior to the transfer of SUMO to the E2 
conjugating enzyme (174, 175). IIF staining using the SAE subunits have shown that 
SAE is distributed throughout the nuclei but excluded from the nucleoli (176). These 
results are consistent with the IIF staining patterns seen with anti-SAE positive sera, 
where a coarse speckled nucleolar sparing staining pattern was observed. The  
additional fine cytoplasmic speckle seen in some anti-SAE-positive cases suggests 
a limited cytosolic pool of the SAE, as previously shown with the sumolyation of 
RANGAP 1 (177). 
Sumoylation is also implicated in the transcriptional repression of histone 
deacetylase a component of the nucleosome remodelling and deacetylase complex 
that also includes the myositis specific autoantigen, Mi-2 (178). Therefore, it is  
possible that the production of autoantibodies to either SAE or Mi-2 in DM maybe 
the consequence of the same post-translational modification event. 
There are other protein targets that are modified by sumoylation (168). Intriguingly 
these include a member of the GATA family of transcription factors, GATA-2, which 
is expressed in adult endothelial cells. GATA-2 plays a key role in the transcriptional 
regulation of endothelial specific genes including endothelin-1 (ET-1), nitric oxide 
synthetase and Von-Willebrand factor. Both SUMO-1 and 2 covalently modify 
GATA-2 regulating ET-1 expression by suppressing promoter gene activity (179). 
This observation is of interest because endothelial cell injury and subsequent 
microvasculopathy in both muscle and skin lesions is well described in DM (74, 75, 
180). 
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In summary, one can hypothesize that disruption of sumoylation of specific target 
proteins either via SUMO and / or the enzyme subunits SAE 1 / 2 play a role in the 
pathogenesis of certain DM clinical phenotypes. The clinical homogeneity of anti-
SAE-positive patients, suggests that this is an important finding. 
4.4.3 Anti-p155/140 autoantibodies 
Over the last two years, several groups have reported an autoantibody termed anti-
p155/140 based on the molecular weights of the polypeptide targets (155 and 140 
kDa) in adult DM. Targoff et al and Kaji  et al have identified this autoantibody  
specificity in 21% and 13% of DM patients respectively (143, 157). In both studies 
anti-p155/140 positive cases had more severe cutaneous involvement including 
more frequent V-sign and Shawl-sign rash, and very interestingly an association 
with malignancy. Furthermore, anti-p155/140 autoantibodies appear to be a 
negative predictor for interstitial lung disease. We have confirmed this observation in 
our cohort of adult DM patients. Chinoy et al investigated this further in larger cohort 
of patients from the AOMIC registry and found that the risk of malignancy in anti-
p155/140 positive cases was significantly higher than anti-p155/140 negative cases 
(odds ratio of 23.2, 95% confidence interval 6.1-84.5) (158). These studies, and the 
work described in this chapter, highlight the future potential of routinely testing for 
anti-p155/140 to aid clinicians in the detection of cancer-associated myositis. The 
next step is to further validate the clinical utility of anti-p155/140, which can then be 
translated into routine clinical practice. 
In this RNHRD cohort study only four patients out the overall IIM cohort had a 
history of malignancy and all were anti-p155/140 autoantibody positive. The 
diagnosis of cancer was either concurrent or within a few months onset of their DM, 
in concordance with the findings described by Kaji et al (157). Kaji et al also  
described two patients who were anti-p155/140-positive without malignancy and two 
patients who were clinically amyopathic although it is not clear if they were the same 
patients. Of interest, in this study, the three patients who were anti-p155/140 
positive / malignancy negative also had CADM. 
Preliminary work has identified the target of the anti-p155 autoantibodies as 
transcriptional intermediary factor 1-gamma (TIF1-γ) (159). Also known as Ret fused 
gene 7 (RFG7), this is a member of unique RING finger proteins involved in cellular 
differentiation (181). The discovery of the p155/140 autoantigen (TIF1-γ) in DM 
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patients with cancer-associated myositis may increase our understanding of the 
relationship between autoimmunity and cancer. 
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CHAPTER FIVE 
RESULTS 
Serological subsets and clinical associations of myositis-specific and 
myositis-associated autoantibodies in juvenile dermatomyositis 
5.1 Introduction 
5.1.1 Epidemiology 
The juvenile idiopathic inflammatory myopathies (IIMs) are a group of rare but  
chronic systemic autoimmune conditions of childhood. Approximately one-fifth of all 
cases of IIM start in childhood, with an annual incidence of 2.5-5 cases per million 
population (19). Juvenile dermatomyositis (JDM) is the most common of the 
idiopathic inflammatory myopathies (IIM) of children, whereas juvenile polymyositis 
and inclusion body myositis are rarely described. The reported incidence of JDM 
ranges between 0.8-4.1 per million children per year (18-20). The peak age of onset 
is 7 years and most studies show that it is just over twice as common in girls than 
boys, although this ratio may be more comparable in patients under the age of 6  
(19, 24). A younger age of onset may confer a worse overall prognosis and 25% 
cases occur before the age of 4 years (182). 
5.1.2 Clinical features 
JDM is chronic and potentially debilitating. Despite improvements in multi-
disciplinary treatment approaches JDM is still associated with significant morbidity 
and mortality. Classic JDM rash is similar to adult DM lesions. Heliotrope rash, 
Gottron’s papules over the fingers or extensor aspects of the limbs, and periungal  
cuticular overgrowth with capillary dilatation are prominent features. Cutaneous 
lesions are the presenting feature in the majority (over 50% cases), and proximal 
muscle weakness is the first symptoms in a quarter (183). JDM is a multi-system 
disease and most children will have other ‘systemic’ manifestations at onset, 
including fever, weight loss, anorexia, mouth ulcers, alopecia and irritability (24). In 
comparison to adult DM, vasculitis is a more prominent feature leading to various 
clinical signs including subcutaneous oedema and subsequent skin ulceration. Other 
systemic involvement includes gastrointestinal (GI) vasculitis causing abdominal 
pain, GI ulceration, bleeding and perforation (24, 183). Dystrophic calcinosis (in the 
skin, subcutaneous tissue or muscle), acquired lipodystrophy and contractures are 
also relatively common manifestations in JDM, and are said to be associated with 
chronic cutaneous inflammation, longer disease duration and delay in diagnosis / 
treatment onset (184, 185). JDM-scleroderma overlap (JDM-SSc) is well recognised 
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in JDM children with a history of Raynaud’s phenomenon, sclerodactly and other  
sclerodermatous skin changes. JDM can also overlap with systemic lupus 
erythematosus (JDM-SLE). In addition, it is well described that a large number of 
JDM children can also develop overlap inflammatory arthritis (usually in association 
with JDM-SSc or SLE) (24, 186). In contrast to adult DM, interstitial pneumonia and 
cancer-associated myositis are very rare in JDM (53, 55-57). Due to the 
heterogeneity of the condition with multi-organ involvement, clinical outcomes and 
prognosis are difficult to predict. Certain clinical features, such as skin ulceration, 
gastro-intestinal involvement (dysphagia and ischaemic ulceration from chronic 
endarteropathy) or respiratory disease / respiratory muscle weakness (especially  
leading to aspiration pneumonia) have been proposed as predictors of severe 
disease course in JDM (21, 25, 57, 187). 
5.1.2 Clinical Assessment 
There are now standardised validated clinical tools used in the assessment of JDM 
both in clinical practice and in clinical trials. These include the Childhood Myositis 
Assessment Scale (CMAS) and the Childhood Health Assessment Questionnaire  
(CHAQ) (188-191). Additional measures of disease activity include the Physicians’ 
global assessment using a visual analogue scale (VAS) or Likert scale, and a 
patient / parent global assessment of overall well-being using the same method 
(VAS) (192). In addition, the Cutaneous Assessment tool (CAT) has been partially 
validated for the assessment of skin disease in JDM (193, 194). 
Standard laboratory markers include muscle enzymes; creatinine kinase (CK), 
lactate dehydrogenase (LDH), aldolase, and other inflammatory markers including 
C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). Magnetic 
resonance imaging (MRI) of proximal muscle groups is now being frequently used 
for diagnostic purposes as well assessment of muscle disease activity, and in some 
cases may be preferred to muscle biopsy. T2 fat suppressed images can 
demonstrate muscle, subcutaneous and cutaneous inflammation and oedema. T1 
weighted images are used to establish the degree of fatty infiltration and muscle 
atrophy, which is representative of damaged muscle (195-197). 
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Childhood Myositis Assessment Scale (CMAS) (188, 189) 
Assessment comprises of a series of timed tasks testing muscle strength,  
endurance and function. See Chapter 5.5: Appendix I. 
Childhood Health Assessment Questionnaire (CHAQ) (190, 191) 
The CHAQ is a functional questionnaire completed by the patient and / or parent to 
assess activities of daily living. See Chapter 5.5: Appendix I. 
Cutaneous Assessment tool (CAT) (193, 194) 
The CAT is used in both adult and juvenile DM to assess skin disease measuring 
both activity and damage, using a priori weighting scale. See Chapter 5.5: Appendix 
I. 
5.1.3 Aetiology and pathogenesis 
The aetiology of JDM remains unclear, however similar to adult IIM, it is well 
recognised that genetic susceptibility combined with environmental triggers leads to 
the development of autoimmunity and thus immune dysfunction. The strongest 
genetic association for autoimmune connective tissue diseases, including JDM is 
the human leucocyte region (HLA) within the major histocompatibility complex 
(MHC). The MHC region consists of clustered multiple alleles coding for proteins 
central to the immune system. The 8.1 ancestral MHC haplotype, (HLA-B*08-
DRB1*03-DQA1*05-DQB1*02) is associated with JDM, where the strongest signal 
appears to come from the HLA class I region (10, 198-200). Recent work 
demonstrates that the DQA1*0301 allele confers an additional risk for JDM, whereas 
certain alleles, DQA1*0201, DQA1*0101 and DQA1*0102 appear protective (200). 
Certain cytokine polymorphisms, including TNFα-0308A and IL-1 receptor 
antagonist, are also associated with Caucasian JDM with a higher risk of cutaneous 
ulceration and calcinosis (201, 202). 
Environmental factors appear to play a role in the development of JDM. Reports 
suggest a temporal association to the disease onset. Various infectious agents have 
been implicated with the onset of JDM, in particular Group A streptococcus and 
several viruses including coxsackie, enterovirus and parvovirus (203-206).  
Seasonal birth patterns have been assessed in juvenile-onset IIM, in comparison to 
patients with adult-onset DM and healthy controls. It was noted that juvenile-onset 
IIM Hispanic patients had a seasonal birth pattern significantly different to controls. 
Birth patterns also differed in patients with certain HLA risk factors including 
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DRB1*0301 and DQA1*0501 alleles. The authors concluded that birth distributions 
appear to have a stronger seasonality in juvenile IIM, suggesting a role for perinatal 
or early-life exposures (95). 
Similar to adult IIM, both cellular and humoral mechanisms are involved in 
pathogenesis of JDM, and recent evidence suggests a role of the innate immune 
system (17, 73, 74, 207-210). Antibody-mediated complement deposition in the 
vessels plus dendritic cell (DCs), CD4+ T cell and B cell perivascular and 
perifascicular infiltration and upregulation of MHC class I and class II molecules by 
myocytes are characteristic. Vasculopathy plays a major pathophysiological role in 
JDM. Affected muscle is characterised by endothelial dysfunction and capillary 
dropout. Clinical features in the skin and GI tract suggest similar pathology (73). 
Hallmark features on muscle biopsy include oedema of the capillary endothelial wall 
with subsequent occlusive vasculopathy, perivascular and perimysial inflammatory 
cell infiltrate, muscle fibre changes including perifascicular atrophy. Evidence of 
muscle degeneration and regeneration is present with neonatal myosin. Recently an 
international consensus scoring system for the analysis of JDM muscle biopsy 
specimens has been published (211). Recent work has highlighted the importance 
of type 1 inteferons (IFN) in JDM disease mechanisms. Type I IFN is believed to be 
critical in the propagation of autoimmunity, and this mechanism has been implicated 
in the pathogenesis of JDM as well as adult DM (212, 213). Studies using 
microarray technology have demonstrated up-regulation of type-1 IFN induced 
genes in DM (214, 215). DM muscle contains high numbers of gene transcripts 
associated with type 1 IFN, the source of which are CD4+ plasmacytoid dendritic 
cells (pDCs) that have chemokine activity. Similar findings were also noted in DM 
skin. Finally, the potential role of maternal microchimerism in JDM has been 
highlighted over the last few years. The presence of maternal cells in peripheral 
blood and diseased muscle of JDM cases may induce autoimmunity i.e. ‘a graft-
versus-host disease’ mechanism (216-218). 
5.1.4 Autoantibodies in JDM and JDM-overlap syndromes 
Until recently, unlike adult IIM, specific autoantibodies in juvenile IIM especially 
JDM, were detected infrequently despite the majority being ANA positive on IIF. As 
in adult IIM, autoantibodies are divided into MSAs and MAAs, the latter typically 
described in JDM-overlap syndromes (JDM-SSc and JDM-SLE). 
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Unlike adults the frequency of anti-aminoacyl tRNA synthetase (ARS) 
autoantibodies in juvenile myositis, in particular JDM, is much lower. Rider et al 
used immunodiffusion and immunoprecipitation (IPP) to screen sera from 77 
children with myositis and overlap CTD, and anti-ARS were detected in only 2.6% 
cases (125). Using the same techniques, Feldman et al investigated 42 children;  
thirty five with JDM and 7 with other forms of IIM, and none had anti-ARS 
autoantibodies (127). The clinical features of anti-ARS-positive JDM cases are 
similar to their adult counterparts: moderate to severe weakness, arthritis, 
Raynaud’s phenomenon, mechanic’s hands, fevers and interstitial lung disease. 
Similar to the ARS molecules, SRP is rarely targeted by autoantibodies in juvenile 
myositis. Based on previous studies the frequency of anti-SRP is 1% (125, 127) 
Recently, Rouster-Stevens et al described three cases of juvenile anti-SRP myositis 
in their cohort of 123 children and based on their clinical features the patients were 
comparable to adults with the same autoantibody specificity. In particular; all three 
children had severe weakness, very high creatinine kinase (CK) levels, were 
refractory to treatment and had myofibre necrosis on biopsy (219). Of interest, the 
ethnic origin of these patients was African American and Love at al has previously 
reported a higher frequency of anti-SRP in adult African American cases (6). 
The reported frequency of anti-Mi-2 autoantibodies in JDM or JDM overlap is up to 
5% (125, 127). Like adult DM, this autoantibody specificity is described in children 
with hallmark cutaneous DM lesions including Gottron’s papules, heliotrope rash, 
cuticular overgrowth and rashes on the neck and trunk Moreover, patients may have 
milder muscle involvement, appear to have a monocyclic clinical course and 
respond well to therapy (125-127). 
MAAs: anti-U1-RNP, anti-PM-Scl, anti-U3-RNP, anti-Ku and anti-topoisomerase are 
typically detected in children with JDM associated with systemic sclerosis features 
including scleroderma skin changes and Raynaud’s. Based on previous data,  
collectively the overall frequency in JDM / JDM-overlap is between 15-20% (57, 220, 
221). 
Previously, the overall frequency of defined MSAs and MAAs in children with IIM 
was between 20-40%, however using full serological testing, specifically IPP this 
frequency is now much higher following the studies described in the next two 
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chapters of this thesis, and earlier reports from Wedderburn et al, Targoff et al and 
Oddis et al (10, 143, 222). 
The work described in this chapter is a clinical and serological study of JDM and 
JDM-overlap children recruited to the JDRR (UK and Ireland). Chapter 6 describes 
the work on novel autoantibody specificities in JDM. 
5.2 Patients and Methods 
5.2.1 Patients and sera 
Subjects for the study described in this chapter were recruited from: 
 The Juvenile Dermatomyositis Registry and Repository (JDRR), UK and 
Ireland (24). 
The JDRR has recruited patients from 10 centres around the UK (for details see 
Chapter 5, Appendix III) with juvenile-onset myositis, below the age of 16 years at 
disease onset and diagnosis. All JDM cases had probable or definite disease 
according to Bohan and Peter criteria  (1, 2). JDM-scleroderma overlap (JDM-SSc) 
was defined as JDM children with a history of Raynaud’s phenomenon, sclerodactly 
and other sclerodermatous skin changes (two or more of the above features). Using 
a standardised proforma demographic and clinical data were recorded at diagnosis 
and prospectively at subsequent visits, on average every 6 months (see Chapter 2, 
Section 2.1.2 and 2.1.3, and appendix). The clinical information recorded included 
specific cutaneous manifestations including the presence of Gottron’s lesions, skin 
ulceration, oedema, calcinosis and the distribution of skin rash over the body. 
Details on muscle involvement included muscle enzymes (CK and LDH) and CMAS 
at disease baseline. The development of malignancy (within three years of 
diagnosis) was not specifically recorded on the clinical proforma. However, clinicians 
were able to enter free text data on clinically significant events during disease 
course, which was therefore likely to capture this information. Data were stored 
using anonymous codes onto a central database. Serum samples were taken at the 
time of diagnosis and stored at -20oC until required. 
5.2.2 Serological Methods 
ANA-Immunofluorescence (IIF) 
IIF was previously performed by standard methods using HEp-2 cells and 
fluorescein-labelled anti-human IgG immunoglobulin (Sigma, UK). 
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Protein Radio-immunoprecipitation (IPP) 
Sera stored at -20oC were thawed at room temperature. IPP from K562 cell extracts 
was performed as described in Chapter 2, see Sections 2.3.2 and 2.3.3. Briefly, 10 
µl sera was mixed with 2 mg protein-A-Sepharose beads (Sigma, UK) in IPP buffer 
(10 mM Tris-Cl pH 8.0, 500 mM NaCl, 0.1% v/v Igepal) at room temperature for 30 
min. Beads were washed in IPP buffer prior to the addition of 120 µl [35S] methionine 
labelled K562 cell extract. Samples were mixed at 4°C for 2 hr. Beads were washed 
in IPP buffer followed by TBS buffer (10 mM Tris-Cl pH 7.4, 150 mM NaCl) before 
being resuspended in 50 µl SDS sample buffer (Sigma, UK). After heating, proteins 
were fractionated by 10% SDS-PAGE, enhanced, fixed and dried. Labelled proteins 
were analysed by autoradiography. 
5.2.3 Ethical approval 
All patients gave fully informed written / parental consent to participate and provide 
biological samples according to the Declaration of Helsinki under both national multi-
centre and local ethical committee regulations. 
5.2.4 Statistical Analysis 
Clinical associations were derived from 2×2 contingency tables using the chi-
squared test, or two-tailed Fisher’s exact test where individual cells valued five or 
less. P values less than 0.05 were considered as significant (uncorrected P values 
presented in view of small numbers in each autoantibody group). SPSS for Windows 
(version 14) was used to perform statistical analysis. 
5.3 Results 
Serum samples for serological typing were available from 162 children recruited to 
the registry. Full clinical data were available on 160 children and 74% were female. 
The median age of disease onset was 6 years, inter-quartile range (IQR) 3-9 and 
median age at diagnosis was 7 years (IQR 4, 10). One hundred and twenty seven 
cases were Caucasian and 35 cases were non-Caucasian. 
The median follow-up from disease onset to the time of data analysis for this study 
was 48 months (IQR 33, 72) for the overall cohort. 
One hundred and thirty seven children had JDM. In this study, 21 children were 
defined as JDM-SSc. Two children were defined as having indeterminate juvenile 
myositis, not specifically JDM or JDM-SSc. 
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5.3.1 Serological profiles 
Following ANA IIF and IPP, autoantibody specificity was categorised into recognised 
MSAs, myositis-associated autoantibodies (MAAs), unidentified / novel or negative. 
The overall frequency of previously defined MSAs and MAAs in this cohort study is 
shown in Table 14. Table 15 shows a breakdown of serological results and ethnicity 
(Caucasian and non-Caucasian). 
IPP results 
Thirteen out of 162 (8%) cases were positive for previously described MSAs: anti-
Jo-1 (1.2%) and anti-Mi-2 (6.8%). No cases were positive for anti-SRP 
autoantibodies. Anti-Mi-2 was found exclusively in JDM patients, with a frequency of 
7.9%, and not in any JDM-overlap patients. Anti-Jo-1 was found in JDM-overlap 
only. The frequency of ‘known’ MSA-positive in JDM was 8% compared to 9.5% in 
JDM-overlap. 
The overall frequency of MAAs in this study cohort was 14.2%: anti-U1-RNP (5.6%), 
anti-PM-Scl (6.8%), anti-U3-RNP (0.6%), anti-Ku (0.6%) and anti-Topoisomerase 
(0.6%). There was a much higher frequency of MAA-positive cases in JDM-overlap 
(81%) compared to MAA-positive JDM (4.4%). Of note, anti-U1-RNP and anti-PM-
Scl was found in higher frequency in Caucasians compared to non-Caucasian 
children. 
Novel autoantibodies were detected in 40% of the overall cohort, and these  
specificities were found exclusively in JDM cases with a frequency of 47.4% (this 
work is described in detail in Chapter 6). In the overall cohort, 37.6% of cases were 
either negative or had undefined bands on IPP. 
See Figures 15A-C for examples of MAAs and MSAs in JDM study. 
For full IPP results see Chapter 5.5, Appendix II. 
ANA IIF results 
For overall results see Chapter 5.5, Appendix II. 
In total, ANA IIF was performed on 124 samples (there were insufficient sera in 38 
samples for both ANA IIF and IPP, therefore only IPP was performed). Out of 124 
cases, 96 (77.4%) were ANA positive by IIF. 
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Figure 15A: Immunoprecipitation of MSAs and MAAs in JDM cohort study 
10% SDS PAGE of immunoprecipitates of [35S] labelled K562 cell extracts. 
JDM sera used for immunoprecipitation: Lane 1; anti-Mi-2, Lane 5; anti-Mi-2, Lane 
7; anti-Mi-2, Lane 9; anti-U1-RNP. 
Mi-2                                    Mi-2 Mi-2 U1RNP 
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Figure 15B: Immunoprecipitation of MSAs and MAAs in JDM cohort study 
10% SDS PAGE of immunoprecipitates of [35S] labelled K562 cell extracts. 
JDM sera used for immunoprecipitation: Lane 1; anti-U1-RNP, Lanes 2 and 9; anti-
PM-Scl, Lane 3 and 5; novel anti-p155/140 (see Chapter 6), Lane 4; possible anti-
U1-RNP, Lane 6; novel anti-p140 (see Chapter 6). 
U1-RNP PM-Scl  155/  p155/  p140
             140           140 
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Figure 15C: Immunoprecipitation of MSAs and MAAs in JDM cohort study 
10% SDS PAGE of immunoprecipitates of [35S] labelled K562 cell extracts. 
JDM sera used for immunoprecipitation: Lane 1; anti-Ku and anti-U3-RNP, Lane 3; 
anti-Mi-2, Lane 7; novel anti-p140 (see Chapter 6), Lane 11; anti-U1-RNP. 
Ku Mi-2 p140 U1-RNP
                           U3-RNP 
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Table 14: Myositis-specific autoantibodies and Myositis-associated 
autoantibodies in JDM and JDM-overlap cohort 
Autoantibody JDM 
n=137 
JDM-overlap 
n=21 
Other myositis 
n=2 
Overall 
n=162 
MSAs 
Anti-ARS 
Anti-Jo-1 0 9.5 0 1.2* 
Anti-PL-12 0 0 0 0 
Anti-PL-7 0 0 0 0 
Anti-EJ 0 0 0 0 
Anti-OJ 0 0 0 0 
Anti-KS 0 0 0 0 
Anti-Ha 0 0 0 0 
Anti-Zo 0 0 0 0 
Anti-SRP 0 0 0 0 
Anti-Mi-2 7.9 0 0 6.8 
MAAs 
Anti-U1-RNP 2.2 28.6 0 5.6 
Anti-PM-Scl 2.2 38.1 0 6.8 
Anti-U3-RNP 0 4.8 0 0.6 
Anti-Ku 0 4.8 0 0.6 
Anti-Topo 0 4.8 0 0.6 
Novel antibodies 47.4 0 0 40.1 
See Chapter 6 
Unknown bands 16.1 9.5 50 15.4 
Negative 25.5 0 50 22.2 
Values shown are in percentages 
MSAs: myositis-specific autoantibodies 
MAAs: myositis-associated autoantibodies 
Topo: Topoisomerase (Scl-70) 
*One anti-Jo-1-positive case also positive for anti-Ro autoantibodies 
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Table 15: Myositis-specific autoantibodies and Myositis-associated 
autoantibodies in JDM and JDM-overlap cohort (ethnic groups) 
Autoantibody 
MSAs 
Anti-ARS (Jo-1) 
JDM 
Caucasian 
n=108 
0 
JDM 
Non-Caucasian 
n=31 
0 
JDM-overlap 
Caucasian 
n=19 
10.5 
JDM-
overlap 
Non-
Caucasian 
n=4 
0 
Anti-SRP 0 0 0 0 
Anti-Mi-2 8 6.5 0 0 
MAAs 
Anti-U1-RNP 1.9 0 31.6 25 
Anti-PM-Scl 0.8 6.5 42.1 0 
Anti-U3-RNP 0 0 5.3 0 
Anti-Ku 0 0 0 25 
Anti-Topo 0 0 5.3 0 
Novel antibodies 
See Chapter 6 
42.6 61.3 0 0 
Unknown bands 17.6 9.7 5.3 25 
Negative 27.8 16.1 0 0 
Values shown are in percentages 
MSAs: myositis-specific autoantibodies / MAAs: myositis-associated autoantibodies 
Topo: Topoisomerase (Scl-70) 
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5.3.2 Clinical associations of myositis autoantibodies in study cohort 
The overall clinical features of the entire cohort are shown in Table 16. The main 
clinical features of MSAs (anti-Jo-1 and –Mi-2) and MAAs are shown in Table 17. 
Two cases were anti-Jo-1-positive with JDM-overlap. The median age at onset was 
9 years and both cases were females. Both children had DM rash with myositis,  
arthritis, sclerodermatous puffy fingers and Raynaud’s phenomenon. This MSA 
subset had no complicating features such as skin ulceration or calcinosis, however 
the numbers are small. One anti-Jo-1-positive child also had interstitial pneumonia 
and mechanic’s hands. 
Anti-Mi-2 was detected in 11 children and all had JDM with hallmark cutaneous 
changes and a wide distribution of rash: Gottron’s papules (100%), cutaneous 
oedema 63%, periorbital (100%) and periungal overgrowth with capillary changes 
(91%). The median age at onset was 12.5 years and 90% cases were girls. 
MAAs (specifically anti-U1-RNP, -PM-Scl, -U3-RNP, -Ku, -Topo) were detected in 
17 children with JDM-overlap and 6 children with a diagnosis of JDM. MAA-positive 
children had a median age at onset of 9 years, and 78% were female. Sixty-five% of 
MAA-positive cases had Gottron’s papules, with periorbital rash (35%), periungal 
changes (57%) and rash on the trunk (17%). Other features were frequent: arthritis 
(65%), scleroderma skin changes (61%), Raynaud’s (48%), calcinosis (21%) and 
lipoatrophy (35%). Both anti-PM-Scl and anti-U1-RNP autoantibodies were present 
in 5-7% of juvenile IIM respectively (a similar frequency to anti-Mi-2). 
When comparing anti-Mi-2-positive children with MAA-positive children the 
frequency of skin lesions - Gottron’s papules (P=0.034) and cutaneous oedema 
(P=0.021), distribution of rash – periorbital (P<0.001), were significantly higher in the 
anti-Mi-2 group. Sclerodermatous features were significantly more frequent in the 
MAA-positive group (P<0.001). 
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Table 16: Overall clinical features of the UK JDM Cohort study (n=160) 
Clinical feature Frequency (%) 
Female 73.8 
Caucasian 79.4 
Skin disease 
Gottron’s 82.9 
Ulceration 25.3 
Lipoatrophy 14 
Oedema 34.8 
Calcinosis 23.3 
Distribution of rash 
Periorbital 71.4 
Periungal 66.2 
Trunk 14.3 
Small joints 70.8 
Large joints 51.3 
Other features 
Arthritis 44.7 
Sclerodermatous features 12.6 
Raynaud’s phenomenon 16.6 
Dysphagia 31.4 
Mouth ulcers 27 
Alopecia 29.7 
Interstitial pneumonia 5 
Values are in percentages 
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Table 17: Clinical features of MSAs and MAAs in JDM and JDM-overlap cohort 
Anti-Jo-1 Anti-Mi-2 MAA 
n=2 (%) n=11 (%) n=23 (%) 
Median age (onset) 9 12.5 7 
Median age 9 12.5 9 
(diagnosis) 
Female 100 90 78 
Type of skin lesion 
Gottron’s papules 100 100 * 65 * 
Ulceration 0 9 13 
Oedema 0 63 ** 17 ** 
Calcinosis 0 9 21 
Lipoatrophy 0 9 35 
Mechanic’s hands 50 0 0 
Rash distribution 
Periorbital 100 100 δ 35 δ 
Periungal 100 91 57 
Small joints 100 82 65 
Large joints 50 45 30 
Trunk 0 0 17 
Other features 
Arthritis 100 36 65 
Scleroderma 100 0 α 61α 
Raynaud’s 100 9 48 
Dysphagia 0 45 30 
Mouth ulcers 0 36 αα 4 αα 
Alopecia 100 30 26 
Interstitial pneumonia 50 0 4 
Myositis 
Raised CK 100 70 76 
Values are in percentages, unless otherwise stated, (n/a: full data not available) 
* P(uncorr)=0.034: anti-Mi-2-positive versus MAA-positive 
** P(uncorr)=0.021: anti-Mi-2-positive versus MAA-positive 
δ P<0.001: anti-Mi-2-positive versus MAA -positive 
α P<0.001: anti-Mi-2-positive versus MAA-positive 
ααP(uncorr)=0.05: anti-Mi-2-positive versus MAA-positive 
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5.4 Discussion 
This chapter describes a serological study of JDM and JDM-overlap in children 
recruited to the JDRR. The aim of the work in this Chapter was to establish the 
frequency of known MSAs and MAAs, and describe the clinical associations in this 
JDM UK cohort. 
In comparison to previous serological studies in juvenile IIM summarised in several 
review articles (221, 223, 224), the overall frequency of MSAs and MAAs are similar, 
especially the anti-Mi-2 and MAAs subsets. In a recent study by Espada et al, 64 
Argentine Caucasian children with juvenile IIM (including 40 JDM cases and 17  
myositis overlap cases) were screened using IPP and RNA immunoprecipitation. 
The frequency of anti-Mi-2 was 6%, anti-PM-Scl was 3% and anti-U1-RNP 
autoantibody was 11%. No children were positive for anti-ARS autoantibodies (225). 
In this cohort study, the frequency of anti-ARS autoantibodies was generally less 
than previously described (125, 127), with less anti-Jo-1-positives and no children  
testing positive for non-Jo-1-ARS. In contrast to adult IIM where autoantibodies to 
ARS are a common target (as described in Chapter 3), this group of MSAs are 
detected infrequently in juvenile myositis. Although the numbers of children with 
anti-ARS autoantibodies were small, the clinical manifestations do resemble that of 
their adult counterparts with the anti-synthetase syndrome (see Chapter 3) (46). 
Anti-SRP autoantibodies were not detected in this cohort, which may reflect the 
ethnic make-up of this cohort (the majority of cases being Caucasian) with no cases 
of ‘juvenile PM’ being recruited to the JDRR at the time of this study. Typically anti-
SRP-positivity is rare in juvenile IIM anyway and a recent report has highlighted how 
this MSA may be generally more prevalent in Afro-American children (219). Anti-Mi-
2 was detected in JDM children with hallmark cutaneous changes,  a wide 
distribution of rash, and a relatively higher frequency of cutaneous / subcutaneous 
oedema in comparison to the anti-Jo-1 and MAA subgroups. In contrast, extra-
muscular / cutaneous complications were relatively less frequent except for 
dysphagia. The frequency of anti-Mi-2 in both juvenile and adult myositis is similar. 
The frequency of MAAs in this juvenile cohort is similar to that seen in adult IIM, 
especially when comparing JDM-SSc patients with adult myositis/CTD overlap 
(139). The most common MAA specificities were anti-U1-RNP and anti-PM-Scl, with 
small number of children testing positive for anti-U3-RNP, -Topo, and -Ku. There 
were no patients with other systemic sclerosis-associated autoantibodies e.g. anti-
centromere or anti-RNA polymerase I, II or III, which highlights differences between 
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juvenile and adult myositis-SSc overlap populations (139, 226). Children with SSc, 
including the diffuse form of the disease, have similar serological profiles. Anti-PM-
Scl and anti-U1-RNP autoantibodies are detected in a higher frequency compared to 
adult onset SSc. Other specificities including anti-centromere, anti-RNA polymerase 
and anti-topoisomerase are more common in adult SSc (226, 227). In general, MAA-
positive children had less classic skin DM lesions but myositis with more arthritis, 
scleroderma skin changes, Raynaud’s and lipoatrophy. In comparison to anti-Jo-1 
and anti-Mi-2-positive children, MAA-positives had a relatively higher frequency of 
calcinosis, and this observation may reflect the predominant overlap features with 
scleroderma. In general, overlap features are seen in about approximately 10% of 
juvenile-onset IIM (21, 22). In this study, 12% of children were defined as having 
JDM-SSc overlap, and although full data was not available to make any conclusions 
regarding severity of muscle disease, it has been observed that children with 
overlap may have milder muscle disease with lower disease activity markers (21). 
In summary, the overall frequency of recognised MSA or MAAs in this cohort was 
around 20%. Therefore, most children with myositis are either autoantibody negative 
or have autoantibodies that target novel autoantigens. The majority have novel 
specificities and this work is described in Chapter 6. 
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5.5 Appendix I 
Reproduced from the American College of Rheumatology 
(http://www.rheumatology.org/sections/pediatric) 
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5.5 Appendix I 
Reproduced from the American College of Rheumatology 
(http://www.rheumatology.org/sections/pediatric) 
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5.5 Appendix I 
Cutaneous Assessment Tool 
Full proforma available on: 
http://dir-apps.niehs.nih.gov/imacs/index.cfm?action1/4home.main 
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5.5 Appendix II – Subjects, ANA IIF and IPP results 
Study ID Diagnosis ANA IIF result IIP result 
UK01PB0001 JDM Negative 140 kDa band * 
UK01SS0002 JDM Negative Negative 
UK01JR0003 JDM Weak Homogeneous 155/140 kDa bands * 
UK01JA0004 JDM Weak FSNS 140 kDa band * 
UK01ZE0005 JDM overlap Homogeneous Ku 
UK01MB0006 JDM FSNS 155/140 kDa bands * 
UK01SP0007 JDM Weak FSNS 155/140 kDa bands * 
UK01ZB0008 JDM Nucleolar PM-Scl 
UK01MV0010 JDM overlap Weak Homogeneous with Topoisomerase 
Nucleolar 
UK01LP0016 JDM Weak FSNS Negative 
UK01AP0017 JDM Negative 140 kDa band * 
UK01JC0018 JDM Weak FSNS 155/140 kDa bands * 
UK01SO0019 JDM Negative Negative 
UK01SM0020 JDM overlap Nucleolar PM-Scl 
UK01NT0021 JDM Negative Negative 
UK01RK0022 JDM overlap DCNS with Cytoplasmic Jo-1 
Speckle 
UK01RC0023 JDM Negative 140 kDa band * 
UK01KS0024 JDM FSNS Mi-2 
UK01SP0025 JDM Weak FSNS 155/140 kDa bands * 
UK01CM0026 JDM Negative Unknown bands 
UK01IP0027 JDM DCNS Unknown bands 
UK01AP0028 JDM Negative Negative 
UK01ES0029 JDM Weak FSNS 140 kDa band * 
UK01ZM0030 JDM overlap Nucleolar PM-Scl 
UK01JB0031 JDM Weak FSNS Unknown bands 
UK01JB0032 JDM Negative 140 kDa band * 
UK01FS0033 JDM Weak FSNS 155/140 kDa bands * 
UK01LT0037 JDM Weak DCNS Unknown bands 
UK01RW0038 JDM Negative Unknown bands 
UK01LS0039 JDM DCNS Unknown bands 
UK01AL0040 JDM overlap Nucleolar PM-Scl 
UK01EM0042 JDM DCNS Unknown bands 
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UK01KH0043 JDM Homogeneous Mi-2 
UK01CB0047 JDM Negative Negative 
UK01FU0048 JDM Homogeneous Mi-2 
UK01GG0049 JDM Negative 140 kDa band * 
UK01JW0050 JDM overlap Nucleolar with Coarse Speckle PM-Scl 
UK01LW0051 JDM overlap Nucleolar with Cytoplasmic PM-Scl 
Speckle 
UK01LP0052 JDM Negative Negative 
UK01EB0053 JDM FSNS with Cytoplasmic Speckle 155/140 kDa bands * 
UK01RS0054 JDM FSNS 155/140 kDa bands * 
UK01ST0056 JDM Weak Fine Cytoplasmic Speckle Negative 
UK01EB0057 JDM FSNS 155/140 kDa bands * 
UK01VA0058 JDM Homogeneous 155/140 kDa bands * 
UK01JG0059 JDM DCNS Unknown bands 
UK01JR0060 JDM Weak FSNS 155/140 kDa bands * 
UK01EK0063 JDM Weak FSNS Negative 
UK01LC0065 JDM overlap Nucleolar with Weak U3-RNP 
Homogeneous 
UK02NS0066 JDM FSNS 140 kDa band * 
UK01KS0068 JDM Negative 140 kDa band * 
UK01JJ0069 JDM Weak FSNS 155/140 kDa bands * 
UK01PB0070 JDM Negative 140 kDa band * 
UK01SB0071 JDM Weak FSNS 140 kDa band * 
UK01BH0073 JDM Weak FSNS Unknown bands 
UK01CW0074 JDM FSNS Mi-2 
UK01NW0075 JDM FSNS Unknown bands 
UK01EB0076 JDM FSNS 155/140 kDa bands * 
UK01JT0077 JDM Homogeneous Mi-2 
UK08KW0079 JDM Weak FSNS Unknown bands 
UK04LM0082 JDM overlap DCNS U1-RNP 
UK04JC0084 JDM Weak DCNS Negative 
UK04BF0085 JDM overlap DCNS U1-RNP 
UK04VL0086 JDM overlap DCNS U1-RNP 
UK10CS0091 JDM Negative 140 kDa band * 
UK05AM0093 JDM Negative 140 kDa band * 
UK04NC0094 JDM DCNS Unknown bands 
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UK04GF0095 JDM overlap Nucleolar with Discrete Speckle PM-Scl 
UK10KM0096 JDM Homogeneous Mi-2 
UK09TH0098 JDM Weak DCNS 140 kDa band * 
UK09LW0099 JDM FSNS 155/140 kDa bands * 
UK09CD0101 JDM DCNS Negative 
UK09SA0104 JDM Weak Homogeneous 140 kDa band * 
UK09HB0105 JDM Negative 140 kDa band * 
UK09LM0110 JDM FSNS 155/140 kDa bands * 
UK06RW0115 JDM Weak Homogeneous 155/140 kDa bands * 
UK01LT0118 JDM γ Unknown bands 
UK02HC0119 JDM FSNS 155/140 kDa bands * 
UK01EB0120 JDM Weak Homogeneous 140 kDa band * 
UK10AW0122 JDM DCNS U1-RNP 
UK01KS0125 JDM overlap Nucleolar with Cytoplasmic Jo-1 
Speckle 
UK07AO0126 JDM Weak DCNS 155/140 kDa bands * 
UK07LF0128 JDM γ Negative 
UK07ZM0129 JDM Weak FSNS 140 kDa band * 
UK07MG0130 JDM FSNS 155/140 kDa bands * 
UK07SL0131 JDM DCNS 140 kDa band * 
UK07MP0132 JDM Weak Cytoskeletal Unknown bands 
UK08IC0135 JDM Negative 140 kDa band * 
UK08CT0136 JDM FSNS Unknown bands 
UK08KP0137 JDM Weak Cytoskeletal Negative 
UK08AD0138 JDM Negative Negative 
UK10SW0139 JDM DCNS 140 kDa band * 
UK01LT0140 JDM Homogeneous Mi-2 
UK01SD0141 JDM FSNS Unknown bands 
UK01ET0142 JDM DCNS 155/140 kDa bands * 
UK01NZ0144 JDM DCNS Mi-2 
UK07LH0148 JDM Weak FSNS 140 kDa band * 
UK08PS0149 JDM Homogeneous Mi-2 
UK10NE0152 JDM Negative 140 kDa band * 
UK07AH0154 JDM Weak Cytoplasmic Speckle Negative 
UK10LS0156 JDM Weak FSNS Negative 
UK01BT0157 JDM FSNS 155/140 kDa bands * 
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UK01KN0158 JDM Weak FSNS 155/140 kDa bands * 
UK01LG0161 JDM FSNS 155/140 kDa bands * 
UK01AP0162 JDM Negative Negative 
UK01CH0164 JDM Weak FSNS 155/140 kDa bands * 
UK01AW0166 JDM Weak FSNS 140 kDa band * 
UK01AW0167 JDM Negative Negative 
UK01LR0169 JDM Negative 140 kDa band * 
UK01AV0171 JDM overlap DCNS U1-RNP 
UK01SB0172 JDM Negative 140 kDa band * 
UK09HB0174 JDM DCNS U1-RNP 
UK01EC0175 JDM γ 140 kDa band * 
UK01IA0176 JDM Weak Cytoplasmic Speckle 140 kDa band * 
UK01JA0177 JDM overlap DCNS U1-RNP 
UK01JS0178 JDM Negative 140 kDa band * 
UK04CJ0179 JDM γ 140 kDa band * 
UK01TB0180 JDM γ Negative 
UK01PO182 JDM DCNS U1-RNP 
UK01LF0183 JDM Weak Homogeneous with Negative 
UK01SA0185 JDM Nucleolar PM-Scl 
UK01NN0186 JDM DCNS Unknown bands 
UK01CH0188 JDM Weak FSNS Unknown bands 
UK01LF0189 JDM Homogeneous Mi-2 
UK01GW0190 JDM Negative Unknown bands 
UK01CL0192 JDM Negative Negative 
UK07LG0194 JDM γ 155/140 kDa bands * 
UK01EW0196 JDM Weak Cytoskeletal Negative 
UK01ST0197 JDM γ Negative 
UK04JN0198 JDM γ 155/140 kDa bands * 
UK07RG0199 JDM γ 140 kDa band * 
UK10CK0200 JDM γ Negative 
UK01AA0201 JDM γ 140 kDa band * 
UK04HS0203 JDM overlap Nucleolar PM-Scl 
UK01AD0204 JDM γ Negative 
UK01CA0206 JDM γ Negative 
UK10CK0208 JDM γ Unknown bands 
UK08LG0209 JDM γ 140 kDa band * 
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UK01JH0212 JDM γ Negative 
UK01TM0213 JDM γ Negative 
UK01RH0217 JDM overlap DCNS U1-RNP 
UK01AL0220 JDM γ 155/140 kDa bands * 
UK01BP0221 JDM γ Unknown bands 
UK01TA0222 JDM γ 140 kDa band * 
UK09NR0223 JDM γ 155/140 kDa bands * 
UK01AS0224 JDM γ 140 kDa band * 
UK01RW0225 JDM γ 140 kDa band * 
UK01LB0226 JDM γ Negative 
UK09AM0227 JDM overlap γ Unknown bands 
UK01KS0228 JDM γ 140 kDa band * 
UK01GM0229 JDM overlap Nucleolar PM-Scl 
UK01EF0231 JDM γ Negative 
UK01AJ0233 JDM γ Negative 
UK01OW0234 JDM γ Mi-2 
UK01CW0236 JDM overlap γ Unknown bands 
UK01SF0237 JDM γ Negative 
UK01PB0239 Indeterminate γ Negative 
UK10YK0244 JDM γ Negative 
UK01RM0246 JDM γ Negative 
UK01RG0247 JDM γ Negative 
UK10KS0248 JDM γ PM-Scl 
UK04CS0250 JDM γ Unknown bands 
UK01KQ0251 Indeterminate γ Unknown bands 
FSNS – fine speckle nucleolar sparing 
DCNS – diifuse coarse nucleolar sparing 
γ - ANA IIF not performed (insufficient serum available) 
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CHAPTER SIX 
RESULTS 
Identification and characterisation of novel autoantigen systems in juvenile 
dermatomyositis 
6.1 Introduction 
Classifying patients using a clinico-serological approach may lead to the 
identification of more homogeneous subsets within the JDM spectrum and therefore 
have prognostic implications. 
The work described in Chapter 5 demonstrates that around 20% of children with 
JDM or JDM-overlap have well-defined autoantibody specificities (anti-ARS, anti-Mi-
2 and MAAs). Therefore, approximately 80% of children would normally be 
serologically classified as either being non-specifically ANA positive or in some 
cases seronegative, when tested by ANA IIF or standard ENA ELISA. Over the last 
few years, a number of novel autoantibodies have been described in adult IIM (as 
outlined in Chapters 3 and 4). Similarly, there has been a preliminary report from  
Oddis et al of a new autoantibody termed anti-MJ, which targets a ∼140-142 kDa 
protein in JDM (222). A further autoantigen target with a molecular weight of 155 
kDa (reported in most cases as a doublet protein with a second weaker band at 140 
kDa) has been described in JDM in a study by Targoff et al (143). The same novel 
specificity anti-p155/140 is detected in adult DM, which was described in the same 
study (143) and was also seen in the RNHRD adult IIM study (see Chapter 4). Two 
further studies have described anti-p155/140 in separate adult DM cohorts (157, 
158). As previously discussed in Chapter 4, anti-p155/140 in adult DM is associated 
with more severe skin disease but more significantly has a strong association with 
malignancy. In the Targoff et al study, anti-p155/140 was seen in approximately 
30% of their JDM population, however the clinical specificity of this cohort was not 
described (143). 
The purpose of the work described in this chapter was to establish the frequency 
and to define the clinical significance of anti-p155/140 and anti-p140 autoantibodies 
in children recruited to the UK JDM Cohort Study. The secondary aims were to 
confirm whether the same p155/140 autoantigen is targeted in adult DM and to 
demonstrate p155/140 and p140 are different targets. As presented in Chapter 5, 
40% of patients tested by IPP were found to be positive for these two different 
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autoantibodies. Both autoantibodies appear to define distinct clinical phenotypes 
within the JDM spectrum. This work has been published in the following journals: 
	 Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy 
H, Davidson JE, Cooper RG, McHugh NJ; Juvenile Dermatomyositis 
Research Group UK. Clinical associations of autoantibodies to a p155/140 
kDa doublet protein in juvenile dermatomyositis. Rheumatology. 
2007;47:324-8 
	 Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier 
WE, Cooper RG, Oddis CV, Ramanan AV, Davidson JE, McHugh NJ; 
Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies 
to a 140-kd protein in juvenile dermatomyositis are associated with 
calcinosis. Arthritis Rheum. 2009;60:1807-14. 
6.2 Patients and Methods 
6.2.1 Patients and sera 
Subjects for the study described in this chapter were recruited from: 
 The Juvenile Dermatomyositis Registry and Repository, UK and Ireland (24). 
Full details are given in Chapter 5 (see Section 5.2.1). In brief, the JDRR has 
recruited patients from 10 centres around the UK (for details see appendix (24)) with 
juvenile-onset myositis, below the age of 16 years at disease onset and diagnosis, 
to form the JDM UK Cohort Study. All JDM cases had probable or definite disease 
according to Bohan and Peter criteria (1, 2). Demographic and clinical data using a 
standardised proforma were recorded at diagnosis and prospectively at subsequent 
visits, on average every 6 months (see Chapter 2, Section 2.1.2 and 2.1.3, and 
Appendix). Data were stored using anonymous codes onto a central database. 
Serum samples were taken at the time of diagnosis and stored at -20oC until 
required. 
6.2.1.1 Study 1 (Anti-p155/140 study) 
The first 116 patients recruited to the JDM National Registry and Repository (UK 
and Ireland) (now termed the JDM UK Cohort Study) were initially studied. The 
median age at symptom onset was 6 years (IQR 3, 9) and at diagnosis was 7 years 
(IQR 4, 10). The median follow-up from disease onset to time of this study was 69.5 
months (IQR 47.5, 105.2) and 44.2 months (IQR 35.7, 65.8) from date of entry into 
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the registry to time of this study. Clinical information included the degree of skin 
involvement; muscle strength tested by the Childhood Myositis Assessment Scale 
(CMAS) (see Chapter 5, Appendix) (188), Physician’s 10-point global assessment 
(PGA) (visual analogue scale) and serum muscle enzymes. When evaluating 
muscle involvement, only those JDM patients with documented muscle enzymes at 
disease onset / diagnosis (with subsequent maximum CK or LDH during follow up) 
were included for analysis. Similarly, those with a baseline CMAS or PGA at the 
time of entry to the registry (plus subsequent serial measures) were included. The 
type of skin lesion, in particular skin ulceration, oedema and Gottron’s lesions 
combined with the distribution (extent) of skin involvement plus CMAS/ PGA score 
was defined as a marker of disease severity for the purpose of this study.  
6.2.1.2 Study 2 (Anti-p140 study) 
Patients 
Serum samples for serological typing were available from the overall cohort of 162 
children recruited to the registry (including the first 116 children initially recruited / 
analysed in the anti-p155/140 study). Clinical data were available on 160 children 
and 74% were female. The median age of disease onset was 6 years, inter-quartile 
range (IQR) 3-9 and median age at diagnosis was 7 years (IQR 4, 10). The median 
follow-up from disease onset to the time of data analysis for this study was 48  
months (IQR 33, 72) for the overall cohort. One hundred and thirty seven children 
had JDM. JDM-scleroderma overlap (JDM-SSc) is well recognised in JDM children 
with a history of Raynaud’s phenomenon, sclerodactly and other sclerodermatous 
skin changes. In this study, 21 children were defined as JDM-SSc with two or more 
of the above features. Two children were defined as having other forms of juvenile 
myositis, not specifically JDM or JDM-SSc. 
Controls 
Sera from 124 juvenile disease controls; twenty scleroderma / linear scleroderma, 8 
systemic lupus erythematosus and 96 juvenile idiopathic arthritis cases were also 
analysed. No sera from healthy children were available, reflecting ethical difficulties 
in studies of this nature. Therefore, sera from 50 healthy adult controls were also 
serotyped. 
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6.2.2 Serological methods 
Study 1 and 2

Indirect immunofluorescence (IIF)

IIF was performed by standard methods using HEp-2 cells and fluorescein-labelled 
anti-human IgG immunoglobulin (Sigma, UK). 
Protein Radio-Immunoprecipitation (IPP) 
IPP from K562 cell extracts was performed as previously described in detail in 
Chapter 2. Briefly, 10  µl sera was mixed with 2 mg protein-A-Sepharose beads 
(Sigma, UK) in IPP buffer (10 mM Tris-Cl pH 8.0, 500 mM NaCl, 0.1% v/v Igepal) at 
room temperature for 30 min. Beads were washed in IPP buffer prior to the addition 
of 120 µl [35S] methionine labelled K562 cell extract. Samples were mixed at 4°C for 
2 hr. Beads were washed in IPP buffer followed by TBS buffer (10 mM Tris-Cl pH 
7.4, 150 mM NaCl) before being resuspended in 50 µ l SDS sample buffer (Sigma, 
UK). After heating, proteins were fractionated by 10% SDS PAGE, enhanced, fixed 
and dried. Labelled proteins were analysed by autoradiography. 
Immunodepletion experiments 
Study 1 
Immunodepletion experiments were performed using reference anti-p155/140-JDM-
positive sera and reference anti-p155/140-adult-positive sera (adult sera from the 
RHHRD serology study – see Chapter 4, Section 4.3.4), to ascertain if the  IPP 
pattern seen was due to precipitation of the same p155/140 autoantigen. Cell 
extracts were depleted of autoantibody targets using anti-p155/140-JDM-positive 
serum or anti-p155/140-adult DM-positive serum and normal serum as a negative 
control. These extracts were then used in further immunoprecipitations using both 
juvenile and adult anti-p155/140 positive serum. 
As described in Chapter 2, Section 2.3.4: duplicate samples each containing 10 mg 
protein A Sepharose beads in 1 ml IPP buffer and 50 µ l reference anti-p155/140 
serum were mixed with end-over-end rotation at room temperature for 30 min. 
Beads were washed four times in 1 ml IPP buffer and 1 tube (A) was placed on ice 
whilst 150 µl [35S] methionine-labelled K562 cell extract and 350 µ l IPP buffer was 
added to the remaining tube (B). Tube B was mixed at 4°C for 2 hr after which the 
supernatant was transferred to tube A, this was mixed at 4°C for a further 2 hr. The 
supernatant from tube A was then transferred to a fresh tube (C) and stored at -
80°C. IPP using JDM or adult DM serum and either 150µl control [35S]-methionine-
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labelled cell extract or the immunodepleted supernatants (C) were completed as 
described for IPP using [35S] methionine. 
Study 2 
Immunodepletion experiments with anti-p140-JDM and anti-p155/140-JDM sera 
Immunodepletion experiments were performed using reference anti-140-JDM-
positive sera and reference anti-p155/140-JDM-positive sera to confirm that these 
autoantibodies target different autoantigens. Cell extracts were depleted of 
autoantibody targets using anti-140-JDM positive serum or anti-p155/140-JDM 
positive serum and normal serum as a negative control. These extracts were then 
used in further immunoprecipitations using different JDM anti-p140 and anti-
p155/140 positive serum. As described in Chapter 2, Section 2.3.4: duplicate  
samples each containing 10 mg protein A Sepharose beads in 1 ml IPP buffer and 
50 µ l reference anti-p140 or reference anti-p155/140 serum were mixed with end-
over-end rotation at room temperature for 30 min. Beads were washed four times in 
1 ml IPP buffer and 1 tube (A) was placed on ice whilst 150 µ l [35S] methionine-
labelled K562 cell extract and 350 µl IPP buffer was added to the remaining tube 
(B). Tube B was mixed at 4°C for 2 hr after which the supernatant was transferred to 
tube A, this was mixed at 4°C for a further 2 hr. The supernatant from tube A was 
then transferred to a fresh tube (C) and stored at -80°C. IPP using JDM serum and 
either 150µl control [35S]-methionine-labelled cell extract or the immunodepleted 
supernatants (C) were completed as described for IPP using [35S] methionine. 
IPP with mouse monoclonal anti-NXP-2 and immunodepletion experiments 
Preliminary data from Oddis et al and Targoff et al have described autoantibodies to 
the MJ antigen, which is a 140-142 kDa protein in JDM (222, 228). The MJ target 
has recently been identified as nuclear matrix protein NXP-2, also termed MORC-3 
(228). Immunodepletion experiments were performed to investigate the identity of 
the p140 target in this UK JDM cohort, which is likely to be the same as the 
previously identified MJ autoantigen. Therefore, immunodepletion experiments were 
perfomed using different reference anti-p140-JDM-positive sera and a commericial 
mouse monoclonal anti-NXP-2 antibody. Ten µl of anti-p140 positive sera or 50 µl of 
commercial mouse antibody to NXP-2 (MORC3) (Medical & Biological Laboratories, 
Nagoya, Japan) were mixed with 100 µl of prewashed protein G Dynabeads (Dynal, 
Liverpool, UK) in sodium phosphate (ph 8.1, 0.1 M) at room temperature for 30 min. 
The antigens were immunoprecipitated as described for IPP, using [35S] methionine 
labelled K562 cell extract. Immunodepletion was performed to ascertain whether the 
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IPP pattern observed with anti-p140 positive JDM sera and the commercial antibody 
to NXP-2 were due to precipitation of the same antigen. Cell extracts were depleted 
of autoantibody targets using a reference anti-p140 positive JDM sera and normal 
serum (NS) as a negative control. In brief, duplicate samples each containing 10 mg 
protein A sepharose beads (when preparing pre-depleted p140 cell extract for IPP 
with commercial anti-NXP-2, 150 µl prewashed protein G Dynabeads were used) in 
1 ml IPP buffer and 50 µ l anti-p140 serum (or 50  µl anti-p155/140 serum) were 
mixed at room temperature for 30 min. The beads were washed in IPP buffer and 1 
tube (A) was placed on ice whilst 120 µl [35S] methionine labelled K562 cell extract 
and 380 µl IPP buffer was added to tube (B). Tube B was mixed at 4°C for 2 h, the 
supernatant was then transferred to the corresponding tube A, which was then 
mixed at 4°C for a further 2 h. The supernatant from the corresponding tubes (A) 
i.e. p140 antigen depleted cell extract were stored at -80°C. IPP with depleted cell 
extracts were completed using 50 µl commercial anti-NXP-2, and different anti-p140 
sera (10 µl). 
IPP Western blotting with mouse monoclonal anti-NXP-2 
As well as immunodepletion experiments, immunoprecipitation western blotting 
studies using mouse monoclonal anti-NXP-2 antibodies were also performed. Forty 
µl of reference sera (anti-p140-JDM sera, anti-p155/140-JDM sera, anti-Mi-2-JDM 
sera) and 40 µl of normal sera were incubated with washed Sepharose protein A 
beads. Samples were centrifuged and the supernatant removed. Samples were 
washed twice with 1 ml triethanolamine and the supernatant removed. Samples 
were cross-linked and incubated with 1 ml 5mM BS3 in triethanolamine (2.86 mg / ml 
– 25 mg into 8.74 ml), centrifuged and the supernatant removed. Samples were 
further incubated with 1 ml 50mM Tris-Cl and then washed three times with PBS 
and twice with IPP buffer prior to the addition of 1 ml unlabelled K562 cell extract. 
Samples were mixed at 4°C for 2 hr. Beads were washed in IPP buffer followed by 
TBS buffer (10 mM Tris-Cl pH 7.4, 150 mM NaCl) before being resuspended in 80 µl 
SDS sample buffer (Sigma, UK). After heating, proteins were fractionated by 10% 
SDS PAGE. 
Nitrocellulose membrane and blotting paper was soaked in Transfer Buffer (Trizma 
Base, sodium acetate, EDTA, 0.1% SDS and 20% methanol). A sandwich of blotting 
paper, gel, nitrocellulose and blotting paper was placed in a transfer cage. Proteins 
were transferred to nitrocellulose membrane following electrophoresis. The 
nitrocellulose membrane was washed with Ponceau stain, rinsed with water and air-
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dried overnight. The membrane was washed with 0.05% PBS-Tween followed by 
blocking solution (10% milk powder in PBS-Tween – 10 grm in 100 ml, pH 7.2). The 
membrane was then incubated with primary antibody (commericial mouse 
monoclonal anti-NXP-2 antibody – 1:200 dilution – 50 µl in 10 ml block solution) for 
1 hr. The membrane was then washed in PBS-Tween, and then incubated with 
secondary anti-mouse IgG antibody (AbCam, UK), at 1:10,000 dilution in block 
solution – 50 µl in 50 ml, pH 7.2, for 1 hr. The membrane was washed again with 
PBS-Tween and water, and then air-dried. 
6.2.3 Statistical analysis 
The frequencies of clinical features were compared using the Chi-squared test with 
Yates’ continuity correction or the Fisher’s exact test for groups with small numbers. 
Where data was not normally distributed the Mann-Whitney-U test was used to 
compare continuous data. Median values (inter-quartile ranges) were expressed 
where appropriate and P values<0.05 were considered significant.  P values (Pcorr) 
were adjusted using the Bonferroni correction. SPSS for Windows (version 14) (for 
clinical data) was used to perform statistical analysis. 
6.3 Results 
6.3.1 Anti-p155/140: autoantibodies targeting a 155/140 kDa doublet protein 
in juvenile dermatomyositis 
Serological results 
Following IPP, sera from a number of JDM patients recognised two distinct proteins 
forming a doublet with molecular weights of 155 kDa and 140 kDa (see Figure 16). 
The same pattern was observed in a subset of adult DM patients (see Chapter 4, 
Figure 13 and this chapter, Figure 16). Non-specific weak nuclear patterns were 
observed on IIF between anti-p155/140 patients (data not shown). 
The immunodepletion results support the co-identity of the p155/140 kDa doublet 
precipitated by sera from both JDM and adult DM groups (see Figure 17). When the 
cell extracts were pre-depleted with normal serum, no targets were removed from 
the extract and the 155 kDa and 140 kDa autoantigens were still precipitated by 
juvenile and adult sera. However, when the cell extract was pre-depleted with either 
juvenile or adult anti-p155/140 positive sera, the autoantigens were no longer 
detectable in juvenile or adult anti-p155/140 positive sera respectively. This provided 
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good evidence that the sera from JDM and adult DM contained the same 
autoantibody specificity. 
Frequency and clinical features of anti-p155/140 autoantibodies 
From 116 juvenile myositis sera, 27 (23%) had anti-p155/140 autoantibodies. 
Information on the degree of skin involvement and other selected clinical features 
are outlined in Table 18. There was a higher frequency of males in the anti-
p155/140 positive children compared to anti-p155/140 negative children (Pcorr=0.04). 
Anti-p155/140 positive JDM patients had an increased frequency of skin lesions 
(Gottron’s papules Pcorr=0.027, ulceration Pcorr=0.045) with a wider distribution of 
cutaneous involvement, particularly over the small joints (Pcorr<0.001) and large 
joints (Pcorr=0.027). Cutaneous oedema was also more frequent in anti-p155/140-
positive children (P=0.013) but this was not significant following multiple corrections. 
Overall, there was no significant difference in those with elevated muscle enzymes 
at diagnosis or during disease course or those with an abnormal MRI or muscle 
biopsy between anti-p155/140 positive and negative groups (data not shown). 
However not all children had data on this, in particular some did not have a MRI or 
biopsy performed. There was a trend towards lower CMAS (lower values indicate 
more severe weakness) and higher PGA in anti-p155/140 positive children at 
baseline and during follow up, although this did not reach statistical significance. 
The frequency of other clinical signs including lipoatrophy, arthritis, Raynaud’s, 
sclerodermatous skin changes, dysphagia, mouth ulcers or alopecia was not 
significantly different between children with or without anti-p155/140. There was no 
history of malignancy in the entire JDM cohort during the follow-up period. 
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Figure 16: Immunoprecipitation of p155/140 kDa autoantigens. 10% SDS PAGE of 
immunoprecipitates of [35S] labelled K562 cell extract. Sera used for 
immunoprecipitation include Lanes 1-3; adult anti-p155/140 positive serum, Lanes 
4-6; juvenile anti-p155/140 positive serum, Lane 9; juvenile anti-Jo-1 (histidyl tRNA 
synthetase) positive serum, Lane 10; juvenile anti-Mi-2 positive serum. Positions of 
the p155 and p140 antigens are indicated on the left. 
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Figure 17: Immunodepletion experiments - Autoradiogram of 10% SDS-PAGE of 
immunoprecipitates using either anti-p155/140-adult DM sera or anti-p155/140-JDM 
positive sera. Immunoprecipitation was performed with control [35S]-methionine-
labelled cell extract or [35S]-methionine-labelled cell extract depleted with either 
normal serum (NS), adult positive anti-p155/140 serum or JDM positive anti-
p155/140 serum. The bands corresponding to the p155 and p140 autoantigens are 
indicated. 
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Table 18: Selected clinical associations of anti-p155/140 autoantibodies in 
JDM patients 
Anti-p155/140 
Positive Negative 
(n=27) (n=89) Pcorr 
Age at diagnosis, median (IQR) 6 years (4, 10) 7 years (5, 10) 
Male:Female 44.4 20.2 0.04 
Type of skin lesion 
Gottron’s papules 100 76.1# 0.027 
Ulceration 51.9 21.3 0.045 
Oedema 63 33.7 NS* 
Calcinosis 11.1 23.6 NS 
Lipoatrophy 17.9 14.3 NS 
Distribution of skin lesion 
Periorbital 92.6 65.9# NS 
Periungal 81.5 59.1# NS 
Trunk 6 (22.2) 10# (11.4) NS 
Small joints 100 62.5# <0.001 
Large joints 77.8 43.2# 0.027 
Muscle disease∂ 
Baseline CMAS, median (IQR) 36 (13.8, 48) 44 (35, 50.5) NS 
Lowest CMAS, median (IQR) 36 (13.8, 46.8) 43 (29, 49.0) NS 
Baseline PGA, median (IQR) 4.7 (2.0, 7.1) 2.8 (1.1, 5.0) NS 
Highest PGA, median (IQR) 5.5 (2.5, 7.1) 3 (1.2, 5.1) NS 
Values in percentages unless otherwise indicated. #Data on 88 children. ∂Not all 
patients had data available for each clinical feature. CMAS (childhood myositis 
assessment scale: 0-53) at baseline and lowest (worst) score during follow-up. PGA 
(physician’s global assessment: 0-10) at baseline and highest (worst) score during 
follow-up. 
*P(uncorr)=0.013 
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6.3.2 Anti-p140: autoantibodies targeting a nuclear matrix protein NXP-2 in 
juvenile dermatomyositis 
Serological results 
Identification of anti-p140 autoantibodies in JDM sera 
Following IPP, sera from a number of JDM patients recognized a distinct protein 
band with a molecular weight of ~140 kDa (see Figure 18). No anti-p140 positive 
sera were found to immunoprecipitate any other known MSAs or MAAs. A weak 
non-specific nuclear pattern or in some cases a negative ANA was observed on IIF 
in all anti-p140 sera. Anti-p140 was not detected in any of the juvenile disease 
control sera or healthy adult control sera. 
Immunodepletion experiments using anti-140 and anti-p155/140 JDM sera 
Immunodepletion confirmed anti-p140 sera target a different protein to JDM sera 
that recognises the p155/140 doublet protein (see Figure 19, lanes 1-4) showing 
respective bands are still present following IPP). 
The IPP Western blotting with mouse monoclonal anti-NXP-2 studies were negative 
(did not yield any results). No reference p140 bands were recognised following 
incubation with primary mouse monoclonal antibody anti-NXP-2 and secondary anti-
mouse IgG antibody. This may be because of loss of immunoreactivity of the p140 
autoantigen following transfer from SDS-PAGE to nitrocellulose membrane. 
Confirmation of the p140 autoantigen 
The results suggest that the p140 protein targeted by JDM sera in this study has the 
same identity as the MJ antigen, NXP-2 (228). Using a commercial antibody raised 
against NXP-2, IPP resulted in the precipitation of a band with the same molecular 
weight and IPP pattern as that observed in anti-p140 positive JDM sera (see Figure 
20, lane 3). When cell extract was pre-depleted with JDM anti-p140 positive sera, 
the IPP band present with commercial anti-NXP-2 was no longer detectable (Figure 
20, lane 4). The immunodepletion results supported the co-identity of the p140 
protein precipitated by different anti-p140 positive juvenile sera. Figure 19 (lanes 5-
6) shows an example where the 140 kDa band is no longer detectable following IPP 
with anti-p140 sera (1) and (2) using pre-depleted reference p140 cell extract. 
Clinical associations of anti-p140 autoantibodies 
Of 162 juvenile myositis sera serotyped by IPP, 37 (23%) had anti-p140 
autoantibodies. This autoantibody specificity was found exclusively in JDM patients, 
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with a frequency of 27%. Anti-p140 was not detected in any overlap JDM-SSc sera. 
Selected clinical features of anti-p140 positive patients compared to the overall anti-
p140 negative JDM cohort are shown in Table 19. Table 20 shows a comparison 
between anti-p140, anti-p155/140 and MAA positive cases. There was no significant 
difference in female:male ratio, age at onset or diagnosis and disease duration (from 
disease onset to time of this study) between anti-p140 positive and negative cases. 
Overall there was no significant difference in the presence of Gottron’s lesions, skin 
ulceration and oedema or the distribution of rash except anti-p140 positive children 
had no rashes on the trunk compared to anti-p140 negatives (Pcorr=0.02). Anti-p140 
positive cases had a significant association with the presence of subcutaneous 
calcinosis compared to anti-p140 negative patients (Pcorr<0.005, odds ratio 7.0, 95% 
CI 3.0-16.1). There was no significant difference between other clinical features 
when comparing anti-p140 positives versus negatives including baseline CK, CMAS, 
childhood health assessment questionnaire (CHAQ), physician’s global assessment 
scale (PGA), and the presence of arthritis, Raynaud’s, dysphagia, mouth ulcers and 
alopecia (data not shown). 
Possible clinical differences were noted when anti-p140 positive patients were 
compared to anti-p155/140 positive patients (Table 18). Overall, age of onset or 
diagnosis and disease duration (anti-p140 positives, median 48 months IQR 34, 72 
versus anti-p155/140 positives, median 52 months, IQR 36, 84) was similar between 
the autoantibody groups. Compared with anti-p155/140 positive children, anti-p140 
positives again had an association with calcinosis, 54% versus 14%, Pcorr=0.015 OR 
7.1 (2-25). In contrast, anti-p155/140 positives compared with the anti-p140 positive 
group had a higher frequency of ulceration and cutaneous oedema however this 
result was not significant after correcting for multiple comparisons. The distribution 
of rash was wider on the trunk Pcorr<0.005 and over the small joints (Pcorr=0.05 OR 
13.5 95% CI 2-113) in anti-p155/140 compared with anti-p140 positive cases. At the 
time of diagnosis, anti-p140 compared to anti-p155/140 positive children had a non-
significantly lower CK (median 202, IQR 76, 2142 versus median 571 IQR 234, 
2495) and LDH (median 845 IQR 710, 1620 versus median 1171 IQR 736, 1647). In 
addition, anti-p140 positives had a higher CMAS at diagnosis compared to anti-
p155/140 positives (median 42, IQR 23, 49 versus median 16, IQR 7, 38) (not 
significant after adjustment for multiple comparisons). There was a non-significant 
trend towards a lower baseline CHAQ and PGA in the anti-p140 group compared to 
the anti-p155/140 group; median CHAQ 1.31 (0.75, 1.63) versus 1.63 (0.78, 2.34), 
median PGA 5 (3, 7.4) versus 7.3 (5, 7.8) respectively. However, this data needs to 
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be interpreted in the context that a small number of patients in either group had this 
data recorded at diagnosis. 
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Figure 18: Immunoprecipitation of p140 autoantigens 
Autoradiogram of 10% SDS PAGE of immunoprecipitates of [35S] labelled K562 cell 
extract. Sera used for immunoprecipitation include Lane 1; normal serum, Lane 2; 
anti-p155/140 positive JDM serum, Lanes 3-14; different anti-p140 positive JDM 
sera. 
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Figure 19: Immunodepletion experiments with anti-p140 and anti-p155/140 
Autoradiogram of 10% SDS-PAGE of immunoprecipitates using different anti-p140 
positive JDM sera (lanes 1-2 and 5-6) and anti-p155/140 positive JDM sera (lanes 
3-4). Immunoprecipitation was performed with [35S] labelled K562 cell extract pre-
depleted with either reference anti-p140 positive JDM serum or reference anti-
p155/140 positive JDM serum. 
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Figure 20: Immunoprecipitation and immunodepletion of mouse monoclonal 
nuclear matrix protein NXP-2 
Autoradiogram of 10% SDS-PAGE of immunoprecipitates of [35S] labelled K562 cell 
extract using normal sera (NS) (lane 1), reference anti-p140 positive JDM sera (lane 
2) and commercial anti-NXP-2 (lane 3). Lane 4, immunoprecipitation using 
commercial anti-NXP-2 with [35S] labelled K562 cell extract pre-depleted with 
reference anti-p140 positive JDM serum. 
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Table 19: Selected clinical associations of anti-p140 positive JDM patients 
compared with JDM patients overall (anti-p140 negative) and with anti-
p155/140 positive JDM patients * 
Anti-p140 All JDM anti- Anti-p155/140 
positive p140 negative positive 
(n=37) ** (n=125)** (n=28) 
Age at onset (yrs) 6 6 6 
Median (IQR) (2, 10) (4, 9) (4, 10) 
Age at diagnosis (yrs) 7 7 7 
Median (IQR) (4.5, 10.3) (4, 10) (4, 10) 
Female 72 74 57 
Type of skin lesion 
Gottron’s papules 85 82 100 
Ulceration 34 23 57 
Oedema 35 35 64 
Calcinosis 54 ¶ 15 14 
Lipoatrophy 18 13 18 
Distribution of skin 
rash 
Periorbital 79 69 96 
Periungal 64 67 86 
Small joints 67 # 72 96 
Large joints 52 51 75 
Trunk 0 ## 18 32 
* Values are the percentage of patients, unless otherwise stated.

** Not all patients had the clinical data available for each feature.

Pcorr: corrected P values, OR: odds ratio (with 95% confidence intervals).

¶ Pcorr<0.005, OR 7.0 (3.0 - 16.1) versus all JDM anti-p140 negative patients and 

Pcorr=0.015, OR 7.1 (2-25) versus anti-p155/140 positive patients.

# Pcorr=0.05 OR 13.5 (2-113) anti-p155/140 positive patients versus anti-p140 

positive patients.

## Pcorr=0.02 versus all JDM anti-p140 negative patients and Pcorr<0.005 versus anti-

p155/140 positive patients.
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Table 20: Clinical associations of anti-p140-JDM patients compared with anti-
p155/140 positive-JDM, and MAA-positive- JDM patients * 
Anti-p140 Anti-p155/140 MAA-
positive positive positive 
(n=37) ** (n=28) ** (n=23) ** 
Age at onset (yrs) 6 6 6 
Median (IQR) (2, 10) (4, 10) (4, 10) 
Age at diagnosis (yrs) 7 7 9 
Median (IQR) (4.5, 10.3) (4, 10) (5, 11) 
Female 72 57 78 
Type of skin lesion 
Gottron’s papules 85 100 ¶ 65 
Ulceration 34 57 ¶¶ 13 
Oedema 35 64 α 17 
Calcinosis 54 αα 14 22 
Lipoatrophy 18 18 35 
Distribution of skin 
rash 
Periorbital 79 96 35 
Periungal 64 86 λ λ 57 
Small joints 67 96 # 65 
Large joints 52 75 ## 30 
Trunk 0 32 ### 17 
Other features 
Arthritis 49 39 65 
Sclerodermatous 61 ∍ 
3 4 
features 
Raynaud’s phenomenon 11 11 48 ∍ ∍ 
Dysphagia 31 43 35 
Mouth ulcers 29 32 4 γ 
Alopecia 37 39 26 
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Key for Table 20 
* Values are the percentage of patients, unless otherwise stated. 
** Not all patients had the clinical data available for each feature. 
Pcorr: corrected P values 
¶ Pcorr=0.01, anti-p155/140-positives versus MAA-positives 
¶¶ Pcorr=0.03, anti-p155/140-positives versus MAA-positives 
α Pcorr=0.02, anti-p155/140-positives versus MAA-positives 
αα Pcorr=0.01, anti-p140-positives versus anti-p155/140-positives / MAA-positives 
λ Pcorr <0.001, anti-p155/140-positives versus MAA-positives 
# Pcorr=0.045, anti-p155/140-positives versus MAA-positives / anti-p140-positives 
## Pcorr=0.03, anti-p155/140-positives versus MAA-positives 
### Pcorr=0.01, anti-p155/140-positives versus MAA-positives and anti-p140-
positives 
∍ Pcorr<0.001, MAA-positives versus anti-p140 / anti-p155/140-positives 
∍∍ Pcorr<0.001, MAA-positives versus anti-p140 / anti-p155/140-positives 
λ λ Pcorr=NS (P=0.045, anti-p155/140-positives versus MAA-positives / anti-p140-
positives 
γ Pcorr=NS (P=0.04, anti-p155/140 and anti-p140-positives versus MAA-positives 
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6.4 Discussion 
As described in this thesis and in previous studies there is now increasing evidence 
that MSAs are associated with clinical subsets in the adult IIM spectrum. The work 
described in Chapter 5 and 6 suggests serological profiles may also be associated 
with clinical phenotypes in JDM. Previously, myositis autoantibodies were detected 
infrequently in JDM with anti-Mi-2 having the strongest association (see Chapter 5) 
(125, 127). Therefore, detection and characterisation of novel MSAs in JDM may 
identify distinct clinical subsets within this disease group. Identification of new  
autoimmune markers may help clinicians predict clinical outcomes and lead to 
further insights in disease pathogenesis. 
There have been reports of novel protein targets including p140 kDa and p155 kDa 
polypeptides in both adult and juvenile DM. Two reports have described 
autoantibodies targeting a 140 kDa protein (anti-MJ) and a 155/(140) kDa protein in 
US JDM patients (143, 222). In adult DM, anti-p155/140 autoantibodies are 
associated with a history of malignancy (see Chapter 4) (143, 157, 158). In the study 
described in Chapter 4 (see Section 4.3.4, Table 12), anti-p155/140 autoantibodies 
were also detected in adults with CADM with no history of cancer and although the 
numbers are small, this group of adults tended to be younger. In this cohort of 
children with JDM, no malignancy has been reported to date in those with anti-
p155/140 autoantibodies; long term follow up studies will be required to ascertain 
whether there is any association with malignancy later in life in this group. In 
addition, validation of anti-p155/140 in larger groups of both adult and juvenile DM is 
required. An important finding of this study is the demonstration by immunodepletion 
that anti-p155/140 autoantibodies appear to target the same autoantigen in both 
adult and juvenile DM. Targoff et al described anti-p155 (in most cases with a 
second weaker 140 kDa band) in approximately 30% of their JDM population (143). 
The clinical specificity of this cohort was not described. This study describes 
detailed clinical features of JDM patients with autoantibodies targeting p155/140 and 
confirms they have similar cutaneous clinical associations to adults with the same 
autoantibody specificity (as described in Chapter 4, Section 4.3.4, Table 11). Like 
adult DM cases with anti-p155/140 these children have more extensive skin 
involvement including Gottron’s papules over a wider distribution. Anti-p155/140 
autoantibodies also appear to define a subset of JDM with more peripheral oedema 
and skin ulceration. There was a trend towards lower baseline and worst ever 
CMAS, and higher PGA in anti-p155/140 positive JDM compared to negative 
patients, although this was not statistically significant. In summary, anti-p155/140 
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autoantibodies occur frequently in JDM and the preliminary findings suggest that 
they may identify patients with more severe skin and possibly muscle disease. 
Identification of this autoantibody at diagnosis may help predict the clinical course. 
In this chapter, a further novel autoantibody specificity in the JDM UK cohort is 
described. Anti-p140 autoantibodies form a major serological subset in juvenile 
myositis found exclusively in JDM and not detected in any JDM-SSc overlap cases. 
Anti-p140 positive sera recognised the same polypeptide and did not 
immunoprecipitate any other known myositis autoantigens, including the anti-
p155/140 autoantibody. Combining the data from Study 1 and 2 in this chapter, anti-
p140 and anti-p155/140 autoantibodies are detected in approximately 40% of JDM 
cases, in contrast to a much lower frequency of anti-Mi-2 and other myositis-specific 
or associated autoantibodies as published previously (10, 125, 127, 219). 
The confirmation of a further serological subset in JDM appears to have important 
clinical implications. Anti-p140 has a significant association with the presence of 
calcinosis when compared to the overall juvenile myositis cohort. In addition, anti-
p140 and anti-p155/140 appear to define JDM into two serological subsets with 
more homogeneous clinical features. Combined with the data from Study 1 in this 
chapter, anti-p155/140 positive children appear to have a wider distribution of skin 
disease, more cutaneous complications including oedema or ulceration and possibly 
overall higher disease activity but a significantly lower frequency of calcinosis 
compared to anti-p140 positive children. The clinical differences observed between 
anti-p140, anti-p155/140 positives and patients without either of these specificities 
are not explained by differences in time between disease onset or disease duration. 
This is an interesting observation because factors suggested to influence the 
development of calcinosis are persistent active disease including chronic cutaneous 
inflammation (185, 201, 229). The association between serotype and clinical 
phenotype suggests that the targeted autoantigens p140 and p155/140 may play 
role in the pathogenesis of skin and soft tissue complications in JDM. Based on 
previous work that showed an association with the TNFα-308A allele, an increased 
production of tumour necrosis factor-α and calcinosis (201); future studies to 
investigate for other potential susceptibility genes including TNF polymorphisms in 
JDM patients with anti-p140 or anti p155/140 autoantibodies would be of major 
interest. 
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The p140 protein targeted by an autoimmune response in our JDM cohort study is 
consistent with nuclear matrix protein NXP-2, the MJ autoantigen described in 
preliminary reports in a US JDM cohort, and most recently in an Argentine JDM 
patient study by Espada et al (222, 225, 228). In the latter study, RNA and protein 
immunoprecipitation and immunoblotting tested 64 patients with juvenile IIM for 
autoantibodies. The anti-MJ autoantibody was detected exclusively in 25% of cases, 
a similar frequency to the anti-p140 autoantibody found in the UK JDM cohort study 
described here. Clinical features of anti-MJ autoantibodies suggest this specificity is 
a marker of disease severity, although the numbers were small and no direct 
comparisons with other serological groups was made. Muscle contractures (44%) 
and lipoatrophy (44%) were more frequent in anti-MJ-positive cases. This specificity 
was detected predominantly in pure JDM cases with proximal weakness and classic 
skin changes. The frequency of calcinosis was 31% and cutaneous vasculitis (with 
skin ulceration) 38% respectively. Clinical similarities with the anti-MJ and anti-p140 
autoantibody are noted between this Argentinean cohort and the UK JDM cohort. 
The main differences, in particular the prevalence of lipoatrophy, may represent 
variations in clinical evaluation and length of follow-up for each study (225). 
In the study by Espada et al  22% of juvenile patients (all JDM) were positive for the 
anti-p155/140 autoantibody, again a similar number to that detected in the work in 
this chapter. All children had proximal muscle weakness with a high prevalence of 
muscle contracture, and the majority has classic DM skin disease. There was also a 
relatively high frequency of cutaneous vasculitis with persistent ulceration (57%)  
(225), the same frequency noted in anti-p155/140-positive children from the UK 
cohort study (see Table 18 and 19). 
A further clinically important complication of JDM is lipodystrophy or lipoatrophy (a 
loss of subcutaneous fat, which is either localised or generalised affecting the face, 
trunk and limbs). Previous studies have reported prevalence rates between 12-40% 
(24, 230, 231). In a recent study, Bingham et al reported a lower frequency of 
lipodystrophy of 8% in a tertiary referral centre juvenile IIM registry (232). In the 
Bingham et al study, generalised lipodystrophy was shown to be associated with the 
anti-p155 (anti-p155/140) autoantibody (143), as well a chronic disease course, 
muscle atrophy, joint contractures, and interestingly calcinosis  (232). In this UK 
cohort study, the overall frequency of lipodystrophy / atrophy was 14% (see Chapter 
5, Section 5.3.2, Table 16), although the prevalence of this complication in anti-
p155/140 and anti-p140 positive children was not significantly different compared to 
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the rest of the cohort. Interestingly, lipoatrophy was seen in a relatively higher 
frequency of children who were positive for MAAs, however this did not reach  
statistical significance. A potential reason for the difference in lipoatrophy 
associations between this study and the work by Bingham et al (232) is the way  
respective clinicians define lipodystrophy or lipoatrophy. Furthermore, the relatively 
higher frequency of lipoatrophy in MAA-positive children may be because this 
overall autoantibody group was associated with JDM-scleroderma overlap. 
Larger collaborative studies are required to evaluate further the clinical specificity of 
both anti-p155/140 and anti-p140 autoantibodies in juvenile myositis populations. 
Work to date and the work presented in this chapter suggest that these two 
specificities are very important autoantibody systems with pathogenic, clinical and 
prognostic implications. When grouped together these two serological subsets are 
positive in between 40-50% of JDM cases, and appear to define those children with 
a more severe disease course including an association with widespread skin  
lesions, skin ulceration, oedema, lipodystrophy, calcinosis and worse muscle 
disease with muscle contracture (222, 225, 232, 233) (and Chapter 6). 
The identity of the p155 kDa and p140 kDa doublet protein requires investigation. It 
is likely that the p155/140 autoantigen identified in this work is the same as the 
p155/140 doublet proteins identified in recent studies (143, 157, 158), although 
immunodepletion or reverse IPP blotting studies with prototype sera are required for 
further confirmation. A preliminary report has identified the target of the anti-p155 
autoantibodies as transcriptional intermediary factor 1-gamma (TIF1-γ) (159). This 
nuclear protein is a member of a novel family of transcriptional coregulator-encoding 
genes, which function in cell differentiation and development (181). As yet, it is 
unclear what relationship the p140 protein (as part of the p155/140 doublet) has to 
the identified p155 TIF1-γ autoantigen i.e. is this a separate protein, which forms 
part of a multi-protein complex, or is it simply a cleaved or modified fragment of the 
same protein. 
Augmented expression myositis-specific autoantigens in diseased muscle and 
cancer tissue suggests a new paradigm for pathogenesis of IIM (107, 137). It is not 
clear why a tumour-associated autoantigen in adult DM should be recognised in 
JDM, particularly because there appears to be no association malignancy. However, 
other clinical features including the degree of skin disease in anti-p155/140 positive 
children and adults are very similar. Longitudinal prospective studies are required to 
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investigate whether this autoantibody in juvenile disease persists into adulthood and 
if so are they clinically significant. Perhaps the observation that the same 
autoantigen system is expressed in younger DM adults without cancer as well JDM 
suggests that some perturbation of p155/140 expression in proliferating cells 
combined with a more efficient anti-cancer response by a younger immune system 
may be a unifying mechanism to explain why it is targeted by an autoimmune 
response in children and adults with DM. 
The p140 autoantigen NXP-2 has nuclear matrix binding, RNA-binding, and coiled-
coil domains that are structurally separated, which implicates a role in diverse 
nuclear functions including regulation of transcription and RNA metabolism (228, 
234). The other dermatomyositis-specific autoantigen targets in children and adults; 
Mi-2 and p155/140 (p155 – transcription intermediary factor 1-gamma) (159, 181) 
are nuclear proteins that also mediate gene transcription. It is of further interest to 
note that autoantibodies to small ubiquitin-like modifier enzyme (SAE), which is 
involved in post-transcriptional modification termed sumoylation, have been 
described in adult dermatomyositis (see Chapter 4, Section 4.3.2) (160). It is 
interesting that anti-SAE autoantibodies were not detected in any sera from the UK 
JDM cohort (Chapters 5 and 6), particularly because NXP-2 has been shown to be a 
sumoylation target involved in transcriptional repression (235). However, this 
observation may suggest shared pathogenic mechanisms in both juvenile and adult 
dermatomyositis. 
In conclusion, anti-p155/140 and anti-p140 are clinically important serological 
markers found in a high frequency of JDM patients that are associated several  
disease complications, which confers significant morbidity. In the future, routine 
testing of these novel autoantibodies at disease onset could have prognostic value 
and identify those children at risk of more severe disease, which may influence 
management. Furthermore, increasing our understanding of autoimmune targets 
and their relationship to clinical phenotype in juvenile myositis may provide further 
insight into pathogenic pathways, which in turn will stimulate new therapeutic 
approaches. 
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CHAPTER SEVEN 
DISCUSSION 
Introduction 
This chapter will outline two preliminary studies conducted alongside the main body 
of this thesis. The chapter will close with a general discussion of the work conducted 
as part of this thesis, and it’s relevance to the current understanding of the 
relationship between pathogenesis, serological subsets and clinical phenotypes in 
adult and juvenile IIM. To conclude, hypothetical models of autoimmune 
dysregulation in distinct microenvironments and how this may lead to disease 
initiation and propagation in IIM, will be explored. Potential future work focusing on 
antigen expression at a cellular and tissue level, and the development of solid phase 
assays for commercial testing of novel myositis-specific autoantibodies (MSAs), will 
be discussed. 
7.1 Other preliminary studies 
7.1.1 Autoantibodies in idiopathic interstitial pneumonia 
Introduction 
As described in previous chapters, interstitial pneumonia is a frequent and 
significant manifestation of adult IIM, particularly the anti-synthetase syndrome 
(ASS) subset. Moreover, interstitial lung disease may be the presenting or 
predominant manifestation of IIM, especially in ASS “sine myositis” and clinically-
amyopathic DM (29, 31, 40-42). 
NSIP has been reported to be the most frequent subtype on both HRCT and lung 
biopsy in IIM (38). AIP, OP and UIP have also been reported and identified as 
patterns responsible for acute or rapidly progressive interstitial pneumonia with AIP 
and UIP associated with the worst prognosis (28-31, 33, 39). It is well recognised 
that interstitial lung involvement may be the first or predominant organ manifestation 
preceding muscle or skin disease, particularly in the anti-synthetase syndrome (see 
Section 1.5.1) and in patients with clinically-amyopathic DM (CADM) (see Section 
1.5.3). Similarly, it is now recognised that interstitial pneumonia can be the major 
complication of systemic sclerosis sine scleroderma, particularly in association with 
the specific scleroderma-associated autoantibody anti-Th/To (227, 236-238). 
Diffuse parenchymal lung disease is labelled idiopathic interstitial pneumonia when 
there is no evidence of a causative agent or coexisting connective tissue disease.  
The standard autoimmune profile is usually negative, even in patients who later 
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manifest a connective tissue disease (CTD). Therefore some patients with interstitial 
pneumonia may have underlying CTD characterised by the presence of specific 
autoantibodies not detected on routine serological testing, particularly ANA ELISA 
(most commonly used in routine clinical laboratories). In this pilot study, a small 
cohort of patients previously diagnosed as having idiopathic interstitial pneumonia 
have been screened for CTD-associated autoantibodies using ANA IIF and protein 
immunoprecipitation (IPP). 
Patients and Methods 
Twenty patients with a previous clinico-radiological diagnosis of idiopathic interstitial 
pneumonia were studied (patients from the Royal United Hospital Interstitial Lung  
disease clinic were invited to participate and not pre-selected). On further detailed 
clinical review by a Rheumatologist (HG), some patients had clinical features 
suggestive of an underlying CTD including a history of Raynaud’s phenomenon (see 
Table 22). 
All patients had high-resolution computerised tomography (HRCT) scans, which 
were re-reviewed (see Section 3.2.2). The subtype of interstitial pneumonia was 
categorised based on the American Thoracic Society / European Respiratory 
Society classification (32). 
Patients’ sera were analysed using ANA indirect immunofluorescence (IIF) and 
further characterised using protein immunoprecipitation of 35S-labelled K562 cells 
combined with SDS-PAGE to identify specific autoantigen targets, as described 
previously (see Chapter 2, Section 2.3.1 and 2.3.2). 
Results 
For detailed results see Table 21 and see Figure 21. Six patients had a positive 
ANA on IIF (>1/40 titre), all with a homogeneous pattern. Of those, two patients’ 
sera were negative on IPP, three cases had strong unidentified bands, and one 
patient was anti-topoisomerase positive on IPP (characteristic 100 kDa band, and 
confirmed by ENA ELISA). Despite two patients testing negative on ANA IIF, both  
had unidentified bands on IPP. 
Five patients’ sera with negative anti-nuclear staining but a strong cytoplasmic 
speckle tested positive for recognised anti-aminoacyl tRNA synthetase (ARS) 
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autoantibodies (one anti-Jo-1, one anti-PL-7, two anti-PL-12, and one patient with 
possible anti-Ha autoantibodies). See Table 22. 
Discussion 
In this preliminary study, 30% of patients with a previous diagnosis of idiopathic 
interstitial pneumonia actually tested positive for CTD-associated autoantibodies. 
One case tested positive for anti-topoisomerase autoantibodies, with NSIP lung 
disease, and clinical features of Raynaud’s phenomenon. Therefore, the patient may 
be re-diagnosed as having systemic sclerosis sine scleroderma (major SSc organ 
involvement, in this case fibrotic lung disease, a positive SSc-autoantibody, without 
characteristic skin changes of scleroderma) (239). In two recent studies by Fischer 
et al, a subset of patients with idiopathic interstitial pneumonia had nucleolar 
staining patterns of ANA IIF, the majority of which were positive for anti-Th/To 
autoantibodies (236, 237). Anti-Th/To is associated with less sclerodermatous 
features and a higher risk of pulmonary hypertension and lung fibrosis (227, 239), 
and this autoantibody specificity should be considered in patients with these clinical 
manifestations. 
Of those 30% with CTD-autoantibodies, the other cases were positive anti-ARS 
autoantibodies, in particular non-Jo-1-anti-ARS. All non-Jo-1-anti-ARS has a clinico-
radiological pattern consistent with UIP, except the anti-PL-7 case, which had NSIP. 
As described in Chapter 3 (see Section 3.3.3), lung fibrosis is often the predominant 
clinical manifestation in non-Jo-1-ARS-postive patients. Furthermore, radiological 
patterns demonstrate more architectural distortion with pronounced traction 
bronchiectasis and honeycombing, and histologically fibroblastic foci. This subtype 
of interstitial pneumonia is synonymous with idiopathic pulmonary fibrosis (formerly 
termed cryptogenic fibrosing alveolitis). Therefore, it is possible a proportion of 
patients with idiopathic pulmonary fibrosis actually have non-Jo-1-ARS, especially 
anti-PL-12 autoantibodies (42, 150). Anti-PL-7 autoantibodies have also been 
shown to be significantly associated with interstitial pneumonia and much milder or 
subclinical muscle disease (145). 
In summary, patients with a presumed idiopathic interstitial pneumonia may have 
subtle features of underlying CTD, and a negative routine autoimmune panel should 
not dissuade clinicians to consider more novel serological markers of autoimmunity 
in some. Moreover, even in patients with UIP lung disease, a negative ANA but a 
strong cytoplasmic pattern on IIF should prompt more detailed investigation. A 
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proportion of these patients may be a “formes fruste” of an underlying CTD, in 
particular anti-synthetase syndrome where lung disease is the only or predominant 
manifestation. Historically, the general consensus has been patients with idiopathic 
lung fibrosis have a limited response to immunomodulatory therapy, whereas 
patients with CTD-associated lung disease do appear to respond or stabilise with 
corticosteroid and immunosuppressive therapies. Thus, early identification of this 
group of patients will influence treatment strategies and long-term prognosis. 
Part of this preliminary study has been published in abstract form: 
Gunawardena H, Betteridge Z, Owen P, McHugh NJ, Foley NM. Novel markers of 
connective tissue disease in patients with idiopathic interstitial pneumonia. 
European Respiratory Journal 2008;32:320s. 
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Table 21: Serological results in idiopathic interstitial pneumonia patients 
Patient Age IIP subset ANA on IIF IPP 
R23840 61 NSIP 1/160 homogeneous Negative 
R23839 73 NSIP Negative Non-specific bands, 
R23838 74 NSIP Negative with strong Anti-Jo-1 
cytoplasmic speckle 
R23837 75 UIP 1/40 homogeneous Negative 
R23843 66 Indeterminate Negative Negative 
R23842 46 NSIP Negative Negative 
R24103 61 UIP Negative Unknown 112 kDa 
band 
R24101 58 NSIP Negative but strong Anti-PL-7 
cytoplasmic speckle 
R24102 53 RBILD 1/40 homogeneous and Unknown 72 kDa band 
fine cytoplasmic speckle 
R24100 58 NSIP Negative Negative 
R25095 68 UIP 1/2560 homogeneous Unknown 25 kDa band 
R23038 62 UIP Negative with strong Anti-PL-12 
cytoplasmic speckle 
R24526 59 Indeterminate Negative with Negative 
cytoplasmic speckle 
R19338 65 UIP 1/640 homogeneous Unknown 72 kDa band 
and fine cytoplasmic 
speckle 
R25133 60 NSIP Negative Unknown 30 kDa band 
R26806 36 UIP Negative with strong Anti-PL-12 
cytoplasmic speckle 
R26812 51 UIP Negative with strong Anti-PL-12 
cytoplasmic speckle 
R26518 64 NSIP Homogeneous 1/640 Anti-Topoisomerase 
R26895 58 UIP Negative with weak fine Unknown 31, 32 and 
cytoplasmic speckle 145 kDa bands 
R15264 75 UIP Negative with strong Unknown 62-63 kDa 
cytoplasmic speckle band (Ha antigen?) 
Possible synthetase 
(not confirmed) 
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Table 22: Clinical features of patients with presumed idiopathic interstitial 
pneumonia with recognised CTD-autoantibodies tested by IPP 
Patient 
R26806 
RP 
Yes 
MH 
Yes 
Clinical Feature 
Fever Arthralgia 
Yes 
Subtype 
IP 
UIP 
of Autoantibody 
Anti-PL-12 
R26518 Yes NSIP Anti-Topo 
R15264 Yes Yes Yes UIP Anti-p62 
(Anti-Ha?) 
R24101 Yes NSIP Anti-PL-7 
R23038 Yes Yes NSIP Anti-Jo-1 
R26812 Yes UIP Anti-PL-12 
RP: Raynaud’s phenomenon 
MH: Mechanic’s hands 
Topo: Topoisomerase 
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Figure 21: Immunoprecipitation study in idiopathic lung disease patients 
21A 
Autoradiogram of 10% SDS-PAGE of immunoprecipitates of [35S] labelled K562 cell 
extract using normal serum (lane 1), reference anti-PL-12 and reference anti-PL-7 
sera (lane 2), reference anti-Jo-1, reference anti-U1-RNP and reference anti-RNAP-
II sera (lane 3), reference anti-PM-Scl, reference anti-Ro and reference anti-La sera 
(lane 4), R23840 serum (lane 5), R23839 serum (lane 6), R23838 (anti-Jo-1) serum 
(lane 7), R23837 serum (lane 8), R23843 serum (lane 9), R23842 serum (lane 10), 
R24103 serum (lane 11), and R24101 (anti-PL-7) serum (lane 12 – arrow). 
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Figure 21: Immunoprecipitation study in idiopathic lung disease patients 
21B 
Autoradiogram of 10% SDS-PAGE of immunoprecipitates of [35S] labelled K562 cell 
extract using reference anti-U3-RNP serum (lane 1), R2518 serum (anti-
Topoisomerase) (lane 2), reference anti-mitochondrial serum (lane 3), reference 
anti-Ku serum (lane 4), R24102 serum (lane 5), R24100 serum (lane 6), R19803 
serum (lane 7), R19338 serum (lane 8), control normal serum (lane 9), R24526 
serum (lane 10), and R25133 serum (lane 11). Arrow – 100 kDa. 
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Figure 21: Immunoprecipitation study in idiopathic lung disease patients 
21C 
Autoradiogram of 10% SDS-PAGE of immunoprecipitates of [35S] labelled K562 cell 
extract using control normal serum (lane 1), reference anti-PL-7 serum (lane 2), 
R26806 serum (anti-PL-12) (lane 3), R26812 serum (anti-PL-12) (lane 4), reference 
anti-PL-7 serum (lane 5), R15264 (anti-p62 / Ha) serum (lane 6) (arrow), and 
reference anti-PL-12 serum (lane 7). 
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7.1.2 Anti-p140 autoantibodies in adult IIM 
Introduction 
As described in Chapter 6, a major autoimmune target in JDM is the p140 
autoantigen, likely to be the nuclear matrix protein NXP-2. Following detailed 
serological analysis of adult IIM patients recruited to the RNHRD cohort study and 
AOMIC UK Registry (work described in Chapters 3 and 4), a subset were noted to 
also immunoprecipitate a p140 kDa band. Therefore, preliminary work was 
undertaken to investigate if autoantibodies to the same p140 autoantigen, are 
present in adult myositis sera. 
Patients and Methods 
Clinical data and serum samples were available from the UK Adult Onset Myositis 
Immunogenetic Collaboration (AOMIC) and the RNHRD IIM cohort study (as 
described in Chapters 2-4). As previously described, serum samples were 
autoantibody typed by immunoprecipitation using [35S] labelled K562 cells. 
Immunofluorescence using HEp-2 cells and fluorescein-labelled anti-human 
immunoglobulin was completed on adult anti-p140 positive samples. 
Results 
Sera from 266 myositis patients were screened for anti-p140 autoantibodies. 
Overall, seven cases (3%) were positive for anti-p140 autoantibodies, which were 
detected exclusively in 5% of DM patients. From the RNHRD cohort study, two 
reference sera (R18883 and R23389) were positive for autoantibodies to a p140 
kDa band. A further five patients’ sera were found to recognise a 140 kDa band on 
SDS-PAGE. No anti-p140 antibody positive patients were positive for other 
recognized autoantibodies (see Figure 22). IPP experiments using cell extract pre-
depleted with reference adult-p140-positive sera (R18883) suggest that the identity 
of the p140 target in adult DM may be the same as the p140 protein recognised in 
JDM, and different to the p155/140 autoantigen (see Figure 23). ANA IIF results are 
shown in Table 23. The major clinical features of anti-p140-positive patients were 
heliotrope rash (73%), Gottron’s lesions (82%), periungal erythema (91%) and 
systemic involvement including weight loss or fever (78%). In particular, five out of 
seven (71%) anti-p140-positive adult patients had interstitial pneumonia. There was 
no cancer-associated myositis in the adult anti-p140 positive subset. In contrast to 
anti-p140-positive JDM patients where calcinosis is a significant feature, this was 
only present in one patient. 
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Dr Zoe Betteridge (and HG) have since conducted further work. This work has 
been published in abstract form: 
Betteridge ZE, Gunawardena H, Chinoy H, Vencovsky J, Allard S, Gordon PA, 
Cooper RG, McHugh NJ. Autoantibodies to the p140 autoantigen NXP-2 in adult 
dermatomyositis. Arthritis Rheum 2009;60:S815. 
In total, serum and clinical data has now been analysed in 443 adults with myositis 
(PM and DM), based on the Bohan and Peter diagnostic criteria, recruited to the 
Adult Onset Myositis Immunogenetic Collaboration, UK, RNHRD Cohort and the 
Institute of Rheumatology, Prague, CZ. All sera were autoantibody typed by 
immunoprecipitation using 35S-labelled K562 cells. Immunofluorescence using Hep-
2 cells and fluorescein-labelled anti-human immunoglobulin was completed on p140 
positive samples. 
Thirteen (2.93%) adult patients with IIM were positive for anti-p140 autoantibodies. 
All anti-p140 positive patients had DM. The prevalence of anti-p140 autoantibodies 
specifically in the DM cohort was 5.86%. Anti-p140 autoantibodies were not 
detected in sera from normal healthy controls or PM, myositis-overlap, SSc or SLE 
patients. 
The major clinical associations of anti-p140 autoantibodies in adults are shown in 
Table 24. In particular, the frequency of interstitial pneumonia in anti-p140 positive 
patients was 61.5% in comparison to 26.2% in the DM anti-p140 negative group 
(p=0.016). In addition, no p140 positive patients had cancer-associated myositis and 
in comparison with the JDM cohort, where calcinosis was a significant association, 
calcinosis was only present in two adult p140-positive patients (15.4%). 
Discussion 
Anti-p140 autoantibodies form a further serological subset in adult DM. In addition, 
preliminary data suggests that the clinical associations of anti-p140 autoantibodies 
in adults differ from JDM. In particular, lung disease appears to be a major feature of 
anti-p140-positive adult DM associated with hallmark cutaneous disease. Screening 
of larger IIM cohorts will further characterise the anti-p140 clinical phenotype in 
comparison to other IIM serological subsets, specifically novel specificities anti-SAE 
and anti-p155/140. 
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Figure 22: Immunoprecipitation of anti-p140 autoantibodies in adult DM 
Autoradiogram of 10% SDS-PAGE of immunoprecipitates of [35S] labelled K562 cell 
extract using normal serum (lane 1), reference anti-p155/140-adult DM serum (lane 
2), R18883 anti-p140-positive serum (lane 3), AOMIC M203 anti-p140-positive 
serum (lane 4), AOMIC M238 serum – unknown p140-142 doublet (lane 5), AOMIC 
M260 serum – faint band at 142 kDa (lane 6), AOMIC M352 serum – negative (lane 
7), AOMIC M86 serum – weak unknown p140-142 doublet (lane 8), AOMIC M89 
anti-p140-positive serum (lane 9), AOMIC M136 anti-p140-positive serum (lane 10), 
AOMIC M145 anti-p140-positive serum (lane 11), AOMIC M212 anti-p140-positive 
serum (lane 12), AOMIC M347 serum – negative (lane 13), and R23389 anti-p140-
positive serum (lane 14). Arrow indicates 140 kDa band. 
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Figure 23: Immunodepletion experiments with reference anti-p140-positive 
JDM and adult DM sera, and anti-p155/140-positive JDM sera 
Autoradiogram of 10% SDS-PAGE of immunoprecipitates using anti-p140-positive 
JDM serum with p140 predepleted [35S] labelled cell extract (using reference 
R18883 anti-p140-positive adult serum) (see corresponding negative lane 13) / 
using R23389 anti-p140-positive adult DM serum with p140 predepleted 35S–
labelled cell extract (using reference R18883 anti-p140-positive adult serum) (see 
corresponding negative lane 12) / using reference anti-p155/140-positive adult DM 
serum with p140 predepleted [35S] labelled cell extract (using reference R18883 
anti-p140-positive adult serum) (see corresponding p155/140 bands lane 11). Arrow 
indicates 140 kDa band. 
 
 
  1      2      3      4      5        6       7       8        9     10     11    12     13	  	  	  	  	  
Table 23: Anti-p140 autoantibody ANA IIF patterns (adult DM) 
Sample ANA IIF pattern 
R18883 Fine speckle nucleolar sparing and fine cytoplasmic speckle 
R23389 Fine speckle nucleolar sparing 1/40 
M89 Homogeneous 
M136 Fine speckle nucleolar sparing 
M145 Homogeneous 
M203 Fine speckle nucleolar sparing 1/40 
M212 Homogeneous 
Table 24: Clinical Features of anti-p140 autoantibodies in adult 
dermatomyositis 
Anti-p140 autoantibodies 
Clinical Feature Positive (n=13) Negative (n=430) 
Gender 53.8% Female 74.2% Female 
Gottron’s Lesions 
Heliotrope Rash 
Raised Creatinine Kinase 
Systemic Features 
Cancer 
Interstitial pneumonia 
92.3% 
76.9% 
53.9% 
76.9% 
0% 
61.5% * 
74.3% 
66.8% 
76.4% 
53.4% 
14.9% 
26.2% 
Weakness 69.2% 88.3% 
*Puncorr=0.016 (OR 4.5 95% CI: 1.4-14.4) 
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7.2 Summary and Final Discussion 
7.2.1 Myositis-specific autoantibodies 
The work described in this thesis combined with various studies over the past few 
years provides evidence highlighting the importance of autoimmunity in myositis. Up 
to 80% adult patients and 60% of juvenile patients now have well defined MSAs and 
MAAs when tested by detailed serological techniques. 
	 Eight anti-synthetase autoantibodies collectively define the anti-synthetase 
syndrome, characterised by myositis, skin disease including mechanic’s 
hands and Gottron’s papules, non-erosive arthritis, fever, Raynaud’s and 
interstitial pneumonia. Lung involvement is a major complication and may the 
predominant clinical manifestation. 
	 Anti-SRP autoantibodies define patients severe acute / subacute necrotising 
myopathy, which may be refractory to standard treatment. 
	 Anti-Mi-2 autoantibodies define patients with classic hallmark DM who 
appear to respond well to standard treatments and run a monocyclic disease 
course. 
	 Anti-CADM-140 (MDA5) autoantibodies appear to be unique to Asian 
clinically-amyopathic DM patients with a high risk of progressive acute 
interstitial pneumonia. 
	 Anti-p155/140 is a novel autoantibody found in both adult DM and JDM. This 
specificity defines patients with severe cutaneous disease, and is associated 
with cancer-associated myositis in older adults. 
	 Anti-SAE autoantibodies are detected in adult DM who may present with 
clinically-amyopathic DM first, progressing to myositis and systemic features. 
Interstitial lung involvement appears infrequent. 
	 Anti-p140 autoantibodies are a major serological subset in JDM, and are 
associated with calcinosis. 
The identification and characterisation of an increasing number of MSAs and their 
corresponding targets has emphasised how we should now consider a clinico-
serological classification in IIM, rather than simply diagnose patients with PM, DM or 
CTD-myositis overlap. In the future, if MSAs are used to define patients into clinical 
syndromes this may help predict outcomes and thus influence treatment strategies. 
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Table 25: Summary: Myositis-specific autoantibodies, autoantigen targets and 
clinical features 
Autoantibodies	 Target autoantigen Clinical Phenotype Autoantibody 
and function frequency (%) 
Adults JDM 
Anti-ARS	 ARS – 
intracytoplasmic 
protein synthesis 
Anti-Jo-1	 Histidyl 
Anti-PL-7	 Threonyl 
Anti-PL-12	 Alanyl 
Anti-EJ	 Glycyl 
Anti-OJ	 Isoleucyl 
Anti-KS	 Asparaginyl 
Anti-Ha	 Tyrosyl 
Anti-Zo	 Phenylalanyl 
Anti-SRP	 SRP – 
intracytoplasmic 
protein translocation 
(6 polypeptides and 
ribonucleoprotein 
7SLRNA) 
Anti-Mi-2	 Helicase protein – 
nuclear transcription 
(Forms the NuRD 
complex) 
Anti-p155/140	 TIF1-γ (p155) – 
nuclear transcription + 
cellular differentiation 
Anti-p140	 Likely to be NXP-2 – 
nuclear transcription + 
RNA metabolism 
Anti-SAE	 SAE - post-
translational 
modification (targets 
include transcription 
factors) 
Anti-CADM-140	 Intracytoplasmic 
MDA5 – innate 
immune responses 
against viral infections 
Anti-synthetase 30-40% 1-3% 
syndrome 
Myositis, mechanic’s 
hands, Gottron’s 
papules, arthritis, fever, 
Raynaud’s 
phenomenon, high 
frequency of interstitial 
pneumonia 
Acute onset necrotizing 5% <1% 
myopathy (severe 
weakness, high CK) 
May be refractory to 
treatment 
Adult DM and JDM <10% <10% 
(hallmark cutaneous 
disease, milder muscle 
disease with good 
response to treatment) 
CAM in adult DM 13-21% 23-
Severe cutaneous 29% 
disease in adult DM 
and JDM 
JDM with calcinosis N/A 23% 
Adult DM 5% N/A 
May present with 
CADM first 
CADM Overall - N/A 
Rapidly progressive unknown 
interstitial pneumonia 
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Figure 24: Summary: Myositis-specific autoantibodies and clinical features 
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7.2.2 Pathogenic mechanisms: MSAs and autoantigens as clues 
There is strong evidence that autoimmune mechanisms play an important role in 
both polymyositis (PM) and dermatomyositis (DM). Previous studies have reported 
that around 40-50% of adults and 20-30% of juvenile IIM patients have the presence 
of high-titre autoantibodies. Myositis autoantibodies can be categorised into myositis 
associated autoantibodies (MAAs) and myositis specific autoantibodies (MSAs). The 
MAAs; anti-U1-RNP, anti-U3-RNP (fibrillarin), anti-PM-Scl and anti-Ku are principally 
seen in myositis-scleroderma overlap syndromes (240), whereas the MSAs are 
highly selective, mutually exclusive and are associated with particular genotypes 
and clinical phenotypes within the myositis spectrum (6, 8, 9, 241). This thesis 
describes a comprehensive, clinical and serological study of adult and juvenile 
idiopathic inflammatory myopathy. Based on this body of work combined with 
additional preliminary studies, the frequency of MSAs/MAAs is nearer 80% in adults 
and 60% in children, therefore dispelling the notion that the majority of myositis 
cases are ‘seronegative’ (241-243). 
MSAs are directed against both cytoplasmic and nuclear components of the cell 
involved in key regulatory intra-cellular processes, including gene transcription, 
protein translocation and anti-viral responses. Interestingly, autoantigens with 
analogous cellular functions are associated with similar clinical subsets. For  
example, as described in previous chapters, the  anti-ARS autoantibodies target  
functionally related cytoplasmic tRNA enzymes involved in protein synthesis. This 
group of autoantigens form the largest subset recognised in adult IIM patients, and 
are associated with distinct clinical features collectively termed the anti-synthetase 
syndrome. A further subset of myositis patients with severe necrotising myopathy is 
characterized by the presence of autoantibodies directed against the signal 
recognition particle (SRP) (121, 122). SRP is a cytoplasmic ribonucleoprotein 
complex that recognizes secreted and membrane-bound proteins regulating protein 
translocation through the endoplasmic reticulum. 
In contrast, autoantibodies associated with DM clinical phenotypes, such as anti-Mi-
2 and novel MSAs anti-p155/140 and anti-p140, target nuclear proteins (126, 143, 
157, 158, 161). Mi-2 is a nuclear helicase protein that forms part of the nucleosome 
remodelling deacetylase (NuRD) complex playing a role in gene transcription, 
specifically chromatin remodelling (129). Targoff et al has identified the p155 target 
of the p155/140 complex as transcriptional intermediary factor 1-gamma (TIF1-γ), a 
nuclear protein involved in cellular differentiation (159). In addition, the p140 target 
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has been identified as nuclear matrix protein NXP-2, which plays a role in RNA 
metabolism and maintenance of nuclear architecture (228, 234). Finally, anti-SAE 
autoantibodies target the small ubiquitin-like modifier activating enzyme subunits 
involved in post-translational modification that is located in both the nucleus, but 
unlike other DM-associated autoantigens, it is also found in the cytoplasm of cells 
(168). The potential relationship between the DM-specific autoantigens is thus of 
interest. It is possible SAE plays a central role forming stable conjugates with other 
proteins including transcription factors (168). Interestingly, a specific target of 
sumoylation is a protein (p66) that has been shown to mediate transcriptional 
repression of the Mi-2/NuRD complex (178). Furthermore, NXP-2 has been reported 
to have a role in sumoylation-mediated regulation of transcription (235). Post-
translational modification can lead to the generation of self-antigens and so this 
observation suggests shared pathogenic mechanisms. 
The exception to the above observations may be the anti-CADM-140 autoantibody, 
now described in two Asian DM cohorts with CADM and severe lung involvement 
(130, 131, 244). The identity of this cytoplasmic protein CADM-140 has recently 
been discovered to be melanoma-differentiation-associated gene 5 (MDA5) (131, 
244). The MDA5 autoantigen appears to be distinct in terms of its biological function 
and disease expression. MDA5 is involved in the innate immune defence against 
viral infections through the detection of viral dsDNA (132). This observation may be 
explained by the fact that anti-CADM-140-autoantibody DM appears to be a unique 
clinical subset found only in Asian ethnicity, with specific genetic and environmental 
determinants. 
In general, the systemic autoimmune diseases are a genetically complex 
heterogeneous group of diseases in which the immune system attacks diverse but 
highly specific intracellular self-structures. In IIM, the striking association between 
specific autoantigen targets and clinical phenotypes, to the degree that IIM can now 
be classified into more homogeneous subsets, suggests that the autoantigen itself 
may be central in determining disease expression. Moreover, in IIM there are key 
target tissues, in particular the muscle, the skin, the lungs, and in some cases 
tumour tissue. It is possible that in IIM syndromes, disease initiation is dependent on 
the structure and concentration of autoantigens (i.e. novel non-tolerized forms – truly 
novel epitopes or previously recognised but modified epitopes that lower the 
threshold for autoreactive T cells to be activated) in certain localised pro-immune 
microenvironments. Several studies have provided insight not only into the potential 
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importance of the autoantigen target but also it’s expression in specific 
microenvironments. Two studies have highlighted how certain autoantigenic -tRNA 
synthetases (histidyl, asparaginyl and tyrosyl) have chemoattractant properties and 
can induce leukocyte migration via the CCR5 and CCR3 receptors respectively 
(135, 245). In comparison, non-antigenic -tRNA synthetases (aspartyl and lysyl) do 
not activate chemokine receptors. In addition, mononuclear cells expressing 
chemokine receptors are present in myositis muscle but not normal muscle (135). 
The authors suggested that autoantigenic ARS are over-expressed in damaged 
muscle cells and their pro-inflammatory properties promote the immune response, 
which leads to the development of myositis. 
Several studies have now demonstrated that certain autoantigens are enriched in 
lesional tissue involved in IIM. In the seminal paper by Casciola-Rosen et al several 
myositis-specific and associated autoantigens (including the Jo-1 and Mi-2 proteins 
were shown to be upregulated in myositis muscle in comparison to normal muscle 
especially in regenerating muscle cells, rather than mature myotubes (107). 
Zampieri et al demonstrated similar findings in newborn skeletal muscle, in the  
absence of infiltrating inflammatory cells. Using immunocolocalisation techniques, 
anti-Jo-1 sera showed a positive reaction within the cytoplasm of tibialis anterior 
muscles (TA) from newborn rat cyrosections and anti-Mi-2 positive serum gave a 
homogenous staining of myonuclei. In contrast, sections of TA from adult rats gave 
negative staining with both anti-Jo-1 and anti-Mi-2 sera. In addition, staining of Jo-1 
and Mi-2 paralleled the staining with anti-MHCemb, further indicating that 
expression of Jo-1 and Mi-2 is enhanced in myotubes (246). Collectively, these 
findings support the hypothesis that the presence of candidate myositis 
autoantigens during reparative myogenesis can drive induction and propagation of 
the autoimmune response. 
It has been proposed that susceptibility to the serine protease, granzyme B, is 
strongly predictive of autoantigen status. Casciola-Rosen et al have shown that  
isoleucyl-, histidyl- and alanyl-tRNA synthetases, Mi-2 and SRP72 are all cleaved by 
granzyme B, leading to the release of unique fragments that contain autoantigenic 
epitopes (104). Work by Levine et al, has emphasized the potential pathogenic role 
of proteolytic cleavage of autoantigens in lesional tissues. They demonstrated that 
the histidyl-tRNA protein exists in two conformations and whilst there are similar 
overall expression levels of Jo-1 in different tissues, the granzyme B cleavable form 
is enriched in the alveolar epithelial layer of lung (108). Therefore, the theory that 
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distinct microenvironments may shape disease expression was emphasised with 
this finding that a novel conformation of Jo-1 is enriched in the lung in comparison to 
other tissues including muscle. This has lead to the suggestion that the initiating 
target tissue for the autoimmune response in the anti-Jo-1 syndrome is the lung with 
secondary attack to muscle. 
Further evidence implicating autoantigen driven responses was suggested in a 
study by Katsumata et al (133). They generated an antigen-induced model of IIM 
following immunisation of congenic mice with either human or murine Jo-1 protein or 
amino terminal peptides of Jo-1 protein. Early antibody responses demonstrated 
strong species-specificity with limited cross recognition of Jo-1 between species. 
Studies on serum samples 8 weeks after immunisation revealed epitope spreading 
with the breakdown of B-cell tolerance to ubiquitously expressed native target 
autoantigens. The presence of anti-Jo-1 IgG isotypes indicated class switching and 
T-cell dependant B-cell responses, likely reflecting a breakdown in T-cell tolerance 
to self Jo-1. Assessments of mice after murine Jo-1 immunization demonstrated the 
presence of skeletal muscle inflammation and interstitial lung disease, which are 
clinical characteristics of the ASS clinical phenotype in humans. 
Work on the Mi-2 protein gives further emphasis to the potential role of target 
proteins in disease expression. Casciola-Rosen et al have previously demonstrated 
that Mi-2 is preferentially expressed in DM muscle rather than PM muscle, 
supporting the association between DM and Mi-2 (107). Using a conditional gene 
targeting approach in a mouse model, Kashiwagi et al demonstrated that Mi-2 is 
essential for the development and repair of the basal epidermis (134). Furthermore, 
studies by Burd et al have reported that following UV radiation, Mi-2 protein levels in 
a human keratinocyte cell line are rapidly up-regulated and maintained by an 
increase in translation efficiency through a regulatory element in the 5’-UTR region 
of mRNA and increased protein stability. This suggests enhanced expression of Mi-
2 in UV exposed keratinocytes leads to the initiation of autoimmunity and 
subsequently the DM phenotype associated with classic skin lesions. Autoantibodies 
to other members of the NURD complex have not been reported in IIM, and the  
effects of UV radiation do not significantly affect other NURD proteins, leading to the 
hypothesis that Mi-2 may act independently of the NURD complex in response to 
DNA damage (247). 
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The association between malignancy and myositis, particularly in adult DM is well 
recognised. Casciola-Rosen et al have demonstrated that Mi-2 and Jo-1 expression 
is increased in certain tumours including breast and lung adenocarcinomas (107). 
Okada et al also demonstrated the presence of autoantibodies to the DNA mismatch 
repair protein PMS1 (248), a further myositis autoantigen in patients with pancreatic 
adenocarcinoma, with protein levels increased in the corresponding lesional tissue 
(249). Furthermore, it has been demonstrated that tumour cells express low levels of 
specific effector caspases (250, 251), leading to the suggestion that with certain 
forms of cancer there may be a relative increase in other proteolytic enzymes, 
including granzyme B. It is therefore plausible that there may be generation of 
uniquely cleaved autoimmune fragments in carcinoma cells. Suber et al have  
suggested a hypothesis that in certain circumstances, the autoimmune response in 
myositis is secondary to a primary anti-cancer response. A further trigger, such as a 
muscle-trophic virus then leads to enhanced expression of autoantigens promoting 
activation of autoreactive lymphocytes and tissue damage (138). This theoretical 
model is supported by Mimuro et al, who demonstrated that the cancer-associated 
anti-p53 antibody is also observed in PM and DM patients, even when not  
associated with malignancy (252). The discovery of the p155/140 autoantigen and 
its clear association with cancer in adult DM is an exciting breakthrough, and may 
increase our understanding of the relationship between autoimmunity and cancer 
(143, 157, 158). What is fascinating is the fact that the same protein is an 
autoimmune target in JDM, which does not appear to be associated with malignancy 
(see Chapter 6) (161), and this also appears to be the case in younger adults with 
amyopathic DM (as described in Chapter 4). Perhaps some perturbation of 
p155/140 in proliferating cells combined with a more efficient anti-cancer response 
by a younger immune system may be the answer. Interestingly p155 (TIF1-γ) has 
been shown to inactivate Smad-4, which regulates TGF-β signalling, thus promoting 
cell growth and differentiation (including malignant tumours) (253). Further studies to 
investigate p155/140 autoantigen expression and conformation in cancer tissue and 
compare this to levels in other lesional tissues may be revealing. Whilst the anti -
p155/140 autoantibody is the only MSA significantly associated with cancer there is 
evidence for roles of other autoantigen targets in malignant processes. These  
include autoantigenic members of the aminoacyl tRNA synthetase family; tyrosyl-, 
isoleucyl-, phenylalanyl- and glycyl-tRNA synthetase. Of particular interest is the 
preferential expression of the interstitial lung disease associated autoantigen, 
phenylalanyl-tRNA synthetase (alpha-subunit) in solid lung tumours and acute 
myeloid leukaemia (254-260). In addition, MORC3 (NXP-2 / p140) is essential for 
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regulating the sub-nuclear localisation of p53 (261), and MDA5 activates IkB (IKK) 
related kinases, known to have a role linking chronic inflammation and cancer (262). 
The next question of whether MSAs are simply epiphenomena or directly linked to 
pathogenesis remains uncertain. Two recent publications have highlighted the 
potential role of anti-Jo-1 autoantibodies in disease activity and pathogenesis. Stone 
et al investigated the association between anti-Jo-1 levels and myositis disease 
activity (263). The authors performed a cross-sectional study of 81 anti-Jo-1 positive 
patients and disease activity was assessed using CK levels and the myositis  
disease activity assessment tool. Anti-Jo-1 levels were measured using a 
commercial ELISA and a custom ELISA using recombinant human autoantigen. 
Anti-Jo-1 levels showed modest correlation with CK, myositis and joint disease 
activity. Longitudinal data was available on 11 patients that showed serial anti-Jo-1 
levels did correlate with CK and disease visual analogue scales. In the second 
study, Eloranta et al concluded that immune complexes containing either anti-Jo-1 
or anti-Ro in the presence of RNA may act as endogenous inducers of type 1 
interferon alpha (IFN-α) (80). Together, these findings suggest that anti-Jo-1 
autoantibodies may play a role in disease propagation, and it would be of interest to 
see whether other MSAs correlate with disease activity and are able to induce pro-
inflammatory cytokine activity. Therefore in IIM, disease propagation and/or disease 
flares may be autoantibody driven in an already primed pro-immune environment, 
which leads to autoantibody mediated autoantigen capture, presentation and 
opsonisation. 
It now appears clear that in IIM specifically targeted autoantigens share unique 
properties, are preferentially expressed in disease-associated tissues and have a 
role in disease initiation and propagation. Investigating the structure and function of 
target molecules, and whether autoantibodies themselves have functional roles 
appears critical for understanding the pathogenic mechanisms in this complex 
spectrum of diseases. This in turn, may lead to therapeutic advances including the 
development of more targeted treatments. 
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7.2.3 Hypothetical models of autoreactivity and pathogenesis in myositis 
subsets 
Figure 25: Summary of observations: autoantigens as clues in target tissues 
	 The Mi-2 protein in enriched in DM muscle in comparison to PM muscle and 
normal muscle (107). 
	 In mouse models, the Mi-2 protein plays a critical role in the development of 
the skin basal epidermal layer (134). 
	 In vitro, UV light upregulates Mi-2 expression in human keratinocyte cell lines 
(264). 
	 The Mi-2 protein is enriched in adenocarcinoma tissue (107). 
	 Expression of the Jo-1 protein is highest in the lung in comparison to other 
tissues including muscle (108). 
	 The Jo-1 protein is highly susceptible to granzyme B cleavage in the lung 
and the immunogenic form of Jo-1 in vivo exists unbound (108). 
	 Mice immunised with the Jo-1 protein develop the muscle inflammation and 
lung fibrosis synonymous with the anti-synthetase syndrome (133). 
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Figure 26: Lung model 
This model is based on the observation and works of others (80, 103, 104, 106, 108, 
135, 137, 265-267). An environmental trigger such as a lung trophic virus and/or an 
environmental toxin (e.g. smoking leading to damage of the lung epithelial barrier) 
may initiate the autoimmune response in genetically susceptible individuals (e.g. 
HLA-DR3 haplotype). Virus particles incorporate into the alveolar epithelial cells 
triggering cytotoxic CD8 T cell mediated release of the serine protease granzyme B. 
This leads to alveolar cell apoptosis and thus modification of the Jo-1 protein via 
granzyme B cleavage. Granzyme B generated fragments of Jo-1 become 
immunogenic. Jo-1 is chemo-attractant via CCR5 receptor binding, thus attracting 
CD4/8 T cells, monocytes and immature dendritic cells (DCs). The Jo-1 autoantigen 
may be incorporated into DCs and then presented to CD4 T cells, which in turn 
initiates T cell autoreactivity and autoantibody production by B cells. This 
mechanism is enhanced by anti-viral type 1 IFN responses leading to DCs 
maturation and further antigen presentation. Anti-Jo-1 autoantibody production is 
also promoted through the interaction of mature DCs with autoreactive B cells via 
BAFF. This scenario is supported by the finding that bronchial-alveolar fluid from 
NSIP lung (the most common subtype of interstitial pneumonia in Jo-1 myositis) is 
rich in CD8 T cells. Therefore, the initiating target tissue in Jo-1 ASS may be the 
lung with muscle and/or skin targeted at later stages of injury as Jo-1 autoantigen 
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levels and corresponding autoantibody production increases. It is likely that the 
other ARS proteins, in particular PL-7 and PL-12 share similar immunogenic 
properties and expression profiles in the lung, particularly because lung damage is 
the predominant feature of this subtype of anti-synthetase syndrome. 
Figure 27: Skin model: Initiation of autoimmunity in Mi-2 dermatomyositis 
syndrome 
In genetically susceptible individuals (e.g. DRB1*07 in Mi-2 syndrome), UV-light 
triggers cutaneous inflammation. CD8 T cell mediated keratinocyte cell death leads 
to upregulation of unique immunogenic fragments of the Mi-2 protein. It is possible 
that the Mi-2 autoantigen also has chemoattractant properties (similar to the Jo-1 
autoantigen), thus recruiting T helper cells and DCs. Antigen presentation promotes 
T cell autoreactivity and anti-Mi-2 autoantibody production by B cells. This process 
is further enhanced by UV-light induced IFN production leading to DCs maturation 
and endothelial cell activation. Finally, loss of normal Mi-2 function disrupts basal 
epidermal cell layer repair mechanisms propagating epidermal damage. Similar to 
the Jo-1 lung model, attack on muscle may be a secondary downstream effect in 
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this model. The p155/140 protein or other DM-specific autoantigens such as SAE  
may be modified by similar mechanisms. 
Cancer model: as proposed by Suber et al (138) 
It is proposed that perhaps in some patients with cancer-associated 
dermatomyositis the first event in the pathogenic cascade is the initiation of an anti-
tumour response. In the early stages of abnormal cell differentiation, the immune 
system recognises highly expressed tumour antigens (based on current 
observations these antigens may include Mi-2 and p155/140). This response is 
either highly effective leading to efficient removal of tumour cells (before any 
pathological and clinical manifestations) (perhaps this mechanism may explain why 
p155/140 is a major autoimmune target in JDM) or ineffective (i.e. development of 
cancer in an ‘older’ less efficient immune system). This powerful anti-tumour 
response combined with other stressors e.g. toxins or trophic viruses leads to 
muscle or cutaneous injury. For example, muscle cells may undergo apoptosis, and 
those antigens initially targeted by the anti-cancer response, become upregulated in 
areas of repair and regeneration. This in turn leads to antigen presentation, 
autoreactive T cell propagation and autoantibody production. Inflammatory cells and 
cytokine production promote further injury and thus repair, which sustains the 
autoimmune response against cancer, muscle and/or skin cells. With the discovery 
of the p155/140 autoantigen, this hypothesis can now be interrogated. 
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7.3	 Future Work 
Future work should focus on increasing our understanding the significance of novel 
protein targets, from how they are expressed at a cellular level to how they classify 
patients based upon clinical features. 
7.3.1	 Screening larger cohorts of IIM patients to further define clinico-
serological subsets 
Further screening is required to establish the prevalence and disease specificity of 
novel autoantibodies in a European-wide cohort of adult patients with IIM. With the 
formation of the European Myositis Consortium, cohorts of adult patients with IIM 
with linked clinical data and serum samples are now available for analysis. This 
combined with patients recruited to the UK AOMIC Registry and UK JDM cohort 
study will form the largest collection of adult and juvenile IIM patients (over 1000 
patients) with comprehensive clinical data (see chapter 2, appendix, proforma 3 and 
4). MSAs are associated with clinical phenotypes and the study of a large cohort of 
patients will form a major biomarkers resource. Rather than diagnose patients with 
PM or DM, the work described in this thesis and future studies will lead to defining 
IIM patients into clinico-serological syndromes, which in the future will aid physicians 
to predict clinical outcomes and plan specific treatment regimes. 
7.3.2	 Investigate the persistence and level of anti- p155/140 in JDM in  
relation to increasing age and clinical course 
Around 20% of children with JDM are positive for anti-p155/140 autoantibodies. The 
same autoantibody specificity is found in adult DM associated with malignancy. 
Therefore, it will be important to investigate how these autoantibodies fluctuate over 
disease course (disease activity and response to treatment). Serial samples on 
children recruited to the UK JDM Cohort Study have been stored during disease 
course annually will be screened for anti-p155/140 using IPP. Autoantibody levels 
can be quantified using immunoprecipitation blotting. Briefly, immunoprecipitations 
will be completed using 40µl serum (p155/140 and control serum), 2mg protein A 
Sepharose and 5 mM bis-(sulphosuccinimidyl)-suberate cross-linker. Beads will be 
incubated in 2ml unlabelled K562 cell extract for a total of 2 hr at 4°C. Samples will 
be resuspended in 80µl SDS sample buffer and are heated. Proteins are 
fractionated by 10% SDS-PAGE and transferred to nitrocellulose by Western 
blotting. Blots will be probed with anti-p155/140 positive sera and bands will be 
detected using an alkaline phosphatase conjugated donkey anti-human IgG 
antibody and the BCIP/NBT liquid substrate solution. The immunoblots will then be 
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quantified by densitometry. Equal loading will be confirmed by spiking samples with 
a pre-defined amount of a lower molecular weight protein. Blots will be stripped and 
re-probed for this protein. Autoantibody data will be linked to prospective clinical 
data collected every six months and recorded on the JDRR database. 
7.3.3 Antigen expression 
Lesional tissue 
As described in section 7.2.2, based on the paradigm suggested by Casciola-Rosen 
and Rosen that in IIM lesional tissue is enriched for certain autoantigens that, under 
certain circumstances, may drive a dysregulated autoimmune response, further 
work is required to investigate this hypothesis. IIM is an excellent model to explore 
this concept further. Muscle, lung, skin and cancer biopsy material is readily 
accessible tissue that can be studied directly. Tissue expression can be investigated 
by immunohistochemistry - biopsy specimens (stored at -800C) will be cryostat (6-8 
um thick), mounted and dried. Slides will be warmed at room temperature, fixed in 
ice-cold acetone and air-dried. Sections will be washed in PBS and rinsed in TBS-
tween. Sections will be blocked and incubated overnight at 40C in a humidified 
atmosphere with commercial monospecific primary antibodies to myositis specific 
antigens (SRP54 chicken polyclonal ab14072, Mi-2 rabbit polyclonal 06-878, TIF1-γ 
mouse monoclonal ab33475, SAE1 sheep polyclonal alx210328, SAE2 rabbit 
polyclonal ap10659, HARS mouse monoclonal ab50835, TARS mouse monoclonal 
ab50147, ALARS rabbit polyclonal ab50147, NARS rabbit polyclonal ab50144, 
GARS rabbit polyclonal ab42905, Isoleucyl tRNA-synthetase rabbit polyclonal 
ab31533, Phenylalanyl tRNA-synthetase alpha H00002193-A01 mouse polyclonal, 
Phenylalanyl tRNA-synthetase beta H00010056-A01 mouse polyclonal. Sections will 
be washed and incubated with the appropriate secondary antibodies (anti-
mouse/rabbit/sheep/chicken IgG) conjugated with horseradish peroxidase, stained 
with 1-Step 4-CN (Perbio) and visualised. Negative controls will be performed by 
omitting or isotype-matching with the primary antibody. Sections will also be probed 
with FITC and TRITC conjugates as secondary antibodies in order to co-localise 
autoantigens by double immunofluorescence with appropriate cell types present in 
lesional tissue. IPP and immunoblotting on cell extracts will be performed to 
ascertain the specificity of commercially prepared antibodies prior to 
immunohistochemistry (as already done with commercial anti-SAE1/2 and anti-NXP-
2 demonstrating that these antibodies do recognise corresponding antigen targets  
derived from human cell lines. 
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Different cell lines 
Although the autoantigen targets can be visualised using 35S, for characterisation 
with mass spectrometry it may be necessary to scale up the quantity of polypeptide 
immunoprecipitated (e.g. if it is constitutively expressed in low copy number). The 
initial approach will be to increase the quantity of protein-A-Sepharose beads and 
source of antigen. However, subsequently, a combination of sub-cellular 
fractionation and immunoaffinity chromatography may be used to optimise antigen 
recovery. In addition, other human cell lines may contain different levels of 
expressed known and novel myositis autoantigens. Differences of expression in 
these seemingly ubiquitously expressed proteins will provide additional insight into 
pathogenic mechanisms. 
7.3.4 Development of quantitative solid-phase assays 
The future development of commercial assays that test for MSAs in routine clinical 
practice is important. To date, certain myositis autoantigens (Jo-1, PL-7, PL-12, Mi-2 
and SRP) have been expressed as recombinant proteins for use in commercial 
ELISAs and line-blots. An important aim is to develop further assays for the novel 
MSAs including the detection of anti-p155/140 (p155 autoantigen - TIF1-γ (159)), 
given the potential importance of this autoantibody in the diagnosis of JDM and its 
association with malignancy in adult-onset DM. Furthermore, the development of 
custom-based ELISAs will enable the quantitative analysis of MSA levels in serum 
samples that can be correlated with measures of disease activity, as previously 
demonstrated with anti-Jo-1 autoantibodies (263). Other autoantigen systems that 
may also become strategically relevant include anti-SAE, anti-p140 and anti-CADM-
140. To develop sensitive immunoblotting techniques and custom based ELISAs 
preparations will be enriched with the appropriate autoantigens by a combination of 
cell fractionation, HPLC and affinity purification using monoclonal antibodies. An 
alternative approach is to extract mRNA from cell lines e.g. K562, A549 cells to 
develop a cDNA library. This will be screened by either PCR or using a SEREX. 
Positive sequences will be expressed in a suitable system for the large-scale 
production of the recombinant peptide. In addition, commercial supplies of the 
relevant autoantigen can be sourced e.g. TIF1-γ peptide (AbCam 47108) that will be 
tested for autoantibody recognition by immunoblotting using a panel of appropriate 
positive and negative controls. A further approach will be the generation of 20-mer 
overlapping synthetic peptides spanning the known sequence of autoantigens. 
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